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ALP Alkaline phosphatase
BBB Blood-brain barrier
BCH 2-Endo-aminobicyclo-(2.2.1)heptane-2-carboxylic acid
bFGF Basic fibroblast growth factor
COMPT Catechol-O-methyl transferase
ecoR Ecotropic retrovirus receptor
EDTA Ethylenediaminetetraacetic acid
FDG Fluorodeoxyglucose
4F2hc Heavy chain subunit of surface antigen CD98
GBR 12909 1-[2-[bis(4-Fluorophenyl)methoxy]ethyl]-4-[3-phenylpropyl]piperazin
GLUT1 Glucose transporter 1
GP IIb/IIIa complex Glycoprotein IIb/IIIa complex
HeLa Human cervix carcinoma cells
5-HT Serotonin
IC50 Inhibitor constant
JAR Human placental choriocarcinoma cells
Kd Constant for the diffusion component
Kt Michaelis-Menten constant, half-saturation constant
L-DOPA L-ß-3,4-Dihydroxyphenylalanine
MAO Monoamine oxidase
MBEC Mouse brain capillary endothelial cells
MeAIB 2-(Methylamino)isobytric acid
MiBi Tetrakis[2-methoxy-2-methylpropaniso-cyanid-] kupfer -[1+]-tetrafluoroborat
MPP 1-Methyl-4-phenylpyridinium
MPTP 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
mRNA/ poly(A)+ RNA Messenger ribonuclease
NLT Novel liver-specific transporter
NMDG N-methyl-D-glucamine chloride
OAT Organic anion transporter
OCT Organic cation transporter
PBS Phosphate buffered saline
P-gp p-Glycoprotein, MDR (multi-drug resistant)
RBE4 Rat brain endothelial cell line, immortalized
RT-PCR Reverse transkriptase-polymerase chain reaction
[S] Concentration of the substrate
TEA Tetraethylammonium
TMA Tetramethylammonium
V, Vmax Transport velocity, maximal transport velocity
γ-GT γ-Glutamyltransferase
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1. Introduction
1.1 Purpose of the study
The delivery of drugs to the brain following systemic administration requires that the drug undergoes
transport through the blood brain barrier (BBB), which is constituted by the brain microvasculature
endothelial cells (Reese and Karnovsky, 1967; Brightman et al., 1970). Since the endothelial cells are
connected to each other by tight junctions and lack pores and fenestrations, any compound must cross the
membranes of the cells to enter the brain from the bloodstream. BBB transport occurs if the molecule has
access to endogenous transport pathways within the BBB (Pardridge, 1998). The systemic administration of
drugs that have been formulated specially to enable the pharmaceuticals to undergo transport through the
brain capillary endothelium will allow the broad distribution of these drugs into the entire brain parenchyma
(Tamai and Tsuji, 2000; Tsuji and Tamai, 1999; Pardridge, 1998). Therefore, the more information that is
acquired on the normal biology of the BBB transport processes, the more diverse and innovative will be
future strategies for the brain drug targeting.
The purpose of this study was the investigation of several transport systems expressed at the BBB. The
identification and functional characterization of such transport systems is essential to provide a basis for
strategies to regulate drug disposition into the brain. The present study was performed using an in vitro
model of the BBB, which has the advantage of no need of animals, does not require expensive preparations
and has an easy handling. Moreover the cell culture model represents a pure cell population of only
endothelial cells (Takakura et al., 1991; Abbott et al., 1995). In addition, in vitro studies provide conditions in
which the composition of the bathing medium can be controlled.
The strategy of the present study follows three steps. First, an in vitro model was selected which exhibits
some main properties of the BBB comparable to the in vivo situation. The cell growth and the vitality of the
cells under experimental conditions were studied in order to ensure comparability of the experiments.
Second, two sodium independent amino acid transport systems (system L and system y+) were
characterized under molecular and functional aspects. These transport systems are already well
characterized at several in vivo and in vitro models of the BBB (Audus and Borchardt, 1986; Pardridge,
1977; Pardridge and Choi, 1986; Stoll et al, 1993) and serve as indicators to provide evidence on the
suitability of the in vitro model for the present study. And third, the presence of several transport systems
(e.g. for 5-HT, L-carnitine and choline) at the BBB has been indicated but they were not fully characterized
and their molecular identity remained unclear at the brain endothelium. Therefore, the uptake of 5-HT, L-
carnitine and choline was functionally characterized and the molecular identity of the responsible transporter
proteins was studied in vitro.
The molecular identification and functional analysis of transport systems for several compounds show that
the brain capillary endothelial cells are equipped with various membrane transport systems (). Accordingly,
utilization of influx transport systems is expected to be useful in delivering many kinds of hydrophilic drugs
into the brain parenchyma. The development of effective BBB drug delivery strategies in the future will be
closely linked to the knowledge of the functional and molecular characteristics of the brain endothelial
transport processes. Therefore the present study was made to provide information about the functional
characteristic and molecular identity of transport systems expressed at the BBB.
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1.2. The blood-brain barrier
1.2.1. Functional and morphological aspects of the blood-brain barrier
The existence of the blood-brain barrier (BBB) was revealed through studies by Ehrlich (1885) in the late 19th
century, describing that brain tissue remained unstained after injection of a vital dye into the systemic blood
circulation of rats. In contrast, only the brain tissue was stained after direct injection of trypan blue into the
brain ventricular system, indicating the existence of some kind of barrier at the site of the brain capillaries
(Goldmann, 1913). Administration of the electron-dense marker horseradish peroxidase revealed that the
BBB is formed by the capillary endothelial cells in the vertebrate brain (Reese and Karnovsky, 1967;
Brightman et al., 1970).
This endothelium has special properties, which distinguish it from peripheral endothelium. It has narrow tight
junctions, no intracellular clefts, minor pinocytotic activity, it is not fenestrated, has a continuous basement
membrane and many mitochondria (Reese and Karnovsky, 1967; Stewart et al., 1994, Betz and Goldstein
1986; Dermietzel and Krause, 1991). Thus the BBB represents a barrier between the blood and the
extracellular fluid of the brain to maintain the homeostasis of the brain by controlling the passage of
molecules into and out of the brain. Only lipid-soluble small molecules with a molecular mass under 400 -
600 Da threshold can freely diffuse through the lipid bilayer of the endothelium (Pardridge, 1998). Examples
of such molecules include fat-soluble forms of vitamins, drugs, alcohol and nicotine. The tightness of the
microvascular endothelium prohibits the transport of hydrophilic and large molecules into the brain. In order
to supply the brain with compounds like nutrients and precursors for neurotransmitters, various transport
systems are present at the BBB (Begley, 1996).
In addition, the BBB may be considered not only as a physical but also as a metabolic barrier (Hardebo and
Owman, 1980). For example, the enzyme monoamine oxidase (MAO, EC 1.4.3.4) is abundant in the brain
microvessels (Kalaria and Harik, 1987) preventing a flood of monoaminergic peripheral neurotransmitters
into the neuronal fluid enviroment by decarboxylizing the monoamines immediately.
Drug delivery to the brain is made difficult by the presence of the BBB. There are different pathways to
overcome the BBB for drug delivery to the brain like invasive drug delivery to the brain, increased lipid
solubility of the drug or osmotical opening of the BBB (Pardridge et al., 1992; Pardridge 1988, 1989).
Another way is the use of existing transport systems of the BBB to deliver drugs to the brain that have been
formulated specially to undergo transport through the BBB (Tsuji and Tamai, 1999).
1.2.2. RBE4 cells as an in vitro model of the BBB
In order to study the expression and functional characteristic of transport systems at the BBB various in vivo
and in vitro models are available (Bonate, 1995; Takakura et al., 1991). Cell lines have the advantage that
there is no need of animals or expensive preparation of primary cell cultures and the cells are not
contaminated with other cells (pericytes, smooth muscle).
An immortalized rat cerebral endothelial cell line (RBE4) was used for the present study. This cell line has
recently been established and provides an in vitro model of the BBB (Roux et al. 1994). The RBE4 cells
show characteristics very similar to primary cultures of cerebral endothelial cells such as the expression of
the specific endothelial markers γ-glutamyltransferase (γ-GT) and alkaline phosphatase (ALP). The formation
of tight junctions, a characteristic feature of the BBB, has not been shown at RBE4 cells. But these cells
retain a robust epithelioid phenotype, in which the cytoskeletal organization necessary for tight junction
formation is triggered by cell-cell contact (Rist et al., 1994). Furthermore the permeability of the RBE4 cell
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monolayer for sucrose could successfully dropped following coculture with astrocytes (Romero et al., 1994).
However, the formation of tight junctions was not absolutely necessary for the purpose of the present study
because here the expression of transport systems and their functional characteristic was observed but no
transendothelial permeabilities.
The expression and functional characterization of the glucose transporter GLUT1 and of the drug-efflux
pump P-glycoprotein (P-gp), i.e. transporters which are known to be present at the BBB, has been shown at
the RBE4 cells (Regina et al., 1997; 1998; Begley et al., 1996; ElHafny et al., 1997 a/b). Moreover, almost
the same mRNA expression patterns of protein kinase C isoforms (Krizbai et al., 1995), G proteins (Fabian et
al., 1998), P-gp and the multidrug resistance-associated protein (Mrp1) (Regina et al., 1998; Begley et al.,
1996; ElHafny et al., 1997a) were found on primary cultures of brain endothelial cells and RBE4 cells.
1.3. Transport systems reported at the BBB
Transport proteins regulate the movement of lipid insoluble nutrients and endogenous compounds across
the hydrophobic domain of the plasma membrane which is essential for protein synthesis, for the supply of
metabolic energy, for maintaining and replacing structural components and for other key physiological
functions (e. g. precursor of neurotransmitters, neurotransmitter functions) (Pardridge, 1983). Several
transport systems are reported at the BBB (Begley, 1996; Pardridge and Oldendorf, 1977; Pardridge, 1984;
Tamai and Tsuji, 2000; Tsuji and Tamai, 1999). They are (a) the hexose transport system for glucose and
mannose, (b) the neutral amino acid transport system for phenylalanine, leucine and other neutral amino
acids, (c) the anionic amino acid transport system for glutamate and aspartate, (d) the cationic amino acid
transport system for arginine, lysine and other amino acids, (e) the ß-amino acid transport system for ß-
alanine and taurine, (f) the monocarboxylic acid transport system for lactate and short-chain fatty acids such
as acetate and propionate, (g) the amine transport system for choline, thiamine and mepyramine, (h) the
nucleosid transport system for purine bases such as adenine and guanine, but not pyrimidine bases, (i) the
peptide transport system for small peptides such as vasopressin and (j) the efflux transport system P-gp for
lipophilic drugs.
Traditionally, amino acid transport systems have been classified considering two main criteria: 1) the
substrate specificity and 2) the sodium dependence of the rate of transport (Deves and Boyd, 1998). In the
present study two sodium independent amino acid transporter (system L and system y+) reported to be
expressed at the BBB were studied in order to confirm the possibility of the use of the RBE4 cells as an in
vitro model of the BBB for transporter studies.
1.3.1. Transport of neutral amino acids
The transport of neutral amino acids is mediated by several transport systems which are present at the BBB
including the system L, the system ASC, the system A and the amino acid transporter B0,+ (Smith, 2000;
Tamai and Tsuij, 2000). These transport systems are localized in the luminal and/or the abluminal membrane
of the BBB. The sodium independent transport system L is present at the luminal as well as at the abluminal
membrane while the other neutral amino acid transport systems are primarily present in the abluminal
membrane (Smith, 2000; Sanchez del Pino et al., 1995).
A well characterized transporter at the BBB is the system L which is a sodium independent, 2-aminobicyclo-
[2.2.1]-heptane-2-carboxylic acid (BCH) sensitive transporter for large neutral amino acids like tryptophan
and leucine (Hargreaves and Pardridge, 1988; Miller et al., 1985; Audus and Borchardt, 1986). The system L
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has been proposed to be the major route for the permeation of large neutral amino acids at the BBB
(Pardridge, 1977, Pardridge and Choi, 1986; Audus and Borchardt, 1986). Various centrally acting drugs and
radiopharmaceuticals are neutral amino acids which are transported across the BBB by the system L
(Pardridge, 1998) later designated as LAT (Christensen et al, 1994).
The molecular basis of system L remained long unknown and belongs to the family of the heterodimeric
amino acid transporters (Wagner et al., 2001). These transporters are comprised of two subunits, a polytopic
membrane protein (light chain) and an associated type II membrane protein (heavy chain). The heavy chain
subunit of system L 4F2 (4F2hc, CD98) has been previously identified and cloned as a surface antigen on
activated lymphocytes (Haynes et al., 1981; Hemler and Strominger, 1982). The light chain of system L
consists of two isoforms LAT1 and LAT2 which differ in their affinities and substrate selectivity for neutral
amino acids. The cloning of LAT1 was first described by Kanai et al. (1998) and it has been shown, that
LAT1 is a subunit of the System L at the BBB (Boado et al., 1999; Matsuo et al., 2000, Prasad et al., 1999).
Later the LAT2 subunit was cloned (Segawa et al., 1999) and it has been shown that LAT2 is also expressed
at the BBB (Kido et al., 2001b).
System A and ASC are sodium dependent amino acid transporters which transport small neutral amino
acids, such as alanine, serine and cysteine and are proposed to be located at the abluminal membrane of
the BBB (Grammas et al., 1992¸ Tayarani et al., 1987; Smith; 2000). The transport of amino acids via system
A is sensitive to α-methylaminoisobutyric acid (MeAIB) (Grammas et al., 1992).
Another sodium dependent system localized at the abluminal side of the BBB is the system B0,+ which
mediates the transport of neutral as well as cationic amino acids (Sanchez del Pino et al., 1995; Sloan and
Mager, 1999; Kilberg, 1993). Furthermore this system is sensitive towards BCH.
System L has been shown at the BBB in vivo (Miller et al., 1985; Pardridge, 1977), in isolated microvessels
(Betz and Goldstein, 1978; Hargreaves and Pardgridge, 1988) and on primary cultures of brain microvessels
(Audus and Borchardt, 1986). In the RBE4 cells the expression of system L is concluded due to the BCH
sensitive uptake of L-DOPA and histidine (Reichel et al, 2000; Gomes and Soares-da-Silva, 1999). The
transport of tryptophan via system L at RBE4 cells was studied to determine if it exhibits similar features as
described at the brain endothelium in vivo and in vitro. Furthermore the expression of LAT1 and LAT2, the
light chains of system L, was investigated.
1.3.2. Transport of cationic amino acids
The cationic amino acid arginine is essential to most tissues because only the kidney and the liver are able
to produce sufficient amounts via synthesis from citrulline (Barbul, 1990). There are at least four different
transporters for cationic amino acids so far identified in adult mammalian tissues (y+, B0,+, b0,+ and y+L) which
differ in their specificity, cation dependence and physiological role (Deves and Boyd, 1998).
The carrier proteins of system y+ are a family of high capacity cationic amino acid transporters called cat’s.
System y+ catalyzes high affinity (in the micromolar range, except in liver) sodium independent transport of
cationic amino acids and the transport of zwitterionic neutral amino acids with low affinity (in the large
millimolar range, affinity increases with chain length) only in the presence of sodium, potassium or lithium
ions (Rojas and Deves, 1999). In the cat family three genes encode for four different isoforms (cat1, cat2a,
cat2b and cat3.) which differ in their tissues distribution, kinetics and regulatory properties (Deves and Boyd,
1998). The cloning of the cDNA encoding the first member of the system y+ amino acid transporter was
coincidental with the cloning of the receptor for the ecotropic retrovirus (ecoR) (Albritton et al., 1989). This
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viral receptor was later shown to be the cationic amino acid transporter cat1 of the system y+ which is
considered to be ubiquitously expressed except in liver (Wang et al., 1991; Kim et al., 1991). The Michaelis-
Menten constant (Kt) of the cat1 mediated arginine transport is reported to be 47-77 µM in several tissues
(Stevens and Vo, 1998, Wang et al., 1991; Stoll et al., 1993; Closs et al., 2000).
To the second family of amino acid transporters, called BAT’s, belong broad-scope transport proteins which
accept cationic amino acids as well as neutral amino acids with a high affinity (Deves and Boyd, 1998).
System y+L and system b0,+ have been found to be heterodimeric amino acid transporters that are comprised
of a type II membrane glycoprotein (heavy chain) that may associate with a number of different polytopic
membrane proteins (light chains). The system y+L consists of the heavy chain 4F2hc and either one of two
different isoforms of light chains y+LAT1 (Torrents et al., 1998) and y+LAT2 (Bröer et al., 2000). The light
chain of system b0,+ is named b0,+AT and was first reported to be associated with the heavy chain rBAT
(Chairoungdua et al., 1999). Further studies revealed evidence that b0,+AT interacts with rBAT as well as with
4F2hc to constitute functionally competent b0,+-like amino acid transport systems (Rajan et al., 2000b).
System y+L and system b0,+ transport cationic amino acids in a sodium independent manner (Deves and
Boyd, 1998). Both transport systems are not reported to be expressed at the BBB.
There is only one sodium dependent transport system for cationic amino acids. This system B0,+ is described
above (1.2.1.1.) and transports cationic as well as neutral amino acids in a sodium dependent manner
(Sloan and Mager, 1999). The amino acid transport of system B0,+ is attenuated in the presence of BCH.
However, system y+ has been found to be responsible for the majority of L-arginine transport (Closs, 2002;
Kakuda, 1998). The cat1 amino acid transporter is the only one reported to be highly enriched in cerebral
microvessels compared with the whole brain (Stoll et al., 1993). Therefore, the arginine uptake and the
expression of cat1 were studied in RBE4 cells to determine if these cells are an useful tool for further studies
of transport systems which are expressed at the BBB.
1.4. Putative transport systems at the BBB
Beside well-known and well-characterized transporters at the BBB there are a number of putative transport
systems which have not been described in detail at the BBB yet. Therefore the expression and functional
characterization of transport systems for serotonin, carnitine and choline was studied at the RBE4 cells.
There are indications that these transporters might exist at the brain endothelium but no study has
completely characterized the functional and molecular aspects of these transport processes.
1.4.1. Transport of serotonin
The indolamine serotonin (5-hydroxytryptamine, 5-HT) plays not only a role as neurotransmitter in the brain,
but it also represents a signal molecule for the brain microvasculature including the BBB (Brust et al. 1996b,
Cohen et al. 1996). In addition to their well established role in BBB functions, there has been accumulating
evidence suggesting that brain capillaries have the potential to modulate vasomotoricity and participate in the
regulation of the vascular perfusion (Cohen et al, 1996). 5-HT has been shown to elicit vasodilatation as well
as vasoconstriction. A direct neurogenic control of the microvascular bed by brain intrinsic 5-HT neurons was
suggested (Underwood et al. 1992, Cohen et al. 1996). The ability of the microvascular bed to respond directly
to intracerebrally released 5-HT is underscored by the expression of distinct 5-HT receptors in the various
cellular compartments of the microvascular bed including the endothelium. The two opposite 5-HT mediated
vascular responses can most likely be explained, at least in part, by differences in the population(s) of the 5-
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HT receptors and in their endothelial vs. smooth muscle location, but possibly also by the original intrinsic tone
of the vessels before exposure to 5-HT (Cohen et al., 1996). The presence of smooth muscle contractile
proteins has been detected in both endothelial cells and pericytes of the brain capillaries (Boado and
Pardridge, 1994). First evidence for the presence of 5-HT receptors at brain endothelial cells was obtained by
Crone and Olesen who measured a decrease of the electrical resistance in cerebral postcapillary venules of
frogs indicating an increase of vascular permeability in response to 5-HT (Crone and Olesen, 1986; Olesen,
1985). Later Sharma and co-workers have shown that the BBB permeability, as measured with Evans blue
and [131I]sodium iodide, is increased after infusion of 5-HT or under stressful conditions associated with
increased levels of circulating 5-HT (Sharma et al. 1990, 1992). Mediation of these effects by 5-HT2 receptors
has been suggested (Sharma et al, 1990). Recently binding studies with different radiotracers revealed the
presence of 5-HT2–like receptors in isolated microvessels of porcine brain (Brust et. al, 1996a). Using reverse
transcriptase polymerase-chain reaction (RT-PCR) the selective expression of 5-HT2B but not of 5-HT2A and 5-
HT2C receptors in human brain endothelial cells was shown (Bouchelet et al., 1997).
The 5-HT released is expected to be inactivated by monoamine oxidase which is expressed in brain
endothelium (Kalaria and Harik, 1987; Brust et al., 1996b). Therefore the presence of an endothelial plasma
membrane transport system that is specific for 5-HT has been suggested (Spatz et al., 1981; Brust et al.,
1995, 1996a). In previous studies, we have demonstrated that the tricyclic antidepressant [3H]imipramine and
the non-tricyclic antidepressant [3H]paroxetine bind specifically to microvessels of the porcine brain. Both
radioligands label the neuronal 5-HT transporter (Langer et al., 1980; Habert et al., 1985). Therefore their
binding to brain microvessels indicates the presence of such a transport system at the level of the blood-brain
barrier (Brust et al., 1995, 1996b). Other authors described the uptake and the metabolism of 5-HT in isolated
microvessels and in the cells of the second to fourth passages of primary endothelial cells from gerbils (Spatz
et al., 1981; Maruki et al., 1984). However, their investigations were not extensive enough to fully characterize
a specific 5-HT transporter at the BBB similar to the transport system in the brain (Graham and Langer, 1988).
In the brain the neurotransmitter is removed from the synaptic cleft by reuptake in the plasma
membrane of the presynaptic cells where it is metabolized. The uptake of 5-HT into the cells is described to be
saturable and temperature dependent and has the need of extracellular sodium and intracellular potassium
(Spatz et al., 1981; Blackburn et al., 1967; Graham and Langer, 1988; O’Reilly and Reith, 1988). The Na+/K+-
gradient through the cell membrane is generated by a Na+/K+-ATPase (Spatz et al., 1981; Graham and
Langer, 1988). Furthermore the 5-HT uptake into platelets was demonstrated to be dependent on extracellular
calcium (Nishio et al., 1995, 1996). Various specific antidepressants are used for the treatment of psychiatric
disorders like bulimia and depression where changes of the serotoninergic system were observed (Leibowitz,
1990; Hyttel, 1982). These antidepressants like paroxetine, fluoxetine, clomipramine, imipramine and
citalopram are known as specific inhibitors of the 5-HT transport (Brust et al., 1995, 1996a; Cohen et al., 1996;
Spatz et al., 1981; Graham and Langer, 1988; O’Reilly and Reith, 1988; Blakely et al., 1991a). In 1991 the
antidepressant sensitive 5-HT transporter was cloned from rat brain and it has been shown that the 5-HT
transporter in the plasma membrane of platelets is identical with the transporter found in the brain (Hoffman et
al., 1991; Lesch et al., 1993).
By using RT-PCR and uptake experiments with radiolabeled serotonin the functionally expression of a
sodium dependent 5-HT transporter at cerebral endothelial cells should be demonstrated. RBE4 cells will
serve as an in vitro model of the BBB and the results obtained in the present study will be compared with
primary cerebral endothelial cells.
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1.4.2. Transport of carnitine
Carnitine (4-N-trimethylamino-3-hydroxybutyric acid) is a small, water soluble molecule which serves as an
essential cofactor in the translocation of long-chain fatty acids into mitochondria where they are subjected to
ß-oxidation (Bremer, 1983). Despite its obligatory function in energy production from long-chain fatty acids,
carnitine is produced endogenously only in a limited number of tissues. Therefore specific transport
mechanisms are necessary to provide the cells with carnitine from the blood. The synthesis of carnitine from
trimethyllysine includes four enzymatic reactions (Rebouche, 1992). Beside in the liver and in the kidney,
carnitine is also synthesized in the brain (Siliprandi et al., 1989; Jacob and Belleville, 1992) where it is
suggested to fulfill a different role than in peripheral tissues (Nałęcz and Nałęcz, 1996). The level of ß-
oxidation in the normal adult brain is very low (Warshaw and Terry, 1976) and the carnitine/acylcarnitine
translocase from rat brain mitochondria has a higher specificity towards short and medium chain acyl
derivatives than towards long-chain acyl derivatives (Kaminska et al., 1993). It is postulated that the major
function of this transporter in the adult brain is the translocation of acetyl moieties from mitochondria into the
cytoplasm (Nałęcz and Nałęcz, 1996). It has been demonstrated that acetyl-L-carnitine is utilized for the
synthesis of acetylcholine (Doležal and Tuček, 1981, White and Scates, 1990; Wawrzeńczyk et al., 1995).
Furthermore acetyl-L-carnitine may modulate cerebral glucose utilization (Aureli et al., 1998). These functions
may contribute to the beneficial effects of carnitine and its acyl esters in patients with neurodegenerative
diseases (Rebouche, 1992; Spagnoli et al., 1991). The neuroprotective properties of acetyl-L-carnitine have
also been demonstrated in vitro on hippocampal cultures chronically treated with the ß-amyloid fragment 25-
35 (Forloni et al., 1994).
However, the expression of γ-butyrobetaine hydroxylase (EC 1.14.11.1), the rate-limiting enzyme in the
biosynthetic pathway of L-carnitine, in the brain is very low as shown by northern blot analysis (Vaz et al.,
1998). This suggests that the brain may depend on plasma carnitine supply. Neural cells accumulate L-
carnitine by a saturable, stereoselective, and sodium dependent transport process (Huth et al., 1981;
Zoccarato et al., 1983; Nałęcz et al., 1995). Recently a high-affinity, sodium dependent carnitine transporter
(OCTN2) has been cloned and functionally characterized (Sekine et al., 1998a; Wu et al., 1998; Tamai et al.,
1998). Interestingly, OCTN2 belongs to the gene family of organic cation transporters and accordingly this
transporter mediates not only the uptake of L-carnitine in a sodium coupled manner but also the uptake of
several organic cations in a sodium independent manner (Wu et al., 1999).
The transport of carnitine has been studied at immortalized rat brain endothelial (RBE4) cells and at primary
cultures of endothelial capillary cells derived from porcine brain. At RBE4 cells the carnitine transport was
found to be sodium independent (Mroczkowska et al., 1996). In porcine brain endothelial cells, evidence for an
asymmetrical uptake was found (Mroczkowska et al., 1997). It was suggested that a novel sodium
independent transport system is present at the apical membrane whereas the transport across the basolateral
membrane, which is diminished by sodium transport inhibitors and amino acids, may be mediated by amino
acid transport system(s). Neither of these studies has provided evidence for the presence of a sodium
dependent carnitine transporter at the BBB.
In this study, the transport of carnitine into RBE4 cells should be characterized with functional and molecular
approaches. The studies will answer the question about the sodium dependence of the carnitine transport
process at the BBB. Furthermore the molecular basis of the carnitine transporter will be clarified and it will be
shown if the OCTN2 transporter is expressed at the BBB.
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1.4.3. Transport of choline
Choline is an anorganic cation that plays a critical role in the structure and function of biological membranes
in all cells as a component of the membrane phospholipid phosphatidylcholine (Klein et al., 1993; Löffelholz,
1998; Jope and Jenden, 1979). In the brain, choline plays an additional role as a precursor for the synthesis
of the neurotransmitter acetylcholine (Jope, 1979; Blusztajn and Wurtman, 1983; Löffelholz, 1998). Since the
synthesis of phosphatidycholine as well as acetylcholine occurs intracellularly, the availability of choline for
these synthesis processes inside the cells is controlled primarily by the transport systems located in the
plasma membrane of the cells. In addition, choline is a polar, water-soluble cation, which is not expected to
diffuse passively across the BBB, and hence requires a specific transport system to reach the intracerebral
space. The transport of choline from the blood into the brain is important because the brain has only a limited
capacity to synthesize choline and consequently depends predominantly on the supply of this precursor from
the systemic circulation (Wurtmann, 1992).
Choline transport has been characterized by various mechanisms. These mechanisms include BBB
transport, high- and low-affinity transport with defining locations and unique characteristics. The high-affinity
transport has been characterized at cholinergic nerve terminals linked to the synthesis of acetylcholine
(Löffelholz, 1998; Jope, 1979; Kuhar and Murrin, 1978). This transport is described to be sodium dependent,
with an apparent half saturation constant (Kt) of 1-3 µM and a high sensitivity against hemicholinium-3 with
an inhibitor constant (Ki) in the nanomolar range (Yamamura and Snyder, 1973; Apparsundaram et al., 2000;
Okuda and Haga, 2000). In contrast, the low-affinity choline transporter is independent on sodium, exhibits a
Kt value of 33-93 µM and hemicholinium-3 shows only a weak inhibitory effect with a Ki value of about 50 µM
(Happe and Murrin, 1993; Yamamura and Snyder, 1973). The sodium independent transport of choline
appears at several cell types (van Rossum and Boyd, 1998; Fisher et al., 1992; Fisher et al., 1989; Oelberg
and Xu, 1998) and seems to provide the precursor for phospholipid synthesis (Jope, 1979).
The transport of choline across the BBB has been investigated in intact animals (Cornford et al., 1978;
Mooradian, 1988; Karlsson et al., 1984; Allen and Smith, 1999), with isolated brain capillaries (Shimon et al.,
1988, 1989; Galea and Estrada, 1992) or purified brain capillary endothelial cells (Estrada et al., 1990).
These studies have demonstrated the presence of a carrier-mediated process for the entry of choline across
the endothelial cell layer of the BBB. The process has been described to be sensitive to hemicholinium-3
with Ki values above 10 µM (Cornford et al., 1978, Shimon et al., 1988) and in one report even to be partially
sodium independent (Estrada et al., 1990).
The sodium dependent high-affinity choline transporter, designated CHT1, has been recently cloned from rat
and human (Okuda et al., 2000; Okuda and Haga, 2000; Apparsundaram et al., 2000). CHT1 is expressed
exclusively in specific regions of the brain (forebrain, striatum, brain stem and spinal cord), strongly
suggesting a role for this transporter in cholinergic neurons (Okuda et al., 2000). The molecular identification
of another choline transporter, called CHOT1, has been reported by Mayser et al. (1992), but studies from
other laboratories have shown that CHOT1 does not transport choline (Gonzalez and Uhl, 1994).
Furthermore its expression pattern in the brain does not match the location of cholinergic neurons (Happe
and Murrin, 1995). The authors concluded that CHOT1 is not a choline transporter of the brain but is actually
a Na+- and Cl--coupled creatine transporter (Gonzalez and Uhl, 1994; Happe and Murrin, 1995). The
molecular basis of the sodium independent, low-affinity choline transporter in several cell types has not been
identified yet as well as the molecular identity of the BBB choline transporter.
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The present study was undertaken to investigate the functional characteristics of the BBB choline transport.
These studies will include the sodium dependence, the kinetic parameters and the inhibitory potency of
several substances. Furthermore the molecular identity of a putative choline transporter expressed at the
BBB should be confined.
2. Materials and Methods
2.1. Materials
2.1.1. Substances
Alanine 3-Aminopropionic acid Sigma
Arginine Sigma
BCH 2-Endo-aminobicyclo-(2.2.1)heptane-2-
carboxylic acid
Sigma
C2H5OH Ethanol Fisher, Merck, Riedel-
deHaen
C3H7OH Isopropanol; 2-Propanol Fisher, Fluka
C3H8O3 Glycerol Sigma
C4H4KNaO6 Na+-K+-tartate Fisher
C4H9OH 1-Butanol; Butyl alcohol Merck
C6H12O6 Glucose Sigma, Merck
C6H5Na3O7 Sodium citrate Fisher
CaCl2 x 2 H2O Potassium chloride-dihydrate Sigma, Merck
Carnitine 1-Propanaminium-3-carboxy-2-hydroxy-
N,N,N-trimethyl hydroxide; ß-Hydroxy-y-
trimethylaminobutyric acid
Sigma
CH3COOH Acetic acid VEB Laborchemie Apolda
CH3COONa Sodium acetate Fisher
CH3NO Formamide Sigma
CHCl3 Chloroform Fisher
Choline (2-Hydroxy-ethyl)-trimethyl-ammonium
chloride
Sigma
Choline chloride [2-Hydroxyethyl]trimethylammonium Sigma
Citalopram 1-[(3-Dimethylamino)propyl]-1-(p-
fluorophenyl)-5-phtalancarbonitrile
H.Lundbeck A/S. 2500
K∅ benhavn-Valby
Clomipramine 3-Chloro-10,11-dihydro-N,N-diethyl-5H-
dibenz[b,f]azepine-5-propanamine
Sigma
Colchicine N-(5,6,7,9-Tetrahydro-1,2,3,10-
tetramethoxy-9-oxobenzo[a]heptalen-7-yl)-
acetamide
Sigma
Creatine Sigma
CuSO4 Copper-II-sulfate Fisher
DEPC Diethyl polycarbonate Sigma
Dextran Sigma
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Dopamine 3,4-Dihydroxyphenylethylamine,
Hydroxytyramine
Sigma, RBI
EDTA Ethylenediaminetetraacetic acid Roth
Ficoll (copolymer of sucrose and epichlorohydrin)
Fluoxetine N-Methyl-γ-[4-(trifluoromethyl)phenoxy]-
benzenepropanamine)
Sigma, Niedenthal/Lilly
GBR 12909 1-[2-[bis(4-Fluorophenyl)methoxy]ethyl]-4-[3-
phenylpropyl]piperazin
RBI
Glutamate 2-Aminopentanedioic acid Sigma
Glutamine 2-Aminoglutaramic acid Sigma
Glycine Aminoacetic acid Sigma
HCl Hydrochloric acid Merck
HCOH Formaldehyde Sigma
Hemicholinium-3 2,2’-[4,4’-Biphenylene]-bis-[2-hydroxy-4,4-
dimethylmorpholinium bromide]
Sigma
HEPES 4-[2-Hydroxyethyl]-N’-2-piperazin-ethane-
sulfonic acid
USB, Boehringer Mannheim
KCl Potassium chloride Fisher, Merck
Ketanserintartate 3-[2-[4-(4-Fluorobenzoyl)-1-piperdinyl]ethyl]-
2,4(1H,3H)-quinazolinedion tartate
RBI
KH2PO4 Potassium dihydrogen phosphate Merck
L-DOPA L-ß-3,4-Dihydroxyphenylalanine; L-3-
Hydroxytyrosine
Sigma
Leucine 2-Amino-4-methylpentanoic acid Sigma
LiCl Lithium chloride Serva
MeAIB 2-(Methylamino)isobytric acid Sigma
MES 2-[N-Morpholino]ethanesulfonic acid USB, Sigma
MgCl2 x 6 H2O Magnesium chloride-hexahydrate Fisher, Roth
MgSO4 x 6 H2O Magnesium sulfate-hexahydrate Merck
MOPS 3-[N-morpholino] propansulfonic acid Sigma
MPP 1-Methyl-4-phenylpyridinium Sigma
MPTP 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine Sigma
Na2CO3 Sodium carbonate Fisher
Na2HPO4 Disodium hydrogen phosphate Merck
NaCl Sodium chloride Sigma, Riedel-deHaen
NaH2PO4 x H2O Sodium dihydrogenphosphate-monohydrate Merck
NaHCO3 Sodium bicarbonate Merck
NaOH Sodium hydroxide Merck
Nisoxetine (±)-γ-(2-Methoxyphenoxy)-N-methyl-
benzenepropanamine
Sigma, RBI
NMDG N-methyl-D-glucamine chloride Sigma
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Noradrenaline Arterenol, 1-[3,4-Dihydroxyphenyl]-2-
aminoethanol
Sigma
Ornithine 2,5-diaminopentanoic acid Sigma
Ouabaine G-Strophanthin, 1ß-3ß,5α,11α,14,19-Hexa-
hydroxy-5ß-card-20[22]-enolide3-[6-deoxy]-
α-L-mannopyranoside
Sigma
Pargyline N-Methyl-N-2-propargylbenzylamine Sigma
Paroxetine (-)-Trans-4-(p-fluorophenyl)-3-[(3,4-
(methylenedioxy)phenoxy)methyl]-piperidine
Sigma, SmithKline Beecham
Pharmacueticals
Percoll (Polyvinylpyrrolidon coated silicondioxide) Sigma
Phenylalanine 2-Amino-3-phenylpropanoic acid Sigma
Polyvinylpyrrolidone Sigma
Procainamide Sigma
Quinidine 6’-Methoxy- cinchonan-9-ol Sigma
Reserpine Methyl-reserpate-3,4,5-trimethoxybenzoic-
acid-ester 
Sigma, AWD
SDS Sodium dodecyl sulfate Sigma
Serotonin 5-Hydroxytryptamine Sigma, Fluka
TEA Tetraethylammonium Research Biochemicals
International, Natrick, MA,
USA
Tetrabenazine 9,10-Dimethoxy-1,3,4,6,7,11b-hexahydro-3-
isobutyl-2H-benzo[a]chinolizin-2-on
Fluka
TMA Tetramethylammonium Research Biochemicals
International, Natrick, MA,
USA
TRIS Tris-[hydroxymethyl]amino-methane USB, Sigma
Tryptophan 2-Amino-3-indolepropionic acid Sigma
Verapamil 5-[N-(3,4,-Dimethoxyphenylethyl)-
methylamino]-2-(3,4-demethoxyphenyl)-2-
isopropyl-valeronitrile
Sigma
2.1.2. Proteins
bFGF Basic fibroblast growth factor Boehringer Mannheim
Bovine serum albumin Sigma
Collagenase/Dispase (von V.alginolyticus, B. polymyxa) Boehrinnger Mannheim
Dispase (von B. polymyxa) Boehrinnger Mannheim
Fetal calf serum Gibco, Sigma
Human serum albumin Germed, Institut für Impfstoffe
Dessau
Rat tail collagen Boehringer Mannheim
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Salmon sperm Sigma
Trypsin Gibco, Serva
2.1.3. Antibiotics
Amphotericin Boehringer Mannheim
Chloramphenicol Sigma
Geneticin Boehringer Mannheim, ICN
Gentamicin Gibco, Boehringer Mannheim
Penicillin/Streptomycin Sigma
2.1.4. Media
α-MEM Gibco
BME Sigma
DMEM Gibco, Sigma
HAM´s F10 Gibco, Sigma
M 199 Sigma
Opti-MEM Gibco
RPMI Gibco, Sigma
2.1.5. Szintillation fluids
Szintillation fluid Fisher
Szintillator „LSC ULTIMA GOLD“ Packard
2.1.6. Radiotracers
[14C]TEA [Ethyl-1-14C]tetraethylammonium
bromide
American Radiolabeled chemicals
[18F]FDG [18F]Fluorodesoxyglucose PET Zentrum, FZ Rossendorf
[3H]Choline [Methyl-3H]choline chloride American Radiolabeled chemicals
[3H]Serotonin [3H]-5-Hydroxytryptamine Amersham, American
Radiolabeled chemicals
[99mTc]MiBi Tetrakis[2-methoxy-2-methylpropaniso-
cyanid-] kupfer -[1+]-tetrafluoroborat
Du Pont
[α- 32P]dCTP Deoxycytidine 5’-triphosphate, [α-32P] Amersham Pharmacia
Acetyl-L-[3H]carnitine Acetyl-L-[3H]–carnitine Moravek Biochemical, Brea, CA.
L-[3H]Arginine L-[2.3.4.5-3H]Arginine
monohydrochloride
Amersham Pharmacia
L-[3H]Carnitine L-[Methyl-3H]–carnitine hydrochloride Moravek Biochemical, Brea, CA.
L-[3H]Trypthophan L-[3H]Typtophan American Radiolabeled chemicals
Propionyl-L-[3H]carnitine Propionyl-L-[3H]–carnitine Moravek Biochemical, Brea, CA.
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2.1.7. Kits, solutions, materials
Agarose Gibco, Sigma
ExpressHyb hybridization solution ClonTec Laboratories, Inc.
Hybond nylon transfer membranes Amersham Pharmacia
LB Agar Gibco
LB broth base Gibco
Lipofectin Gibco
Magna nitrocellulose transfer membranes Micron Separations, Inc., Western, MA, USA
Magna nylon transfer membranes Micron Separations, Inc., Western, MA, USA
Oligo(dT) cellulose Gibco
pGEM®-T and pGEM®-T Easy vector systems Promega
ProbeQuantTM G-50 microcolums Amersham Pharmacia
Protein determination kit by Lowry Sigma
QIAEX II gel extraction kit Qiagene
Ready-to-GOTM oligo labeling kit Amersham Pharmacia
Restriction enzymes Promega
RT-PCT kit Perkin Elmer
SuperScriptTM plasmid system Gibco
Trizol reagent Gibco
Wizard midipreps Promega
Wizard minipreps Promega
2.1.8. Primers
The primers were obtained from the Molecular Biology Core Laboratory at the Medical College of Georgia;
Augusta, USA.
2.1.9. Cells
Fibroblasts V79 Hamster lung fibroblasts Max-Delbrück Zentrum, Berlin
HeLa Human cervix carcinoma American Type Culture Collection, Rockville, MD, USA
JAR Human placental
choriocarcinoma
American Type Culture Collection, Rockville, MD, USA
RBE4 Rat brain endothelium F. Roux, INSERM, Paris, Frankreich
2.1.10. Equipment
24 well multi well plates Fisher, Sarstedt
24 well multi well plates Cell++ Sarstedt
Agar plates Fisher
Cell counting Neubauer-Zählkammern, Blau Brand
Centrifuges Janetzki T5; Beckman; Sigma 2K15
Electrophoresis BIO-RAD Laboratories
Flasks 75 cm2, 150 cm2 Fisher, Sarstedt, Corning
Gamma counter Cobra II, Packard
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GeneAmp PCR systems 2400 Perkin Elmer
Hood (horizontal) Jouan; Baker Company Inc.
Hood (vertical) VEB Elektromat Dresden
Incubator (bacterias) Fisher Scientific
Incubator (mammalian cells) Forma Scientific; Jouan
Microscopes Olympus
Petri dishes Fisher, Sarstedt, Greiner
pH meter Fisher
Pipetting support Pipetus akku; Fisher
Protein determination Anthos HT II, anthos labtec instruments
Scintillation counter J2-Mi and J2 HS, Beckman; TriCarb 2100 TR, Packard
Ultracentrifuges KR 22, Jouan; Beckman
UV linker UV Stratalinker 1800, Stratagene
2.2. Buffers
PBS- -
2.7 mM KCl
1.5 mM KH2PO4
137 mM NaCl
7.3 mM Na2HPO4 bzw. Na2HPO4 x 2 H2O
pH 7.4
stored sterile at 4°C
PBS + +
2.7 mM KCl
1.5 mM KH2PO4
137 mM NaCl
7.3 mM Na2HPO4 bzw. Na2HPO4 x 2 H2O
0.5 mM MgCl2  x 6 H2O
0.9 mM CaCl2 x 2 H2O
pH 7.4
stored sterile at 4°C
Earle’s buffer
117 mM NaCl
5.4 mM KCl
1.2 mM CaCl2 x 2 H2O
1 mM MgSO4 x 7 H2O
1 mM NaH2PO4 x H2O
26 mM NaHCO3
5 mM Glucose
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pH 7.4
stored sterile at 4°C
Trypsin-EDTA solution
0.05 % Trypsin
0.025 % EDTA
in PBS- - solved
stored sterile at -20°C
Krebs-Ringer buffer (buffer 1)
10 mM HEPES
122 mM NaCl
3.0 mM KCl
1.2 mM CaCl2 x 2 H2O
1.2 mM MgSO4
25.0 mM NaHCO3
0.4 mM KH2PO4
5 mM Glucose
pH 7.4
stored sterile at 4°C
Buffer 2
122 mM NaCl or LiCl
5.0 mM KCl
1.2 mM CaCl2 x 2 H2O
1.2 mM MgSO4
10.0 mM Na2HPO4 NaH2PO4
10 mM Glucose
pH 7.4
stored sterile at 4°C
Uptake buffer
140 mM NaCl
5.4 mM KCl
1.8 mM CaCl2
0.8 mM MgSO4
5 mM Glucose
NaCl was replaced by NMDG in some experiments
25 mM Tris (HEPES added)
pH 5.5 to 8.5
fresh made at the day of the experiments
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1 x SSPE buffer
0.15 M NaCl
10 mM NaH2PO4
1 mM EDTA
pH 7.4
stored sterile at room temperature
1 x SSC buffer
0.15 NaCl
15 mM C6H5Na3O7
pH 7.0
stored sterile at room temperature
Wash solution 1
2 x SSC
0.05% SDS
stored sterile at room temperature
Wash solution 2
0.1 x SSC
0.1% SDS
stored sterile at room temperature
1 x Denhardt’s solution
0.02% Ficoll
0.02% Polyvinylpyrrolidone
0.02% bovine serum albumin
stored sterile at –20°C
High salt buffer
0.5 M NaCl
10 mM Tris, pH 7.5
1.0 mM EDTA
0.5% SDS
stored sterile at room temperature
Low salt buffer
10 mM Tris, pH 7.5
1.0 mM EDTA
0.2% SDS
stored sterile at room temperature
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2.3. Methods
2.3.1. Cell culture
2.3.1.1. Preparations
2.3.1.1.1. Primary endothelial cells
Primary cultures of porcine brain microvessel endothelial cells were obtained according to Mischeck et al.
(1989). Pig brains were obtained from the slaughterhouse and transported in ice cold PBS++. In the lab they
were cleaned of meninges, white matter and larger blood vessels. The brains were minced and incubated for
3 h at 37°C in medium 199 containing 0.8 % dispase, 200 µg/l streptomycin, 200000 U/l penicillin and 5 mg/l
amphotericin with continuously stirring. Then the solution was mixed 1 : 1.5 with 15% dextran in Earles buffer
and centrifuged at 6800 x g for 10 min at 4°C. The isolated capillaries were obtained as a pellet at the bottom
of the bottle. Then the pellet was dissolved in medium 199 without serum and digested with 0.1 %
collagenase/dispase for 3 h at 37°C with continuously stirring. After digestion the endothelial cells were
collected by centrifugation at 330 x g for 10 min at room temperature. The pellet was resuspended in
medium 199 containing 200 µg/l streptomycin, 200000 U/l penicillin and 5 mg/l amphotericin. Endothelial
cells were separated from erythrocytes and cell debris by a Percoll gradient (density 1.08 and 1.04 g/cm3)
and centrifugation of the gradient at 980 x g for 10 min at room temperature. The layer between the two
gradients was collected in medium 199 with 10% FCS, 100 µg/l Streptomycin, 100000 U/l Penicillin and 2.5
mg/l amphotericin. Resuspended cells were seeded on collagen coated petri dishes with a density of 1-2 x
104 cells/cm² or stored in cryo vials in medium 199 with 20 FCS and 10 % DMSO in liquid nitrogen.
2.3.1.1.2. Collagen coating
Rat tail collagen (10 mg) was dissolved in sterile 0.2% acetic acid to a final concentration of 2 mg/ml and
kept at 4°C until needed. For coating flasks the collagen solution was diluted 1:10 in sterile PBS++. This
solution was filled into the flasks in an amount of about 2.5 µg collagen/cm3 and the flasks were shaken until
the whole bottom was covered by the collagen solution. Then the flasks were kept in the laminar box for at
least 1 hour with loosed caps. Later the solution was removed and the flasks were washed three times with
PBS++. It was allowed to store the flasks at 4°C with PBS++ covering the bottom of the flasks and closed caps
until use.
2.3.1.2. Culture of the cell lines
2.3.1.2.1. Primary endothelial cells from pig brain
The cells were prepared from pig brain as described above (2.3.1.1.1.). These cells had to be freshly seeded
for each experiment. The culture of the cells was done in medium 199 with 10% fetal calf serum, 100 U/ml
penicillin, 100 µg/ ml streptomycin and 2.5 µg/ml amphotericin at 37 °C with 5 % CO2. The medium was
changed every second day.
2.3.1.2.2. RBE4 cells
The RBE4 cells were prepared from second-passage rat brain endothelial cell primary cultures by
transfection with the plasmid pE1A neo, which carries the entire E1A region of adenovirus 2 conferring
immortalization without oncogenic transformation, and the neo gene for resistance to the aminoglycoside
G418 (geneticin) (Durieu-Trautmann et al. 1993, Roux et al. 1993, 1994). The cells were seeded in a density
of 1-2 x 104 cells/cm2, either (a) in culture flasks coated with collagen or (b) in 24-well Cell+-plates ® without
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collagen. The cells were grown in humidified 5% CO2/95% air at 37oC in culture medium consisting of α-
minimal essential medium (α-MEM)/Ham's F10 (1:1 vol./vol.), supplemented with 2 mmol/L glutamine, 10%
heat-inactivated fetal bovine serum (FBS), 1 ng/ml of basic fibroblast growth factor (bFGF) and 300 µg/ml of
geneticin (G418). In the 24-well cell culture plates the cells reached confluence after 2 - 3 days. The
experiments were conducted at confluence with cell densities between 105 - 106 cells per well (equivalent to
about 100-150 µg protein).
2.3.1.2.3. Fibroblast cells
Hamster lung fibroblasts V79 were seeded in a density of 103-104 cells/cm2 in flasks for stem culture and in
uncoated 24-well plates for the experiments. The culture of the cells was performed in RPMI 1640 medium
with 10% fetal bovine serum, 100000U/l penicillin and 100 mg/l streptomycin in an atmosphere containing
5% CO2 at 37oC for 46-48 h before starting the experiments.
2.3.1.2.4. JAR cells
JAR cells are human choriocarcinoma cells and were cultured in RPMI-1640 medium supplemented with 10
% fetal bovine serum, 100000 units/l penicillin and 100 mg/l streptomycin at 37°C in humidified atmosphere
with 5% CO2. Confluent stock cultures were treated with trypsin in the presence of EDTA and the released
cells were seeded in a density of 150000 cells/cm2 in 24 well plates for the experiments. The culture medium
was replaced with fresh medium on the following day and the cells were used for uptake measurements one
day later.
2.3.1.2.5. HeLa cells
The HeLa cells are human cervix carcinoma cells and were grown in DMEM medium without glutamine
supplemented with 10% FBS , 100000 units/l penicillin, 100 mg/l streptomycin and 1% glutamine. They were
grown in a humidified atmosphere with 5% CO2 at 37°C. For the experiments the cells were seeded in a
density of 0.05 x 106 cells per well in 24 well plates and used at about 0.1 x 106 cells per well after one day.
2.3.2. Biochemical methods
2.3.2.1. Uptake studies
Uptake studies with various radiotracers were performed to study the functional expression of transport
systems at the brain endothelium. The transport buffer was Krebs-Ringer solution supplemented with 0.5%
serum albumine for the experiments done with [3H]serotonin and uptake buffer supplemented with 0.5%
serum albumine for all other experiments with radiotracers. All uptake studies were performed at room
temperature except for the determination of the temperature dependence and the studies with L-
[3H]carnitine, its esters, [14C]TEA and L-[3H]arginine which were done at 37°C.
At the beginning of each experiment the culture medium was removed from all wells of the 24-well multi
plate. If a pre-incubation protocol was used 1 ml buffer with or without (as a control) a inhibitor was filled into
each well. After preincubation the buffer was removed and the incubation was started with 0.25 ml buffer
containing the radiotracer (50 nM [3H]serotonin, 20 nM [3H]choline, 20 µM [14C]TEA, 20 nM L-[3H]carnitine or
it’s acyl- and propionylesters, 37 nM L-[3H]arginine with 20 µM cold L-arginine, 50 nM L-[3H]tryptophan) with
or without inhibitor placed into each well. Various times of incubation were chosen for the study of the time
dependence of each radiotracer. The saturation analyses were carried out in the presence of various
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concentrations of unlabeled tracer (see results and legends of the figures) and a constant concentration of
the labeled radiotracer. When the influence of the pH on the transport was investigated, transport buffers
with different pH were prepared by varying the concentrations of TRIS, HEPES and MES. For the
investigations of the sodium dependence of the [3H]serotonin the uptake buffer 2 was used. Sodium chloride
in the uptake buffer was replaced by lithium chloride and the buffers were prepared as shown in Tab. 1. For
all other radiotracers the sodium dependence was studied using uptake buffer with NMDG instead of
sodium. At the end of the incubation period the uptake was terminated by aspiration of the uptake buffer
followed by three washes with 1 ml ice-cold phosphate buffered solution. For the determination of the
radioactivity in the cells and the protein determination the cell suspension was handled in two different ways:
(a) 0.5 ml Lowry reagent was added to the adherent cells and 0.350 ml of this solution was filled into vials
containing 4 ml scintillation cocktail. The radioactivity (dpm) in each vial was measured with a TriCarb. Two
aliquots of this solution of 0.05 ml each were used for the determination of the protein content. (b) The cells
were solubilized in 0.5 ml of 1% SDS in 0.2 M NaOH. The solution in each well was transferred to a vial
containing scintillation cocktail and the radioactivity was measured by a scintillation counter from Beckman.
One well per plate was used for protein determination only.
Uptake studies with transfected cells were carried out at room temperature with uptake buffer without
albumin. The uptake time was always 30 minutes and the whole solubilized cell solution was transferred to a
scintillation vial. No protein determination was necessary because the amount of cells in one well was
determined before starting the uptake study.
Tab. 1 Composition of buffer 2 for the different sodium concentrations in the experiment.
[NaCl] in the experiment Buffer 2 with NaCl Buffer 2 with LiCl or choline Cl
122 mM NaCl whole none
61 mM NaCl ½ vol ½ vol
12.2 mM NaCl 1/10 vol 9/10 vol
without NaCl none whole
2.3.2.2. Protein determination
Protein concentration was determined by the Lowry method (Lowry et al., 1951). Two ways of protein
determination were carried out.
(a) When Lowry reagent from the Sigma kit was added to the cells two aliquots of 0.05 ml of the solubilized
cells from each well were transferred to a 96-microtiter plate. Also the protein standards of serum bovine
albumin dissolved in Lowry reagent were used on each 96 microtiter plate in 4 different concentrations(400
µg/ml, 160 µg/ml, 80 µg/ml and 40 µg/ml). As a blank 0.05 ml Lowry reagent alone was used. To each
sample, standard or blank 150 µl Lowry reagent was added and mixed for 10 minutes. Then 70 µl of folin
reagent was added to each well and the plate was incubated for 30 minutes with continuous shaking.
Colorimetric reading was made at 620 nm. Using the values obtained from the standards and the blank the
protein content in each sample well was estimated (Fig 1).
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Fig. 1 Calibration curve for
protein determination by
Lowry et al. (1951). The
extinction of protein standards
was determined at 620 nm.
(b) One well per plate of cells solubilized in 0.5 ml of 1% SDS in 0.2 M NaOH was used for the determination
of the protein content. Reaction buffer was prepared by mixing 1 volume of 1%CuSO4, 1 volume of 2% Na-K-
tartate and 100 volumes of 2% Na2CO3 in 0.1 N NaOH. Protein samples were used at a volume of 0.2 ml
which made it possible to have duplicates of each 0.5 ml protein sample. Also 0.2 ml of 1% SDS in 0.2 M
NaOH were used as blank. All samples and the blank were then adjusted to a volume of 1 ml and 5 ml
reaction buffer was added. The mix was well shaken and incubated for 10 minutes at room temperature.
Then 0.5 ml of 1 N folin phenol reagent was added to each sample and the blank and incubation was
continued after well shaking for 30 minutes. The colorimetric reading was made at 660 nm. A standard
curve, constructed by using serum bovine albumin and stored as a calibration file in the colorimeter, was
used to determine the protein content of the samples.
2.3.3. Methods of molecular biology
2.3.3.1. Preparation of total RNA
Total RNA from tissues like rat brain, rat kidney and rat placenta and RBE4 cells was prepared using Trizol
Reagent according to the protocol supplied by the manufacturer. Tissue samples were solubilized in Trizol
Reagent (1 ml/50 – 100 mg tissue) using a Polytron homogenizer. The homogenate was stored at room
temperature for 5 minutes. Cultured cells grown in 150 cm2 flasks were washed twice with ice cold PBS
prepared in DEPC-treated water before lysis with 15 ml Trizol Reagent (1 ml/10 cm2) under continuos
shaking. The lysate was passed at least 10 times through a 10 ml pipette and the homogenized samples
were incubated at room temperature for 5 min to permit the complete dissociation of the nucleoprotein
complexes.
The homogenate was mixed with chloroform (0.2 ml/1 ml Trizol Reagent) and shaken vigorously for 15
seconds. The mixture was stored at room temperature for 15 minutes followed by a centrifugation at 12,000
x g for 15 minutes at 4°C. The upper aqueous phase was transferred into a fresh tube and the RNA was
precipitated with isopropanol (0.5 ml/1 ml Trizol Reagent). The sample was stored at room temperature for
10 minutes and then centrifuged at 12,000 x g for 10 minutes at 4°C. The RNA pellet was washed with 75%
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ethanol (at least 1 ml/1ml Trizol reagent) by vortexing and centrifugation at 7,500 x g for 5 min at 4°C. Finally
the RNA pellet was air-dried and resuspended in RNAse free water.
2.3.3.2. Isolation of Poly(A)+RNA
For isolation of poly(A)+RNA the total RNA dissolved in water was supplemented by NaCl solution to a final
concentration of NaCl of 0.5 M. Then the total RNA was loaded on a oligo(dt)cellulose column. The eluate of
non bound RNA was reapplied 5 times. The column was washed with high salt buffer (10 ml, 5 ml, 5ml)
followed by eluating the poly(A)+RNA with pre warmed (50°C) low salt buffer (4 x 1ml). The sodium
concentration of the poly(A)+RNA eluate was adjusted to 0.5 M NaCl and the column was washed twice with
10 ml high salt buffer. Thereafter the poly(A)+RNA eluate was 5 times reapplied to the column. The column
was then washed with high salt buffer (10 ml, 5 ml, 5ml) and poly(A)+RNA was eluted with pre-warmed low
salt buffer (50°C, 4 times 0.5 ml). After 10 min of centrifugation at 600 x g the solution containing the
poly(A)+RNA was transferred to a fresh tube and 15% sodium acetate was added to the solution. Then
ethanol (2 – 2.5 times) was added to the solution and the tube was stored for at least 1 hour at –70°C. After
30 min centrifugation at 12,000 x g and 4°C the supernatant was discarded and the pellet was dissolved in
75% ethanol. This mixture was centrifuged at 12,000 x g and 4°C for 30 min. After centrifugation the
supernatant was discarded and the pellet was dried at 37°C for 10 to 15 minutes. Finally the pellet was
dissolved in RNAse free water and the concentration of RNA was determined.
2.3.3.3. Construction of the cDNA library of RBE4 cells
The RBE4 cell cDNA library was constructed with the SuperScriptTM plasmid system using poly(A)+RNA
isolated from confluent cultures of RBE4 cells. In the first strand synthesis reaction, a modified oligo(dT)
primer adapter containing a Not1 site was used. The following second strand synthesis included the addition
of Sal1 adapters. Then the cDNA was digested with Not1 to generate cDNA with Not1 and Sal1 termini for
unidirectional cloning. Prior to ligation to Not1/Sal1-digested pSPORT vector, double-stranded cDNA was
size fractionated by sephacryl chromatography. Fractions containing cDNA of size larger than 1 kb were
used for library construction. Vector-ligated cDNA was introduced into DH10B competent cells by
electroporation. The titer of the electroporated cells was determined and 40,000 – 50,000 cells per plate
were seeded on agar plates supplemented with ampicillin. Prints of these library plates were made with
nylon or nitrocellulose transfer membranes (depending on the availability of the membranes at the time of
the cDNA library construction) and used for screening or kept at –80°C for storage of the cDNA library.
2.3.3.4. Screening of the cDNA libraries
The plasmid cDNA library, grown on nylon or nitrocellulose transfer membranes, was screened by the colony
screening method as described by Vogeli and Kaytes (1987). Appropriate cDNA probes (Tab. 2) were
labeled with [α-32P]dCTP using the Ready-to-Go™ oligolabeling kit. Purification of the labeled probes was
made with ProbeQuantTM G-50 microcolumns,. The probes were then used to screen the RBE4 cDNA
library. Hybridization was carried out at 65°C in a solution containing 5 x SSPE buffer, 5 x Denhardt’s
solution, 0.5% SDS, and 100 µg/ml of denaturated salmon sperm DNA for 24 h. Post-hybridization washing
was done at low stringency conditions several times with 3 x SSPE buffer, 0.5% SDS at room temperature
for 30 minutes. Positive clones were identified and the colonies purified by secondary screening.
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cDNA probes for library screening were obtained using cDNA clones kindly provided by X. Wu, Augusta or
cDNA obtained from RT-PCR. 10 µg of plasmid cDNA was digested with appropriate restriction enzymes for
about 5 hours. The cDNA fragments were separated on 1% agarose gel by electrophoresis in 1 x TEA
buffer. The appropriate size fragment was cut from the gel and was purified with QIAEX II gel extraction kit.
Probes derived from RT-PCR were run on a 1% agarose gel by electrophoresis in 1 x TEA. The expected
cDNA band was cut from the gel and was purified with QIAEX II gel extraction kit.
Tab. 2 Probes used for RBE4 cell cDNA library screening
Probe origin                 Plasmid vector                          Size                                Restriction enzymes
rOCT1 pSPORT 1.6 kb SalI / StyI
rOCT2 pSPORT 1.2 kb StyI
rOCT3 pSPORT 1.2 kb ApaI / NcoI / KpnI
rOCTN2 pSPORT 2.1 kb Pst1
CHT1  - (PCR)*  - *  - *
rLAT1 pSPORT 1.6 kb EagI / SacII
rcat1 pGEM-T Easy (PCR) 1.2 kb EcoRI
Thiamine pSPORT 1.8 kb DraIII / SalI
rSERT pGEM-T (PCR) 0.6 kb SacII / SpeI
* this screening including the preparation of the probe was made by R. George; Augusta
2.3.3.5. DNA sequencing
Sequencing of the cDNA subcloned from RT-PCR or obtained by library screening was done with the T7 or
SP6 primers. Sequencing by the dideoxynucleotide chain termination method was performed by Taq
DyeDeoxy terminator cycle sequencing with an automated Perkin-Elmer Applied Biosystems 377 Prism DNA
Sequencer. Database searches were done using the GenBank program BLAST.
2.3.3.6. Functional expression of OCTN2 cDNA in HeLa cells
The cDNA was functionally expressed in HeLa cells by the vaccinia virus expression system (Ramamoorthy
et al. 1994; Blakely et al. 1991b). The cDNA cloned into the pSPORT vector has such an orientation that the
cDNA is under the control of the T7 promoter in the plasmid. Subconfluent HeLa cells (100,000 – 200,000
per well of a 24-well plate) were first infected with the recombinant vaccinia virus (VTF7-3) encoding T7 RNA
polymerase, at 10 plaque-forming units per cell. Thirty minutes following the virus infection, the cells were
transfected in the presence of Lipofectin, with pSPORT-OCTN2 cDNA isolated from the RBE4 cell cDNA
library. Transport measurements were performed 12 h post-transfection at room temperature for 30 minutes
using 20 nM L-[3H]carnitine and uptake buffer. The tracer uptake was terminated by aspiration of the uptake
buffer followed by two washes with ice-cold uptake buffer. Following this the cells were solubilized with 0.5
ml of 1% SDS in 0.2 NaOH and transferred to vials for quantification of the radioactivity associated with the
cells. Nonspecific transport was assessed in parallel transfections with the empty plasmid vector.
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2.3.3.7. Reverse transkriptase-polymerase chain reaction (RT-PCR) analysis
2.3.3.7.1. RT-PCR with specific primers
Poly(A)+RNA was prepared as described above or using the poly(A)+RNA isolation kit from Invitrogen. The
primer pairs used in the RT-PCR were designed based on the nucleotide sequences of the transporters as
shown in Tab. 3. For designing the primers the computer program Oligo 6.13, Molecular Biology Insighs,
Inc., Cascade, CO, USA was used.
Tab. 3 Primer pairs used for the RT-PCR and expected size of the PCR products.
Transporter Sense/antisense primers Annealing
temperature
Size
(bp)
Reference
rSERT 5‘ CATCTGGAAAGGCGTCAAAAC 3’/
5‘ ACGATGAGCACGAACCATTC 3‘
55°C 600 bp Hoffman et
al., 1991
rOCTN2 5‘ CCT TCA TTT CGG GAC AGC 3’/
5‘ GAC AGG ACT TCT CGG TGG 3‘
55°C 1342 bp Wu et al.,
1999
rOCT1 5‘ TGC AGA CAG GTT TGG CCG TAA 3‘/
5‘ TCG AGG CCG CTA TTG GGT AGA 3‘
60.1°C 722 bp Gründemann
et al., 1994
rOCT2 5‘ GCT GGT TAA TTG GCT ACA TCC 3‘/
5‘ TCC TTG GCC TCT GCA TAT TC 3‘
56.1°C 960 bp Okuda et al.,
1996
rOCT3 5‘ CCA CCA TCG TCA GCC AGT TT 3‘/
5‘ ACA CGA CAC CCC TGC CAC TA 3‘
57.8°C 851 bp Kekuda et
al., 1998
rLAT1 5‘ GGG CTG TGT GCG GCG TCT 3‘/
5‘ CCA GAA GGA CAC GGC GAT GAG 3‘
60.9°C 1103 bp Kanai et al.,
1998
mLAT2 5‘ GAT GAA GCC CAC ATA GTT GAT 3‘/
5‘ CCG CTC TTC CCT ACC TG 3‘
56.5°C 738 bp Rossier et
al., 1999
rcat1 5’ GGT CCT GCC ATC GTC ATC 3’/
5’ TCT CGG CTG CTG GTA AAA 3’
56.5°C 1219 bp Aulak et al.,
1996
rcat1 5‘ CCC GCT GCC TCA ACA CCT AT 3‘/
5‘ ATG CAG TCA AAG CCC ACG AAG 3‘
59.2°C 715 bp Aulak et al.,
1996
The following amplification conditions were used: 1 minute denaturation at 95ºC, annealing 1 – 1.5 minutes
at the specific temperature for the primer pair and synthesis 1 - 2 minutes at 72ºC, 35 cycles. The RT-PCR
reaction of the RBE4 cell poly(A)+RNA without the reverse transcriptase was used as the negative control.
Poly(A+)RNA from rat placenta was used as a positive control (Shearman et. al, 1998) for the serotonin
transporter. For the OCTN2 transporter poly(A)+RNA from rat kidney was used as control (Wu et al., 1999).
As a positive control for the organic cation transporters OCT1, OCT2 and OCT3 we used poly(A)+RNA from
rat kidney. For the cat1 transporter poly(A)+RNA from rat brain was used as a positive control (Stoll et al.,
1993). The PCR products were separated on 1.0% agarose gel containing ethidium bromide and examined
in ultraviolet light. DNA ladder was run on the same agarose gel to determine the length of the PCR
products.
The 600 bp RT-PCR product from the RBE4 cells was subcloned into pGEM-T vector (Promega) for
sequence analysis. Sequence comparisons were made using the GCG sequence analysis software package
GCG version 7.B (Genetics Computer Group, Inc., Madison, WI, USA).
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2.3.3.7.2. RT-PCR with degenerated primers
An alignment of the amino acid sequences of the following transporters was performed: rOCTN1, hOCTN1
(Tamai et al., 1997), rOCTN2 (Wu et al., 1999), hOCTN2 (Tamai et al., 1998), mOCT3 (Verhaagh et al.,
1999), rOCT3 (Kekuda et al., 1998), hOCT3 (Gründemann et al., 1998b), mOCT1 (Schweifer and Barlow,
1996), rOCT1(Gründemann et al., 1994), hOCT1 (Zhang et al., 1997), rOCT2 (Okuda et al., 1996), mOCT2
(Mooslehner and Allen, 1999), hOCT2 (Gorboulev et al., 1997). Areas with high homology were selected and
a sequence of six amino acids was used to design the primers. Degenerated primers based on all codons for
the selected amino acids were made (Tab. 4). One primer contains the “neutral base” inosine (5) at a
position where all four bases appear in the same position of the codons for the amino acid. By pairing in an
equivalent fashion with all four conventional bases, inosine neither confers stability on double-stranded
helices nor detracts from it (Martin et al., 1985). The following amplification conditions were used: 1 min
denaturation at 95ºC, annealing 2 min at a temperature between 56°C and 50°C, synthesis 2 min at 72ºC, 35
cycles. As a positive control mRNA from rat kidney was used.
Also degenerated primers as described by Kusuhara et al. (1999) for organic anion transporters (Tab. 4)
were synthesized. The following amplification conditions were used 95°C for 1 minute, 49°C for 1 minute,
and 72°C for 1 minute, 40 cycles. All PCR products were run on 1% agarose gels with DNA ladder as a
control for the size of the bands.
Tab. 4 Degenerated primers used for RT-PCR with Poly(A)+RNA derived from RBE4 cells and rat kidney.
PESPRW.up 5’ CCD GAR WSB CCD CGY TGG 3’
AELYPT.down 5’ NGT HGG RTA VAG YTC NGC 3’
aELYPT.down 5’    GT HGG RTA VAG YTC 5GC 3’
DRFGRK.up 5’ GAY CGY TTY GGB CGY AAR 3’
dANION.up 5’ TYM YWG ART CHS CMC GST GG 3’
dANION.down 5’AKS AMW GTR GGG TAC ARC TC 3’
The primers pairs during the RT-PCR were:
DRFGRK.up and AELYPT.down
DRFGRK.up and aELPYT.down
PESPRW.up and AELYPT.down
PESPRW.up and aELYPT.down
dANION.up and dANION.down.
2.3.3.8. Northern blot analysis
Poly(A)+RNA isolated from various rat tissues (kidney, placenta, brain, liver) and the cell line RBE4 was used
in Northern blot analysis.
An amount of 5 µg of poly(A)+RNA of each sample was size-fractionated by electrophoresis in 1%
fromaldehyde-agarose gel and subsequently capillary transferred onto a Hybond nylon membrane for 24
hours. After the RNA was UV-crosslinked to the nylon membrane the blot was treated in one of two different
manners.
25
(a) Prehybridization with hybridization solution (50% formamide, 5 x Denhardt’s solution, 2% SDS, 5 x
SSPE, 100 µ/ml salmon sperm) for northern blots was done for at least 6 hours at 42°C and hybridization
with the same hybridization solution substituted by the radiolabeled probe was done for at least 16 hours
at 42°C. The membranes were probed with the same probes also used for cDNA library screening and
with human ß-actin cDNA by sequential hybridization. The probes were labeled with [α-32P]dCTP using
the Ready-to-GoTM oligolabeling kit from Pharmacia. Washing was done twice in 3 x SSPE buffer/ 0.5%
SDS at room temperature for 15 minutes and twice in 0.5 x SSPE buffer/ 0.5% SDS at 65°C for 30
minutes. For ß-actin probes, the last washing was done in 0.1 x SSPE buffer/ 0.1% SDS at 65°C.
(b) When ExpressHyb solution was used for Northern blotting, prehybridization of the membrane was
carried out in a minimum of 5 ml of this solution with continuous shaking at 68°C for 30 minutes. The
denatured radiolabeled probe was added to 5 ml of fresh ExpressHyb solution and mixed well.
Hybridization of the membrane was done at 68°C for 1 hour with continuous shaking. The membrane
was then washed with wash solution 1 at room temperature for 40 minutes. In that time the wash
solution was replaced several times. The Northern blot was rinsed in wash solution 2 at 50°C for 40
minutes with continuous shaking.
After the washing procedure the blot was removed and excess wash solution was drained. The blot was then
covered with plastic wrap immediately and exposed to a X-ray film at –70°C.
2.3.4. Statistics
Each experimental point was determined at least in triplicates and each experiment was repeated at least
once. The results were expressed as means ± SEM from. Statistical significance was determined by the
Student’s test. The symbols for the significance p were used as followed:
* p < 0.05
** p < 0.01
*** p < 0.001
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3. Results
The present study was performed to determine the expression of several transport systems at the BBB. The
further purpose of such studies is the use of existing transporters systems of the BBB to transport drugs that
have been specially designed to allow transport through the BBB (Tsuji and Tamai, 1999). For the studies of
the BBB transport systems immortalized rat brain endothelial cells (RBE4) were used as an in vitro model of
the BBB.
The strategy in this study can be described in three steps:
1) The cells were studied in order to determine the best time for the experiments during the cell growth
which is commonly the case when the cells reach confluence. Also the influence of the experimental
conditions such as buffers and temperature on the vitality of the cells were determined using
radiolabeled tracers suitable for this purpose.
2) Two sodium independent amino acid transport systems (system L and system y+), which are already
characterized at several in vivo and in vitro models of the BBB, were functionally characterized and their
molecular identity in the RBE4 cells was shown in order to proof the suitability of this in vitro model of the
BBB for transporter studies.
3) The uptake of 5-HT, L-carnitine and choline has been described but not fully characterized at the BBB so
far. Therefore, the uptake of these compounds will be functional characterized and the molecular identity
of the responsible transporter protein was tried to determine.
3.1. In vitro model of the BBB, RBE4 cells
The studies were performed using an immortalized rat cerebral endothelial cell line (RBE4). Cell lines have
the advantage that there is no need of animals or expensive preparation of primary cell cultures and the cells
are not contaminated with other cells (pericytes, smooth muscle). The RBE4 cell line has recently been
established and provides an in vitro model of the BBB (Roux et al. 1994). The RBE4 cells represent a
nontransformed phenotype, since they do not induce any tumor, when injected in athymic nude mice.
Moreover the cells show characteristics very similar to primary cultures of cerebral endothelial cells such as
the expression of the specific endothelial markers γ-glutamyltransferase (γ-GT) and alkaline phosphatase
(ALP). Furthermore the expression and functional characterization of the glucose transporter GLUT1 and of
the efflux-pump P-glycoprotein (P-gp), i.e. transporters which are known to be present at the BBB, has been
shown in the RBE4 cells (Regina et al. 1997, 1998; Begley et al., 1996; ElHafny et al., 1997 a/b). Control
experiments to study the usefulness of the in vitro model under the present conditions were performed with
the RBE4 cells. The cells were usually grown in collagen coated 75 flasks and seeded on 24 cell++-well
plates for the experiments.
3.1.1. Growth curve of the RBE4 cells
Uptake studies with adherent cell cultures are commonly done on confluent monolayers. Such monolayers
consist of a single layer of cells which guarantees, in contrast to multi-layer cell cultures, the access of the
incubation medium to each single cell.
The standard format of a culture cycle of cells begins with a lag phase, proceeds through the logarithmic
phase to a stationary phase and finalizes in a decline and the death of cells (Freshney, 1992). To maintain
reproductive conditions during the different experiments the cells had to be in the logarithmic phase at the
time of the experiment. During the logarithmic phase the cells have a constant proliferation, the population of
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the cells is uniform and the vitality of the cells remains high (Freshney, 1990). The cells of different days of
seeding should behave similar during this growth phase. These are the best conditions to obtain comparable
results within different experiments with the cells. To determine the time when the cells were in the
logarithmic phase, the growth of the RBE4 cells in our laboratory was studied.
To obtain a growth curve, the RBE4 cells were cultured on collagen coated Ø 60 mm dishes (Fig 2). The
cells were seeded in a density of 0.01 * 106 cells/cm2 and each day two dishes were used for cell counting in
Neubauer counting chambers.
When the RBE4 cells were seeded as described by Roux et al. (1994) they reach confluence after 4 days of
culture. Then the cells were still in logarithmic growth. Because of the three dimensional growing of the
RBE4 cells the didn’t reach a plateau phase where they would decrease proliferation. After about six days of
culture the cells grew in several layers one upon the other. Therefore the upper layers of the cells flow off
when they were rinsed with buffer which leads to the plateau phase shown in Fig. 2.
Fig. 2 Growth curve of RBE4 cells on collagen coated dishes. The cells were seeded in a density of 0.01*
106 cells/cm2. Results are given as the amount of cells per 60 Ø mm dish versus the day of culture. Data are
means ± SEM, n = 8.
3.1.2. Vitality of the RBE4 cells during the experiments
During the experiments the RBE4 cells were incubated in Krebs-Ringer buffer or uptake buffer. To determine
if the cells are still in a healthy condition during the incubation period, vitality tests were performed. There are
various methods which are useful to determine the vitality of cells. In this study, the uptake of [99mTc]MiBi or
[18F]FDG into the cells over a time period was examined.
3.1.2.1. [99mTc]MiBi uptake in RBE4 cells
The fundamental cellular mechanism of uptake and retention of [99mTc]MiBi, a positively charged lipophilic
molecule, involves nonmediated diffusion across both plasma and mitochondrial membranes in response to
large negative transmembrane potentials, thereby favoring mitochondrial localization of this agent (Chiu et
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al., 1990; Maffioli et al., 1996). Only membranes and mitochondria of healthy cells maintain a proton gradient
with the negative charge at the inside of the cell membrane. Consequently the positively charged MiBi
molecules concentrate in the cytosolic fraction of the cells including the mitochondria (Chiu et al., 1990;
Carvalho et al., 1992). [99mTc]MiBi is therefore suitable as an indicator of the vitality of the cells.
It is known that P-glycoprotein (P-gp), an energy dependent efflux-pump, is present at the microvascular
endothelial cells of the brain, including RBE4 cells (Regina et al., 1998; Begley et al., 1996) and that
[99mTc]MiBi is one of the substrates of the P-gp (Piwnica-Worms et al., 1993). Therefore the accumulation of
[99mTc]MiBi in RBE4 was between 20% and 40% higher in the presence of verapamil, due to the inhibition of
the efflux pump P-gp (Fig. 3).
The accumulation of [99mTc]MiBi in the RBE4 cells was linear over a time period of 60 minutes (Fig. 3).
Verapamil increased the [99mTc]MiBi uptake inside the cells. At 4°C only a small amount of [99mTc]MiBi went
into the cells. This amount consisted of passive diffusion with no concentration of [99mTc]MiBi inside of the
cell membrane because of a membrane gradient.
Fig. 3 Determination of the MiBi uptake in RBE4 cells as a vitality test. After preincubation for 10 minutes in
the presence (circles) or absence (triangles) of 50 µM verapamil the uptake of [99mTc]MiBi was measured in
confluent RBE4 cells incubated for various time periods between 5 minutes and 60 minutes in Krebs-Ringer
buffer (pH 7.5) at room temperature (filled symbols) or at 4°C (open symbols). The results are given as
percent uptake of the [99mTc]MiBi doses applied to each well per mg of protein. Data are means ± SEM,
n = 2 – 6.
3.1.2.2. [18F]FDG uptake in RBE4 cells
Another radiotracer which accumulates in healthy cells is [18F]fluorodeoxyglucose (FDG). This tracer passes
through the cell membrane of cerebral microvessel endothelial cells by facilitated diffusion. The carrier called
GLUT1 is a sodium independent glucose transporter, selectively expressed at the BBB (Pardridge et al.,
1990) and therefore also found in the RBE4 cells (Regina et al., 1997). Within the cells [18F]FDG, as an
glucose analogue, is metabolized only in the first step of the glycolysis and remains trapped within the cells
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as [18F]FDG-6-phosphate due to the fact that the molecule is now charged and cannot pass anymore the cell
membrane (Visser, 2001).
RBE4 cells take up [18F]FDG in a linear manner over a time period of 120 min (Fig. 4). At 4°C only 6% to
15% of the [18F]FDG uptake at room temperature is taken up by the RBE4 cells. No cellular metabolism of
glucose should take place at 4°C and therefore no trapping of metabolized [18F]FDG takes place in the cells
at this temperature.
Both uptake studies with [99mTc]MiBi and with [18F]FDG have shown that RBE4 cells stay in a healthy state in
Krebs-Ringer buffer at pH 7.4 at room temperature for at least up to 120 minutes.
Fig. 4 Determination of the FDG uptake of the RBE4 cells as a vitality test. After preincubation for 10 minutes
the uptake of [18F]FDG was measured in confluent RBE4 cells incubated for various time periods between 10
minutes and 120 minutes in Krebs-Ringer buffer (pH 7.5) at room temperature (filled circles) or at 4°C (open
circles). The results are given as percent uptake of the [18F]FDG doses applied to each well per mg of
protein. Data are means ± SEM, n = 4.
3.2. Transporter studies at RBE4 cells
To manifest if the cell culture model of the RBE4 cells is an suitable tool for transporter studies two
transporters known to be expressed at the BBB were first examined at this in vitro model. Amino acid
transporters are well known to be present at the BBB (Pardridge, 1983). A well characterized transporter at
the BBB is the system L which is an transporter for large neutral amino acid like tryptophan and leucine
(Hargreaves and Pardridge, 1988; Miller et al., 1985). Another transport system, specific for cationic amino
acids, is system y+ which has been shown to be expressed at the BBB (Stoll et al., 1993). System L and
system y+ are functionally well characterized and molecularly identified and will therefore serve as indicators
that the RBE4 are functionally active and are comparable to endothelial cells forming the BBB.
The uptake of 5-HT, L-carnitine and choline has been described but not fully characterized at the BBB. The
presence of a 5-HT transporter at the BBB was suggested after demonstration of specific binding of
[3H]imipramine and [3H]paroxetine to isolated microvessels of porcine brain (Brust et al. 1995, 1996a). Both
radioligands label the neuronal 5-HT transporter (Langer et al. 1980, Habert et al. 1985). The transport of
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carnitine has been studied at RBE4 cells and at primary cultures of endothelial capillary cells derived from
porcine brain cells and this transport was found to be abluminally sodium independent and luminally
influenced by sodium transport inhibitors (Mroczkowska et al., 1996, 1997). In addition a high-affinity, sodium
dependent carnitine transporter (OCTN2) has recently been cloned and functionally characterized (Sekine et
al., 1998a; Wu et al., 1998; Tamai et al., 1998). While the present study was done the functional
characteristic of the BBB carnitine transport was not completely known and no molecular basis was reported.
Previous studies have demonstrated the presence of a carrier-mediated process for the entry of choline
across the endothelial cell layer of the BBB (Cornford et al., 1978; Shimon et al., 1988; Mooradian, 1988;
Estrada et al., 1990; Galea and Estrada, 1992). There are controversies concerning sodium dependence
and affinity. Furthermore the molecular basis of the choline transporter at the BBB remained unknown.
Therefore, it was the aim of the present study, to characterize the uptake of 5-HT, L-carnitine and choline
into the RBE4 cells functionally and to identify the structure of the responsible transporter protein.
3.2.1. Large neutral amino acid transporter, system L, LAT1 and LAT2 in RBE4 cells
The major route of neutral amino acids through the BBB is proposed to be mediated by the system L
(Pardridge, 1977; Pardridge and Choi, 1986; Audus and Borchardt, 1986). This transport system was
designated as LAT by Christensen et al. (1994). The system L belongs to the group of the heterodimeric
amino acid transporters which consists of two subunits, a light and a heavy chain (Wagner et al., 2001). The
heavy chain subunit (4F2hc) of the system L was previously identified as a surface antigen (Haynes et al.,
1981; Hemler and Strominger, 1982). Kanai et al. (1998) have first cloned LAT1, representing a light chain of
system L. LAT1 furthermore is reported to be a subunit of the System L at the BBB (Boado et al., 1999;
Prasad et al., 1999; Matsuo et al., 2000). While the present study was done LAT2, a second light chain of
the system L, was cloned (Segawa et al., 1999). At the time of the experiments it was not known whether or
not LAT2 is present at the BBB.
3.2.1.1. L-[3H]Tryptophan uptake in RBE4 cells
The transport studies of the L-[3H]tryptophan uptake in RBE4 cells were carried out in uptake buffer (pH 7.4)
at room temperature. The uptake of L-[3H]tryptophan in RBE4 cells was linear over time up to 10 minutes
(Fig. 5). Therefore the uptake measurement in further studies were performed for a time period of 5 min. The
kinetic analysis of L-tryptophan uptake was studied with 50 nM of L-[3H]tryptophan and different
concentrations of unlabeled tryptophan ranging from 0.05 µM to 1 mM. As a result of the kinetic analysis we
have obtained the Michaelis-Menten constants for the L-tryptophan transport into RBE4 cells by nonlinear
regression of the uptake data. The data were, therefore, analyzed by fitting them to the following equation:
V =
Vmax * S
+ KD * S
Kt + S
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where V is the uptake rate, S is the concentration of L-tryptophan, Vmax is the maximal velocity for the
saturable component, Kt is the Michaelis-Menten constant, and KD in the rate constant for the diffusional
component. Fig. 6 shows that the transport of L-tryptophan into the cells had a saturable and a non-saturable
component. For the saturable component the half-saturation constant Kt of 31.31 ± 0.23 µM and the
transport capacity Vmax of 1.071 ± 0.003 nmol/mg/min have been determined.
Fig. 5 Time course of the L-tryptophan uptake in RBE4 cells. The uptake of L-[3H]tryptophan (50 nM) was
measured in confluent RBE4 cells incubated for various time periods between 0.5 minutes and 10 minutes in
the presence (open circles) or absence (filled circles) of 500 µM L-tryptophan in uptake buffer pH (7.5) at
room temperature. The specific transport (filled triangles) was calculated by subtracting the uptake in the
presence of 500 µm from the L-[3H]tryptophan uptake without an inhibitor. Data are means ± SEM, n = 3 - 4.
The system L of the BBB is described as a sodium independent, bidirectional and, therefore, an equilibrative
transport system (Hargreaves and Pardridge, 1988; Miller et al., 1985; Audus and Borchardt, 1986). The
synthetic amino acid 2-aminobicyclo[2.2.1]heptane-2-carboxylic acid (BCH) was found to be specific for the
system L (Christensen et al., 1967). whereas α-[methylamino]isobutyric acid (MeAIB) is described as an
specific inhibitor for the A system with no influence on the system L (Christensen et al., 1969). Uptake
studies were performed in a sodium containing uptake buffer and in uptake buffer where NMDG is replacing
sodium. Thus the influence of sodium and specific system L and A inhibitors on the L-[3H]tryptophan uptake
into RBE4 cells was determined (Fig 7). It could be shown that the uptake of L-[3H]tryptophan was sodium
independent and that the specific system L inhibitor BCH clearly decreases the tracer uptake into the RBE4
cells in sodium containing uptake buffer by about 87% while MeAIB, an inhibitor of system A, was without
effect. These features characterize the transport of L-[3H]tryptophan as primarily system L mediated.
However, a small part of about 8% seemed to be sodium dependent because replacement of NaCl by
NMDG significantly (p < 0.05) reduced the uptake of L-[3H] tryptophan. Also L-tryptophan showed a
significantly (p < 0.01) stronger inhibition than BCH at similar affinities of those two amino acids (Sanchez del
Pino et al., 1995) The difference between the BCH (1 mM) inhibited L-[3H]tryptophan uptake and the uptake
inhibited by 1 mM tryptophan was about 43% in sodium containing as well as in sodium free uptake buffer.
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Fig. 6 Saturation kinetic analysis of the L-tryptophan uptake in RBE4 cells. The uptake of L-[3H]tryptophan
(50 nM) was measured in confluent RBE4 cells incubated for 5 minutes in uptake buffer (pH 7.5) at room
temperature. Unlabeled L-tryptophan was added at various concentrations between 0.05 and 1000 µM. The
saturable uptake (filled circles) was calculated by subtracting the nonsaturable uptake (open triangles) from
the whole uptake (open circles) of L-tryptophan in RBE4 cells. The results are given as whole L-tryptophan
uptake versus the whole L-tryptophan concentration. Data are means ± SEM, n = 6.
Fig. 7 Inhibition of L-tryptophan uptake in RBE4 cells by unlabeled tryptophan and synthetic amino acids.
The uptake of L-[3H]tryptophan (50 nM) was measured in confluent RBE4 cells incubated for 5 minutes either
in the absence (control) or in the presence of an inhibitor (1 mM) in uptake buffer pH (7.5) at room
temperature. The buffer contained sodium (filled bars) or isoosmotical replacement of sodium by NMDG
(open bars). Data are means ± SEM, n = 5 – 6.
* - p < 0.05, *** - p < 0.001 vs. Sodium containing buffer; ++ - p < 0.01 vs. BCH
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Fig. 8 Inhibition of L-tryptophan uptake in RBE4 cells by various amino acids. The uptake of L-[3H]tryptophan
(50 nM) was measured in confluent RBE4 cells for 5 minutes either in the absence (control) or in the
presence of various amino acids (1 mM) incubated in uptake buffer (pH 7.5) at room temperature. The
results are given as percent of control L-[3H]tryptophan uptake measured in the absence of inhibitors (0.85 ±
0.14 pmol/mg/min). Data are means ± SEM, n = 5 – 6.
Several large neutral amino acids like tryptophan, leucine, phenylalanine and L-DOPA (L-3.4-
dihydroxyphenylalanine) inhibited the L-[3H]tryptophan uptake in RBE4 cells while small neutral amino acids
like glycine and alanine or acidic amino acids (glutamate) did not (Fig. 8).
3.2.1.2. LAT1 and LAT2 expression in RBE4 cells
Kanai et al. (1998) have cloned a protein from rat C6 glioma cells which mediates the Na+-independent
transport of neutral amino acids when it is coexpressed in Xenopus laevis oocytes with the heavy chain of
the 4F2 antigen (CD98). This protein, designated rLAT1, is not capable to transport amino acid on its own.
But as a heterodimer with the heavy chain of 4F2 antigen (4F2hc), rLAT1 possesses amino acid transport
activity with the characteristic of system L. A closely related protein to LAT1 is LAT2, which shows 50%
identity to LAT1 (Segawa et al., 1999). Co-expressed with the heavy chain of the 4F2 antigen LAT2
expresses a sodium and chloride independent transport of L alpha-amino acids with a broad substrate
selectivity. This transport is inhibited by BCH, indicating that LAT2 is a second isoform of the system L
transporter. In contrast to LAT1, the expression of LAT2 at the BBB was not shown at the time the present
study was made. The presence of the rLAT1 and rLAT2 subunits in the RBE4 cells (Fig. 9) was
demonstrated with RT-PCR. The expression of the system L subunit LAT1 and LAT2 was shown in the
RBE4 cells in comparison to the rat brain. The PCR products of 1103 bp (LAT1) and 738 bp (LAT2) were
specifically digested by BamH1 to confirm them as parts of the LAT1 and LAT2 cDNA from rat. The expected
fragments after digestion with BamH1 were 804 bp/299 bp and 405 bp/333 bp for LAT1 and LAT2
respectively (Fig 10).
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Fig. 9 RT-PCR with specific primers for the rat LAT1 and rat LAT2 transporter subunit. Poly(A)+RNA
samples, isolated from RBE4 cells (RBE4) and rat brain (RB) as the positive control, were used for the RT-
PCR with the specific primer pairs. The negative control was done with Poly(A)+RNA from RBE4 cells lacking
the reverse transkriptase (w/o RT) during the RT-PCR procedure. The RT-PCR products were size-
fractionated with molecular size-markers run in parallel on a 1% agarose gel.
Fig. 10 Digestion of the RT-PCR products derived with specific primers for the rat LAT1 and LAT2
transporter subunits. Poly(A)+RNA samples, isolated from RBE4 cells (RBE4) and rat brain (RB) as a
positive control, were used for the RT-PCR with specific primer pairs for rat LAT1 and rat LAT2. The
restrictionendonuclease enzyme BamH1 was used for the digestion of the cDNAs. The enzyme digested the
RT-PCR products with the typical pattern 804 bp/299 bp (LAT1) and 405 bp/ 333 bp (LAT2). The cDNA
fragments were-size fractionated with molecular size-markers run in parallel on a 1% agarose gel.
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Fig. 11 Northern blot analysis of
the expression of the subunit
LAT1 large neutral amino acid
transporter in RBE4 cells, rat
kidney and rat brain.
Poly(A)+RNA samples, isolated
from RBE4 cells (RBE4), rat
kidney (RK) and rat brain (RB)
were size-fractionated on a
denaturing formaldehyde-
agarose gel and probed by
sequential hybridization under
high stringency conditions with
[32P]dCTP labeled cDNA
specific for rat LAT1.
To support the results of the RT-PCR for LAT1 a Northern blot was made using mRNA derived from rat
brain, rat kidney and RBE4 cells. In brain and kidney LAT1 is reported to be expressed which make these
tissues useful as a positive control (Prasad et al., 1999; Kanai et al., 1998). The Northern blot analysis
revealed a strong expressing of LAT1 in the rat brain and the endothelial cell line (RBE4) (Fig. 11). In a
smaller amount LAT1 was also expressed in rat kidney.
3.2.2. Cationic amino acid transporter, system y+, cat1 in RBE4 cells
At the rat BBB a sodium independent cationic amino acid transporter is reported (Stoll et al., 1993), the so
called system y+. The cloning of the first cDNA for an cationic amino acid transporter was coincidental with
the cloning of the receptor for the ecotropic retrovirus (ecoR) (Albritton et al., 1989). This viral receptor was
shown to be the cationic amino acid transporter of the system y+ (Wang et al., 1991; Kim et al., 1991) and so
named cat1.
3.2.2.1. L-[3H]Arginine uptake in RBE4 cells
Uptake studies with 3H-labeled arginine showed a sodium independent uptake of the radiotracer into RBE4
cells (Fig. 13). For all uptake studies with L-[3H]arginine the cells were incubated for 5 minutes in uptake
buffer containing 37 nM L-[3H]arginine and 20 µM of unlabeled arginine. Kinetic analysis for the L-arginine
uptake in RBE4 cells was performed using concentrations of unlabeled L-arginine between 20 µM and 5 mM
(Fig. 12). Nonlinear regression analysis of the uptake data revealed a half saturation constant Kt of 55.26 ±
0.37 µM and a maximal velocity of the arginine uptake in RBE4 cells Vmax of 0.559 ± 0.002 nmol/mg/min. To
assess the substrate selectivity of the L-[3H]arginine uptake, inhibition studies with different natural and
synthetic amino acids were performed. The uptake of L-[3H]arginine was significantly decreased (p < 0.001)
by the cationic amino acid ornithine but not by the acidic amino acid glutamate (Fig. 13). The system L
inhibitor BCH and the system A inhibitor MeAIB did not influence the uptake of L-[3H]arginine into RBE4 cells
(Fig. 13). These results lead to the conclusion that RBE4 cells, as an in vitro model of the BBB do express
the transporter for cationic amino acids named system y+, ecoR or cat1.
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Fig. 12 Saturation kinetic analysis of the L-arginine uptake in RBE4 cells. The uptake of L-[3H]arginine (0.5
µCi/ well) was measured in confluent RBE4 cells incubated for 5 minutes in uptake buffer (pH 7.5) at 37°C
containing additional 20 µM unlabeled arginine. Furthermore unlabeled L-arginine was added at various L-
arginine concentrations between 20.037 µM and 5 mM. The saturable uptake (filled circles) was calculated
by subtracting the nonsaturable uptake (open triangles) from the whole uptake (open circles) of L-arginine in
RBE4 cells. The results are given as whole L-arginine uptake versus the whole L-arginine concentration.
Data are means ± SEM, n = 3 – 6.
Fig. 13 Inhibition of L-arginine uptake in RBE4 cells by natural and synthetic amino acids and influence of
sodium ions on the L-arginine uptake. The uptake of L-[3H]arginine (37 nM) was measured in confluent
RBE4 cells incubated for 5 minutes in uptake buffer( pH 7.5) at 37°C. The buffer contained sodium (control,
amino acids) or isoosmotical replacement of sodium by NMDG (w/o Na+) and additional 20 µM unlabeled L-
arginine. The results are given as percent of control L-[3H]arginine uptake measured in the absence of
inhibitors (20.7 ± 4.1 pmol/mg of protein/min). Data are means ± SEM, n = 5 – 6.
*** - p < 0.001 vs. control
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3.2.2.2. cat1 expression in RBE4 cells
The expression of cat1 in the RBE4 cells was examined by RT-PCR with specific primers of the rat cat1
transporter (Aulak et al., 1996). Two different primer pairs were used to obtain RT-PCR products of the sizes
1219 bp (Fig 14A) and 715 bp (Fig. 14B). As positive controls served mRNA from rat placenta (Kamath et al.,
1999) or rat brain (Kim et al., 1991; Aulak et al., 1996). The existence of the cat1 mRNA in all three samples
could be demonstrated. The experiment shown in figure 14B also contained a lane lacking the enzyme
reverse transkriptase during the RT-PCR procedure to exclude genomic contamination of the RBE4 cell
mRNA. The larger RT-PCR product derived from RBE4 cells (Fig. 14A) was subcloned into the pGEM-T
vector, transformed in DH-5alpha and subsequently partially sequenced (Fig. 15). The sequenced part of the
RT-PCR product derived from RBE4 cells showed 99% homology to the known rcat1 transporter (Aulak et
al., 1996). The smaller RT-PCR product with a size of 715 bp derived from RBE4 cell mRNA (Fig. 14B) was
digested by the restrictionsendonuclease enzymes Hpa1 and Sac1. After digestion the obtained bands
showed a specific digestion pattern of the used enzymes for the rcat1 transporter (451 bp/264 bp for Hpa1
and 477 bp/238 bp for Sac1) (Fig. 16).
The Northern blot analysis showed a strong expression of cat1 in rat brain, a medium expression of the
transporter in rat kidney and also a weak signal for cat1 in RBE4 cells (Fig. 17).
Fig. 14 RT-PCR with specific primers for the rat cat1 transporter. Poly(A)+RNA samples, isolated from RBE4
cells (RBE4) and as positive controls: A - rat placenta (RP), B - rat brain (RB), were used for the RT-PCR
with the specific primer pairs. The negative control was done with Poly(A)+RNA from RBE4 cells lacking the
reverse transkriptase (w/o RT) during the RT-PCR procedure. (A) Used primer pair is 5’ GGT CCT GCC ATC
GTC ATC 3’/ 5’ TCT CGG CTG CTG GTA AAA 3’ for the upper and lower primer respectively. (B) Used
primer pair is 5’ CCC GCT GCC TCA ACA CCT AT 3’/5’ ATG CAG TCA AAG CCC ACG AAG 3’ for the
upper and lower primer respectively. The RT-PCR products were size-fractionated with molecular size-
markers run in parallel on a 1% agarose gel.
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RBE4: 65   tggtcctgccatcgtcatctccttcctgatcgctgctcttgcctcagtgctggccggcct 124
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
rcat1: 265 tggtcctgccatcgtcatctccttcctgatcgctgctcttgcctcagtgctggccggcct 324
RBE4: 125  gtgctatggcgagtttggtgcccgtgtccccaagacgggctcagcctacctctacagcta 184
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
rcat1: 325 gtgctatggcgagtttggtgcccgtgtccccaagacgggctcagcctacctctacagcta 384
RBE4: 185  tgtgacagtgggggagctctgggccttcatcactggctggaacctgattctctcctacat 244
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
rcat1: 385 tgtgacagtgggggagctctgggccttcatcactggctggaacctgattctctcctacat 444
RBE4: 245  catcggtacatccagcgtggcaagagcctggagtgcaacttttgacgagctgataggcaa 304
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
rcat1: 445 catcggtacatccagcgtggcaagagcctggagtgcaacttttgacgagctgataggcaa 504
RBE4: 305  acccatcggagagttctcgcgtcaacacatggccctgaacgcccctggggtgctggccca 364
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
rcat1: 505 acccatcggagagttctcgcgtcaacacatggccctgaacgcccctggggtgctggccca 564
RBE4: 365  aaccccggatatatttgctgtgattataattatcatcctgacaggactgttaactctcgg 424
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
rcat1: 565 aaccccggatatatttgctgtgattataattatcatcctgacaggactgttaactctcgg 624
RBE4: 425  tgtgaaagaatcagccatggtcaacaaaatcttcacctgtatcaatgtcctggtcttgtg 484
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
rcat1: 625 tgtgaaagaatcagccatggtcaacaaaatcttcacctgtatcaatgtcctggtcttgtg 684
RBE4: 485  cttcatcatggtgtcgggattcgtgaaaggctccattgagaactggcagctcacgganga 544
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||| ||
rcat1: 685 cttcatcatggtgtcgggattcgtgaaaggctccattgagaactggcagctcacgga-ga 743
RBE4: 545  ataaatccagtcctctctgtgggaacaattgacacanacgtgaaatacggtgaagggaag 604
           |||||||||||||||||||||||||||| ||||||| ||||||||||||||| ||||| |
rcat1: 744 ataaatccagtcctctctgtgggaacaa-tgacacaaacgtgaaatacggtg-agggagg 801
RBE4: 605  gttcatgccctttggattctctggtgtcctgtcagggggcagcgacctgcttttatgcct 664
           |||||||||||||||||||||||||||||||||| |||||||||||||||||||||||||
rcat1: 802 gttcatgccctttggattctctggtgtcctgtca-ggggcagcgacctgcttttatgcct 860
RBE4: 665  tcgtgggctttgactgcatcgccaccacaggggaagaagtcangaaacccccagaaggnc 724
           |||||||||||||||||||||||||||||||||||||||||| | ||||||||||||| |
rcat1: 861 tcgtgggctttgactgcatcgccaccacaggggaagaagtcaag-aacccccagaaggcc 919
RBE4: 725  attcctgtgggcat 738
           ||||||||||||||
rcat1: 920 attcctgtgggcat 933
Fig. 15 Alignment of the partially cDNA sequence obtained by subcloning of the 1219 bp product from the
RT-PCR with mRNA from RBE4 cells with the nucleotide sequence of the cat1 transporter (Aulak et al.,
1996). The sequences show 99% homology.
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Fig. 16 Digestion of the 715 bp RT-PCR products derived with specific primers for the rat cat1 transporter.
Poly(A)+RNA samples, isolated from RBE4 cells (RBE4) and rat brain (RB) as a positive control, were used
for the RT-PCR with the specific primer pair. Restrictionendonuclease enzymes Hpa1 and Sac1 were used
for the digestion of the cDNAs. The enzymes digested the RT-PCR products with the typical pattern for rat
cat1 451 bp/264 bp (Hpa1) and 477 bp/ 238 bp (Sac1). The cDNA fragments were size-fractionated with
molecular size-markers run in parallel on a 1% agarose gel.
Fig. 17 Northern blot analysis of
the expression of cationic amino
acid transporter (cat1) in RBE4
cells, rat kidney and rat brain.
Poly(A)+RNA, isolated from
RBE4 cells (RBE4), rat kidney
(RK) and rat brain (RB), were
size-fractionated on a denaturing
fromaldehyde-agarose gel and
probed by sequential
hybridization under high
stringency conditions with
[32P]dCTP labeled cDNA specific
for rat cat1.
To conclude so far, it was shown that the RBE4 cells express the system L with its light chain subunits LAT1
and LAT2. This neutral amino acid transport system was functional characterized by determination of the
uptake of L-tryptophan, an neutral amino acid transported by system L. The results correlate well with the
findings of previous reports about the system L features. Furthermore the sodium independent uptake of L-
arginine into RBE4 cells was shown and its characteristic resemble the cationic amino acid transport system
y+. The expression of the cat1 transporter, one of four isoforms of the system y+, could be shown in the
RBE4 cells. Together these results indicated the suitability of the RBE4 cells as an in vitro model of the BBB
for transporter studies.
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The following transporter studies were performed to investigate transport systems at the BBB, which were
not characterized in detail at the beginning of these studies. Therefore, functional uptake studies of the
corresponding radiolabeled tracers were performed accompanied by investigations of the molecular identity
of the respective transporters.
3.2.3. Serotonin transporter, SERT in RBE4 cells
The sodium dependent serotonin transport in various tissues is described to be inhibited by antidepressants
(Spatz et al., 1981; Ramamoorthy et al., 1993; Faraj et al., 1994). The transporter itself (SERT) was cloned
from rat by Hoffman et. al (1991). At the BBB the presence of a plasma membrane transport system that is
specific for 5-HT has been suggested (Spatz et al. 1981; Brust et al. 1995, 1996a). Some of these authors
have demonstrated that the tricyclic antidepressant [3H]imipramine and the non-tricyclic antidepressant
[3H]paroxetine bind specifically to microvessels of the porcine brain. Both radioligands label the neuronal 5-
HT transporter (Langer et al. 1980; Habert et al. 1985). Therefore the binding of these radiotracers to brain
microvessels indicates the presence of such a transport system at the level of the blood-brain barrier (Brust
et al. 1995, 1996b). Other authors described the uptake and the metabolism of 5-HT in isolated microvessels
and primary endothelial cells (Spatz et al., 1981; Maruki et al., 1984). However, none of these studies
provided clear evidence of the molecular identity extensive enough to fully characterize a specific 5-HT
transporter at the BBB similar to the transport system in the brain (Graham and Langer, 1988).
3.2.3.1. [3H]5-HT uptake in RBE4 cells
Confluent monolayers of RBE4 cells were used to study the specific [3H]5-HT uptake. Fig. 18 shows the time
course of this uptake. The most selective 5-HT uptake inhibitor citalopram (50 µM) (Hyttel et al., 1982;
D’Amato et al., 1987) was used to define the non-specific transport which was subtracted from the total
transport measured at room temperature. The data demonstrate linearity of the serotonin transport at RBE4
cells up to 60 min (p < 0.0001).
Fig. 18 Time course of the 5-HT uptake in RBE4 cells. After preincubation without (filled circles) or with 50
µM citalopram (open circles) for 10 minutes the uptake of [3H]5-HT (50 nM) was measured in confluent RBE4
cells incubated for various time periods between 0.5 minutes and 60 minutes in Krebs-Ringer buffer (pH 7.4)
at room temperature. The specific 5-HT transport (filled triangles) was calculated by subtracting the [3H]5-HT
uptake in the presence of citalopram from the total uptake. Data are means ± SEM, n = 6.
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An incubation time of 10 min was chosen to determine the concentration dependence of the specific 5-HT
uptake (Fig. 19). Saturation of transport was reached at a concentration of about 5 µM. Kinetic analysis of
the uptake data, as computed by non-linear regression analysis yielded a Kt of 0.397 ± 0.064 µM and Vmax of
51.7 ± 3.5 fmol/mg/min.
Fig. 19 Saturation kinetic analysis of the 5-HT uptake in RBE4 cells. The [3H]5-HT (50 nM) uptake was
measured in confluent RBE4 cells incubated for 10 minutes in Krebs-Ringer buffer (pH 7.4) at room
temperature. Unlabeled 5-HT was added at various concentration between 0.05 µM and 5 µM. The graph
represents the specific 5-HT uptake calculated by subtracting the nonsaturable uptake from the whole 5-HT
uptake. Data are means ± SEM, n = 6.
The sodium dependence of the transport was demonstrated by stepwise isoosmotical replacement of NaCl
in the incubate by either lithium or choline chloride (Fig. 20). When NaCl in the uptake buffer was replaced
by lithium chloride, the uptake rates were about 2/3 of the rates in the presence of Na+. The same ratio was
found when a high concentration of citalopram was used to block the [3H]5-HT transport. Interestingly, a
significantly higher uptake inhibition was observed using choline chloride instead of lithium chloride (p <
0.01).
The imbalance of Na+ and K+ across the cell membrane provides a driving force for the uptake of serotonin
(Rudnick, 1977). An energy dependent Na+/K+-ATPase, which is inhibited by ouabain, maintains this
gradient. Preincubation of RBE4 cells with Krebs-Ringer buffer containing 1mM ouabain for at least 1 hour
led to a slight but significant (p < 0.05) decrease of the total [3H]5-HT uptake into the cells (Fig. 21).
Furthermore, it was reported by Nishio et al. (1995; 1996) that the 5-HT uptake in blood platelets can be
reduced by EGTA in the extracellular medium. This effect was only detectable at 37°C. The cells were
incubated in buffer containing Ca2+ chloride and buffer without Ca2+ chloride but supplemented with or
without 1 mM EGTA. RBE4 cells showed the same influence of EGTA on the [3H]5-HT uptake as described
in rabbit blood platelets (Fig. 22). No influence of EGTA or Ca2+ depletion was visible at room temperature
but a significant decrease of the [3H]5-HT uptake of more than 6% in RBE4 cells could be observed at 37°C
in Ca2+ free buffer. An even higher inhibition of 11.8% could be shown in Ca2+ free buffer supplemented with
1 mM EGTA (Fig. 22).
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Fig. 20 Influence of sodium on the 5-HT uptake in RBE4 cells. After Preincubation in buffer with the
equivalent sodium concentration of the incubation for 10 minutes the [3H]5-HT uptake (50 nM) was measured
in confluent RBE4 cells incubated for 60 min in Krebs-Ringer buffer (pH 7.4) at room temperature. The buffer
contained sodium (122 mM) or stepwise isoosmotical replacement of sodium with choline (open bars) or Li+
ions (filled bars). The results are given as percent of control [3H]5-HT uptake measured in the presence of
122 mM sodium (choline 18.0 ± 1.3 fmol/mg of protein/min. Li+ ions 17.5 ± 0.2 fmol/mg of protein/min). Data
are means ± SEM, n = 6 - 12.
*** - p < 0.001 vs. Control (122 mM)
++ - p < 0.01, +++ - p < 0.001 vs. Replacement by Li+ 
Fig. 21 Influence of ouabain on the 5-HT uptake in RBE4 cells. After preincubation in buffer with or without
(control) the corresponding concentration of ouabain for 60 minutes the uptake of [3H]5-HT (50 nM) was
measured in confluent RBE4 cells incubated for 60 minutes in Krebs Ringer buffer (pH 7.4) at room
temperature. Different concentrations of ouabain or no ouabain (control) were used in the incubate. Data are
means ± SEM, n = 6.
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Fig. 22 Influence of extracellular calcium on the 5-HT uptake in RBE4 cells. After preincubation with (1 mM)
or without EGTA (control) and the corresponding buffer for 60 minutes the uptake of [3H]5-HT (50 nM) was
measured in confluent RBE4 cells incubated for 60 minutes in Krebs-Ringer buffer (pH 7.4) with (w calcium)
or without (w/o calcium; EGTA) CaCl2 at 37°C (filled bars) or at room temperature (open bars). Data are
means ± SEM. n = 6 - 12.
** - p < 0.01 vs. Control w calcium
++ - p < 0.01 vs. Control w/o calcium
Furthermore, the ability of various drugs to inhibit the serotonin transport at RBE4 cells was evaluated (Fig
23). The 5-HT uptake inhibitors paroxetine, clomipramine, imipramine, fluoxetine and citalopram were found
to be most potent. Reserpine and tetrabenazine as inhibitors of the vesicular monoamine transporter
(Knepper et al., 1988; Erickson and Eiden, 1993; DaSilva et al., 1994; Yelin and Schuldiner, 1995) did not
affect the [3H]5-HT uptake. Interestingly Ketanserin, a 5-HT2a receptor antagonist showed 19.4% inhibition of
the [3H]5-HT uptake in RBE4 cells. Quinidine is a potassium channel blocker and also an inhibitor of the P-gp
(Jette et al., 1995; Kusuhara et al., 1997). This drug showed a strong inhibition of 32.5% of the [3H]5-HT
uptake in RBE4 cells. Another potent inhibitor of the P-glycoprotein, verapamil (Volm, 1998), elicited a
decrease of the [3H]5-HT uptake which was similar to the effect of citalopram. On the other hand colchicine,
which also inhibits the P-gp (Drion et al., 1996; Begley et al., 1996), did not have any significant effect on the
[3H]5-HT transport in the RBE4 cells. In addition, co-incubation of verapamil and citalopram did not have any
additive inhibitory effect on the [3H]5-HT uptake. That led to the conclusion that the inhibitory effect of
quinidine and verapamil was not due to the effect on the P-gp. Verapamil decreased the [3H]5-HT uptake
also in a human placental choriocarcinoma cell line (JAR) (data not shown). This cell line is known to
express a sodium dependent 5-HT transporter (Ramamoorthy et al., 1993). GBR 12909, which is a powerful
inhibitor for the dopamine transporter (Heikkila and Manzino 1984), inhibited serotonin transport significantly
at RBE4 cells. However, a high concentration dopamine (1 mM) did not affect the [3H]5-HT uptake. Co-
incubation of GBR 12909 with citalopram exhibited no additive effect on the [3H]5-HT uptake. Therefore it
could be concluded that GBR 12909 acted directly at the 5-HT transporter and 5-HT at RBE4 cells was not
additionally transported by a dopamine transporter.
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Fig. 23 Effect of several biogenic amine uptake inhibitors and amines on the  5-HT uptake in RBE4 cells.
After preincubation with or without (control) inhibitors for 10 minutes the [3H]5-HT (50 nM) uptake was
measured in confluent RBE4 cells incubated for 60 minutes in the absence (control) or the presence of
biogenic amine uptake inhibitors in Krebs-Ringer buffer (pH 7.4) at room temperature. The results are given
as percent of control [3H]5-HT uptake measured in the absence of inhibitors (67.3 ± 0.2 fmol/mg of
protein/min). Data are means ± SEM, n = 4 - 12.
** - p < 0.01, *** - p < 0.00 vs. Control
The total [3H]5-HT uptake was also compared in different cell types. The V79 cell line from hamster lung
fibroblasts was used as a 5-HT transporter negative cell line. On the other hand the JAR cell line was used
as a positive control. The fibroblast cell line, primary cultures from porcine brain endothelial cells and RBE4
cells were incubated for 10 minutes with [3H]5-HT (Fig. 24). The studies were performed with and without 10
µM citalopram to block the specific uptake. A significant transport inhibition was only observed at porcine
endothelial cells (26% inhibition) and RBE4 cells (30% inhibition). Incubating the cells at 4oC inhibited [3H]5-
HT uptake by 65% (fibroblasts), 51% (primary cells) and 75% (RBE4 cells), respectively. It indicated that a
significant part of the nonspecific uptake was temperature sensitive. The JAR cells and RBE4 cells were
incubated with [3H]5-HT for 5 minutes in Krebs-Ringer buffer (Fig. 25). 10 µM citalopram causes a 42% and
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22% inhibition of the [3H]5-HT uptake in JAR cells and RBE4 cells, respectively. Furthermore JAR cells took
up about 17 times more [3H]5-HT than RBE4 cells.
Fig. 24 Uptake of 5-HT in different cell types. The influence of clomipramine. verapamil and citalopram (all at
10 µM) on the [3H]5-HT uptake was studied. After preincubation in the absence (control) or in the presence
of inhibitors for 10 minutes the [3H]5-HT (50 nM) uptake was measured in confluent cell cultures of
Fibroblasts (open bars), primary porcine endothelial cell (lined bars) and RBE4 cells (filled bars) incubated
for 10 minutes in Krebs-Ringer buffer (pH 7.4) at room temperature and at 4°C. (A) The uptake at 4°C was
subtracted from the uptake at room temperature. (B) Results are given as percent of the control [3H]5-HT
uptake of each cell line calculated from the data above (A). Data are means ± SEM, n = 5 - 6.
** - p < 0.01, *** - p < 0.001 vs. Control
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Fig. 25 Uptake of 5-HT in JAR cells
and RBE4 cells. After preincubation
in the absence (control) or in the
presence of 10 µM citalopram for 5
minutes the [3H]5-HT (50 nM) uptake
was measured in confluent JAR cells
(open bars) and RBE4 cells (filled
bars) incubated for 5 minutes in the
absence (control) or in the presence
of 10 µM citalopram in Krebs-Ringer
buffer (pH 7.4) at room temperature.
Data are means ± SEM, n = 6 - 9.
** - p < 0.01, *** - p < 0.001 vs.
Control
3.2.3.2. SERT expression in RBE4 cells
Using RT-PCR the presence of the serotonin transporter (SERT) mRNA in the immortalized rat brain
endothelial cell line RBE4 was demonstrated as shown in Fig. 26. The RBE4 cell line was compared with rat
placenta as a positive control (Ramamoorthy et al., 1993). The presence of 5-HT transporter mRNA was
demonstrated in both samples. A control lacking the reverse transcriptase enzyme was run in parallel to
monitor for possible genomic contamination. The length of the amplification products was found to be
between the marker for 500 bp and 650 bp which corresponds to the expected length of 600 bp. DNA
sequencing was performed for the RT-PCR product obtained from the RBE4 cells. Sequence identity of 99%
with the cloned rat serotonin transporter (Hoffman et. al., 1991) was observed (Fig. 27).
Fig. 26 RT-PCR with specific
primers for the sodium dependent
rat 5-HT transporter. Poly(A)+RNA,
isolated from RBE4 cells (RBE4)
and from rat placenta (RP) as a
positive control was used. The
negative control was performed
with Poly(A)+RNA from RBE4 cells
lacking the reverse transkriptase
(w/o RT) during the RT-PCR
procedure. The RT-PCR products
were size-fractionated with
molecular size-markers run in
parallel on a 1% agarose gel.
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RBE4: 1    catctggaaaggcgtcaaaacatctggcaaggtggtgtggttgacagccaccttcccata 60
           |||||||||||||||||||||||||||||||||||||||| |||||||||||||||||||
rSERT: 807 catctggaaaggcgtcaaaacatctggcaaggtggtgtgggtgacagccaccttcccata 866
RBE4: 61   cattgtcctctctgtcctgctggtgaggggggccacccttcctggagcctggagaggggt 120
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
rSERT: 867 cattgtcctctctgtcctgctggtgaggggggccacccttcctggagcctggagaggggt 926
RBE4: 121  cgtcttctacttgaaacccaactggcagaaactcttggagacaggggtgtgggtagatgc 180
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
rSERT: 927 cgtcttctacttgaaacccaactggcagaaactcttggagacaggggtgtgggtagatgc 986
RBE4: 181  cgccgctcagatcttcttctctcttggcccgggctttggggttctcctggcttttgctag 240
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
rSERT: 997 cgccgctcagatcttcttctctcttggcccgggctttggggttctcctggcttttgctag 1046
RBE4: 241   ctacaacaagttcaacaacaactgttaccaagatgccctggtgaccagtgtggtgaactg 300
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
rSERT: 1047 ctacaacaagttcaacaacaactgttaccaagatgccctggtgaccagtgtggtgaactg 1106
RBE4: 301   catgacaagcttcgtctctggcttcgtcatcttcacggtgcttggctacatggcggagat 360
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
rSERT: 1107 catgacaagcttcgtctctggcttcgtcatcttcacggtgcttggctacatggcggagat 1166
RBE4: 361   gaggaatgaagatgtgtcagaggtggccaaagacgcaggccccagcctcctcttcatcac 420
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
rSERT: 1167 gaggaatgaagatgtgtcagaggtggccaaagacgcaggccccagcctcctcttcatcac 1226
RBE4:  421  gtacgcagaggcaatagccaacatgccagcatccacgttctttgccatcatcttcttcct 480
            ||| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
rSERT: 1227 gtatgcagaggcaatagccaacatgccagcatccacgttctttgccatcatcttcttcct 1286
RBE4: 481   catgttaatcacgctgggattggacagcacgttcgcaggcctggaaggtgtgatcacagc 540
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
rSERT: 1287 catgttaatcacgctgggattggacagcacgttcgcaggcctggaaggtgtgatcacagc 1346
RBE4: 541   tgtgctggatgagttccctcacatctgggccaagcgcagggaatggttcgtgctcatcga 600
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
rSERT: 1347 tgtgctggatgagttccctcacatctgggccaagcgcagggaatggttcgtgctcatcgt 1406
Fig. 27 Sequence alignment of the cDNA obtained by RT-PCR with mRNA from RBE4 cells with the
nucleotide sequence of the rat SERT (Hoffman et al., 1991). The sequences show 99% identity.
3.2.4. Carnitine transporter/organic cation transporter, OCTN2 in RBE4 cells
It is reported that carnitine is transported at RBE4 cells by a sodium independent transporter, localized at the
abluminal side of the cells (Mroczkowska et al., 1996). The molecular basis of this transporter remained
unknown. Later a sodium dependent carnitine transporter was cloned from human kidney and shown to be
expressed in the brain (Tamai et al., 1998).
The transport of carnitine has been studied at immortalized rat brain endothelial (RBE4) cells and at primary
cultures of endothelial capillary cells derived from porcine brain (Mroczkowska et al., 1996, 1997). In the
latter, evidence for an asymmetrical uptake was found (Mroczkowska et al., 1997). It was suggested that a
novel sodium independent transport system for L-carnitine is present in the apical membrane whereas the
transport across the basolateral membrane, which is diminished by sodium transport inhibitors and amino
acids, may be mediated by amino acid transport system(s). The molecular basis of the L-carnitine transport
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at the BBB remained unknown. Recently a sodium dependent carnitine transporter was cloned from human
kidney, intestine and placenta as well as from rat placenta (Sekine et al., 1998a; Wu et al., 1998; Tamai et
al., 1998). Northern blot analysis of these reports also showed the expression of this transporter in the brain.
The purpose of this study was the functional characterization of the L-carnitine uptake into RBE4 cells as an
in vitro model of the BBB. Furthermore, the molecular basis of this transporter was investigated.
3.2.4.1. L-[3H]Carnitine uptake in RBE4 cells
The transport of L-[3H]carnitine was studied at confluent RBE4 cells grown on 24-well plates. Fig. 28
represents the time course of the L-[3H]carnitine uptake at a concentration of 20 nM. The uptake was
measured at 37°C in uptake buffer (pH 7.4) containing sodium or isoosmotical replacement of sodium ions
by NMDG. Replacement of sodium caused a significant inhibition of the L-[3H]carnitine uptake. The inhibition
was about 68% after 4 h uptake measurement. The difference between the uptake measurements made in
the presence and absence of sodium represents the specific sodium dependent L-[3H]carnitine uptake. As
shown in Fig. 28, the uptake was linear over a time period of 4 h. Subsequent studies were performed with
an incubation time of 60 min.
Fig. 28 Time course of L-carnitine uptake in RBE4 cells. The uptake of L-[3H]carnitine (20 nM) was measured
in confluent RBE4 cells incubated for various time periods between 2.5 minutes and 4 hours in the presence
of sodium(filled circles) or isoosmotical replacement of sodium by NMDG (open circles) in uptake buffer (pH
7.5) at 37°C. The specific sodium dependent L-carnitine transport (filled triangles) was calculated by
subtracting the uptake in the absence of sodium from the L-[3H]carnitine uptake in the presence of sodium in
the buffer. Data are means ± SEM, n = 3 - 4.
For kinetic studies the transport of L-[3H]carnitine at RBE4 cells was measured in the presence of unlabeled
L-carnitine at concentrations between 20 nM and 500 µM. Therewith evidence for the saturability of the
transport process was provided and the kinetic parameters of the L-[3H]carnitine transport process were
determined. Fig. 29 shows the saturation kinetics of the specific L-carnitine uptake in RBE4 cells. The uptake
of L-[3H]carnitine was measured in the presence of different concentrations of unlabeled L-carnitine for 1h at
37°C in sodium-containing buffer at pH 7.4. Kinetic analysis revealed that the uptake was best described by
a single saturable transport system plus a nonsaturable component representing diffusion. Specific uptake,
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shown in Fig. 29, was calculated from the total uptake by subtracting the nonsaturable component obtained
from the fit. The diffusional component determined from this analysis represented 55% of the total transport
at 20 nM carnitine. This value was close to the nonspecific uptake measured in the absence of sodium (45%
at 60 min) (see Fig. 28). This showed that the nonsaturable component represents the sodium independent
uptake of carnitine into the RBE4 cells. The kinetic parameters Vmax and Kt were calculated for the saturable
component. The maximum velocity Vmax was 3.57 ± 0.58 pmol/mg/min and the Kt was 54 ± 10 µM.
Fig. 29 Saturation kinetic analysis of L-carnitine uptake in RBE4 cells. The uptake of L-[3H]carnitine (20 nM)
was measured in confluent RBE4 cells incubated for 60 minutes in the presence of sodium in uptake buffer
(pH 7.5) at 37°C. Unlabeled L-carnitine was added at various concentrations between 20 nM and 500 µM.
The graph represents the saturable L-carnitine transport calculated from the whole uptake of L-carnitine by
subtracting the nonsaturable uptake. Data are means ± SEM, n = 4 - 6.
The sodium dependent carnitine transporter in other cell types is also capable of mediating the transport of
short-chain acyl esters of carnitine in a sodium dependent manner and the transport of the organic cation
TEA in a sodium independent manner (Wu et al., 1999). To assess whether this occurs also in RBE4 cells,
we measured the uptake of L-[3H]carnitine, acetyl-L-[3H]carnitine, propionyl-L-[3H]carnitine, and [14C]TEA in
these cells in the presence and absence of sodium. Fig. 30 shows that the RBE4 cells accumulated acetyl-L-
[3H]carnitine and propionyl-L-[3H]carnitine in a sodium dependent manner. The uptake of the carnitine esters
was significantly higher (p < 0.001) than that of L-[3H]carnitine. Isoosmotical replacement of sodium ions by
NMDG inhibited the uptake of L-[3H]carnitine and its esters by more than 70% (p < 0.001). In contrast, the
uptake of [14C]TEA was not sodium dependent. The uptake of this tracer was significantly higher (p < 0.001)
in sodium-free buffer than in buffer with sodium.
The L-[3H]carnitine uptake was also studied in primary rat brain endothelial cells. The results showed that
similar to RBE4 cells primary rat brain endothelial cells exhibit a sodium dependent L-[3H]carnitine uptake
(Fig 31). The total uptake in the presence of sodium was about 50% higher than that observed in RBE4 cells.
In the absence of sodium it was 33% higher compared to RBE4. The sodium dependent part of the whole L-
[3H]carnitine uptake represented 45% in RBE4 cells and about 40% in primary endothelial cells. In contrast
to the RBE4 cells, in the primary endothelial cells a small part of (about 13%) of the sodium independent L-
[3H]carnitine uptake was inhibited by L-carnitine, TEA and choline (p < 0.05).
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These data strongly suggested that the organic cation/carnitine transporter OCTN2 is functionally expressed
in RBE4 cells. Primary endothelial cells also exhibited a sodium dependent L-[3H]carnitine uptake which was
significantly (p < 0.001) inhibited by L-carnitine and TEA but, in contrast to the RBE4 cells, not by choline.
Fig. 30 Uptake of L-carnitine, carnitine esters and TEA  in RBE4 cells. The uptake of L-[3H]carnitine (20 nM),
acetyl-L-[3H]carnitine (20 nM), propionyl-L-[3H]carnitine (20 nM) and [14C]TEA (20 µM) was measured in
confluent RBE4 cells incubated for 4 hours in the presence of sodium (filled bars) or isoosmotical
replacement of sodium by NMDG (open bars) in uptake buffer (pH 7.5) at 37°C. The results are given as the
percent radiotracer uptake per dose applied to the cells (L-[3H]carnitine: 0.150 ± 0.001 NaCl, 0.066 ± 0.001
NMDG, acetyl-L-[3H]carnitine: 0.229 ± 0.004 NaCl, 0.062 ± 0.001 NMDG, propionyl-L-[3H]carnitine: 0.275 ±
0.005 NaCl, 0.079 ± 0.004 NMDG; values are pmol/mg of protein/h and [14C]TEA: 23.32 ± 0.50 NaCl, 33.16
± 0.82 NMDG, values are nmol/mg of protein/h). Data are means ± SEM, n = 6.
*** - p < 0.001 vs. Control (with sodium); +++ - p < 0.001 vs. L-[3H]carnitine
Fig. 31 L-carnitine uptake in rat primary cerebral endothelial cells. The uptake of L-[3H]carnitine (20 nM) was
measured in confluent rat primary cerebral endothelial cells incubated for 1 hour in the presence of sodium
(filled columns) or isoosmotical replacement of sodium by NMDG (open columns) in uptake buffer (pH 7.5) at
37°C. The uptake of L-[3H]carnitine was inhibited by various organic cations (1 mM). Data are means ± SEM,
n = 3 - 4.
*** - p < 0.001 vs. Control (NaCl); + - p < 0.05, ++ - p < 0.01 vs. Control (NMDG)
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3.2.4.2. OCTN2 expression in RBE4cells
To provide molecular evidence for the expression of OCTN2 in RBE4 cells, RT-PCR was performed (Fig. 32)
with a primer pair specific for rat OCTN2 (Wu et al., 1999). RT-PCR with mRNA from RBE4 cells and from
rat kidney, a positive control for OCTN2 expression, yielded an identical product. The size of the product
(1342 bp) was as expected from the positions of the primers in rat OCTN2. A control lacking the reverse
transcriptase enzyme was run in parallel to monitor for possible genomic DNA contamination in the mRNA
preparation. Furthermore a Northern blot analysis using mRNA from RBE4 cells and rat kidney was
performed (Fig. 33). The radiolabeled 2.1 kb probe was obtained from the cDNA clone from rat kidney (Wu et
al., 1999). As expected OCTN2 is abundantly expressed in rat kidney. A weak expression of the OCTN2
transporter in RBE4 cells was observed.
Fig. 32 RT-PCR with specific primers for the rat OCTN2 transporter. Poly(A)+RNA samples, isolated from
RBE4 cells (RBE4) and rat kidney (RK) as a positive control, were used for RT-PCR. The negative control
was performed with Poly(A)+RNA from RBE4 cells lacking the reverse transkriptase (w/o RT) during the RT-
PCR procedure. The RT-PCR products were size-fractionated with molecular size-markers run in parallel on
a 1% agarose gel.
3.2.4.3. Transfection of HeLa cells with OCTN2 cDNA
To demonstrate the expression of a functional full-length OCTN2 in RBE4 cells, we screened the cDNA
library constructed with mRNA from these cells. Radiolabeled rat OCTN2 cDNA (2.1 kb) was used as probe
for the screening. Several positive clones were identified in the library. The restriction analysis of these
clones revealed that all the clones were related to each other (data not shown), each differing only from the
truncation of variable length at the 5‘ end. The longest clone was selected for functional and structural
analysis. Partial sequencing of the clone (data not shown) confirmed its identity with rat OCTN2. The
function of the clone was assessed by heterologous expression in HeLa cells. The uptake of L-[3H]carnitine 
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Fig. 33 Northern blot analysis of the
expression of the carnitine
transporter/organic cation transporter
(OCTN2) in RBE4 cells and rat kidney.
Poly(A)+RNA, isolated from RBE4 cells
(RBE4) and rat kidney (RK), was size-
fractionated on a denaturing
formaldehyde-agarose gel and probed by
sequential hybridization under high
stringency conditions with [32P]dCTP
labeled cDNA specific for rat OCTN2. 
and [14C]TEA in cells transfected with the cDNA clone was about four- to six-fold higher than in cells
transfected with the pSPORT vector alone (data not shown). Because HeLa cells themselves express a
weak OCTN2 activity (Wu et al., 1998), only the cDNA-specific uptake data are shown in Fig. 34. These data
were derived by subtracting the L-[3H]carnitine uptake in HeLa cells transfected with vector clone from the
uptake in cells transfected with the cDNA. The cDNA-specific L-[3H]carnitine transport was sodium
dependent. The transport was reduced by 80% when sodium was replaced by NMDG. In contrast, the
cDNA-specific [14C]TEA transport was not sodium dependent. In fact, replacement of sodium with NMDG
increased significantly the transport of [14C]TEA mediated by the cDNA.
To study the substrate specificity of the transporter clone isolated from RBE4 cells, three unlabeled organic
cations and unlabeled L-carnitine were used at a concentration of 1 mM in competition experiments with L-
[3H]carnitine (20 nM) and [14C]TEA (20 µM) (Fig. 35). The competition experiments were performed with
HeLa cells expressing the RBE4 OCTN2 cDNA and the uptake of the radiotracers measured in vector-
transfected cells was taken as the endogenous transport activity. Transfection of the cells with the cDNA
increased L-[3H]-carnitine uptake 5-fold compared to vector-transfected cells. TEA and unlabeled L-carnitine
abolished the cDNA-induced uptake of L-[3H]carnitine completely. 1-Methyl-4-phenyl pyridinium (MPP) was
also a very effective inhibitor of cDNA-mediated L-[3H]carnitine uptake (Wu et al., 1999). When [14C]TEA was
used as the substrate for RBE4 OCTN2, the uptake was 2.5-fold higher in cDNA-transfected HeLa cells than
in vector-transfected cells. L-carnitine and unlabeled TEA abolished almost completely the cDNA-induced
uptake of [14C]TEA. This cDNA-mediated [14C]TEA uptake was also very effective inhibited by MPP. Choline
showed a moderate inhibitory effect (17%) on [14C]TEA uptake in transfected HeLa cells whereas L-
[3H]carnitine uptake was inhibited by almost 40%.
R
K
R
B
E4
3.5 kb
53
Fig. 34 Transport of L-carnitine and TEA by OCTN2-cDNA transfected HeLa cells. The cDNA was isolated
by screening the cDNA library of RBE4 cells with a radiolabeled rat OCTN2 probe, The clone was then
functionally expressed in HeLa cells using the vaccina virus technique. The cells were transfected with either
pSPORT vector alone or the rat OCTN2 cDNA. The uptake of L-[3H]carnitine (20 nM) and [14C]TEA (20 µM)
was measured for 30 minutes in uptake buffer (pH 7.5) containing sodium (filled bars) or isoosmotical
replacement of sodium by NMDG (open bars) at room temperature. The uptake in vector transfected cells
was subtracted from the corresponding uptake in cDNA transfected cells to calculate rOCTN2 mediated
uptake. The results are given as the specific L-[3H]carnitine uptake mediated by rOCTN2 cDNA. Data are
means ± SEM, n = 5 - 6.
** - p < 0.01, *** - p < 0.001 vs. NaCl
Fig. 35 Substrate specificity of the transport of L-carnitine and TEA mediated by OCTN2-cDNA transfected
HeLa cells. The cDNA was isolated by screening the cDNA library of RBE4 cells with a radiolabeled rat
OCTN2 probe. The clone was then functionally expressed in HeLa cells using the vaccina virus technique.
The cells were transfected with either pSPORT vector alone or the rat OCTN2 cDNA. The uptake of L-
[3H]carnitine (20 nM) and [14C]TEA (20 µM) was measured for 30 minutes in uptake buffer (pH 7.5)
containing sodium at room temperature. The uptake in rOCTN2 cDNA transfected cells was inhibited by
various organic cations (1 mM). Results are given as the L-[3H]carnitine uptake in rOCTN2 cDNA or vector
(pSPORT) transfected HeLa cells. Data are means ± SEM, n = 3 - 4.
*- p < 0.05, ** - p <p 0.01, *** - p < 0.001 vs. Control (OCTN2-cDNA transfected)
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3.2.5. Choline transporter in RBE4 cells
Evidence for the presence of a specific choline transporter at the BBB was first obtained by studies with
living animals (Cornford et al., 1978; Karlsson et al., 1984; Allen and Smith, 1999; Mooradian, 1988). Also
choline uptake in isolated microvessels from rat brain is reported (Shimon et al., 1988, 1989; Galea and
Estrada, 1992). Bovine cerebral capillary endothelial cells were found to transport choline in a partially
sodium dependent manner (Estrada et al., 1990). Several reports differ in their results concerning the
sodium dependence of the choline transport at the BBB. Some authors describe a dependence on sodium
(Estrada et al., 1990; Galea and Estrada, 1992) while others describe a sodium independent choline
transport (Allen and Smith, 1999). The process has been described to be sensitive to hemicholinium-3 with
an inhibitor constant (Ki) above 10 µM (Cornford et al., 1978, Shimon et al., 1988). The sodium dependent
high-affinity choline transporter, designated CHT1, has been recently cloned from rat and human brain
(Okuda et al., 2000; Okuda and Haga, 2000; Apparsundaram et al., 2000). On the other hand the molecular
nature of the choline transporter at the BBB has not been shown yet.
One purpose of this study was the functional characterization of the choline transport at the BBB using RBE4
cells as an in vitro model. The transport of choline was characterized concerning sodium dependence, the
kinetic parameters and the inhibitory potency of several substances. Furthermore the molecular identity of a
putative choline transporter expressed at the BBB should be confined.
Fig. 36 Time course of choline uptake in RBE4 cells. The uptake of [3H]choline (10 nM) was measured in
confluent RBE4 cells incubated for various time periods between 1 minute and 30 minutes in the presence of
sodium (filled circles) or isoosmotical replacement of sodium by NMDG (open circles) in uptake buffer (pH
8.5) at room temperature. Data are means ± SEM, n = 3 - 4.
3.2.5.1. [3H]Choline uptake in RBE4 cells
Rat brain endothelial cells were incubated at room temperature in uptake buffer with sodium or isoosmotical
replacement of sodium by NMDG over different time periods between 1 minutes to 30 minutes. The buffer
contained 10 nM of [3H]choline. Fig. 36 describes the time course of the uptake of [3H]choline in RBE4 cells
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in the presence and absence of sodium. The uptake was not stimulated by the presence of a
transmembrane sodium gradient. In fact, the uptake of [3H]choline increased by about 20% in the absence of
sodium. The uptake was linear at least up to 10 minutes. The influence of the extracellular pH on the
[3H]choline uptake process was assessed in the presence and in the absence of sodium ions (Fig. 37).
Uptake buffers of varying pH were prepared by mixing appropriately two uptake buffers containing either 25
mM MES/TRIS (pH 5.5) or 25 mM TRIS/HEPES (pH 8.5). The uptake of [3H]choline was found to be
inhibited significantly (approx. 32%, p < 0.001) when the extracellular pH was changed from 7.5 to 5.5. This
inhibition caused by acid pH was seen in the presence as well as in the absence of sodium ions. However
the uptake of [3H]choline was not influenced when the pH was changed from 7.5 to 8.5. Based on this data
all further uptake studies with [3H]choline were performed with 10 minutes incubation time in the presence of
sodium ions at pH 7.5.
Fig. 37 Influence of pH on the choline uptake in RBE4 cells. The uptake of [3H]choline (10 nM) was
measured in confluent RBE4 cells for 10 minutes in the presence of sodium (filled bars) or isoosmotical
replacement of sodium by NMDG (open bars) in uptake buffer with varying pH at room temperature. Data are
means ± SEM, n = 6.
*** - p < 0.001 vs. pH 7.5 
The saturation kinetics was analyzed over a concentration range from 2.5 to 200 µM. Fig. 38 describes the
total uptake, the saturable and the nonsaturable component at each concentration of choline. More than 80%
of the total uptake was represented by the saturable component at concentrations between 2.5 and 50 µM.
Even at the highest concentration of choline employed in this experiment (200 µM), the nonsaturable
component represented only about 50% of the total choline uptake. Nonlinear regression was performed with
the data obtained by subtracting the nonsaturable component from the total choline uptake. These data
showed saturation with increasing concentrations of choline. The Michaelis-Menten constant for the
saturable choline uptake was 22.3 ± 3.4 µM and the maximal velocity was 51.5 ± 4.1 pmol/mg of protein/min.
Substrate selectivity of the choline uptake process was investigated at the RBE4 cells. This was
done by assessing the ability of various organic cations (2 mM) to inhibit the uptake of [3H]choline (10 nM).
Several organic cations were found to cause marked inhibition of [3H]choline uptake (Fig. 39). The inhibitors
included tetramethylammonium (TMA), procainamide, clonidine, 1-methyl-4-phenyl pyridinium (MPP), 1-
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methyl-4-phenyl-1,2,3,6,-tetrahydropyridine (MPTP), and hemicholinium-3. The order of the inhibitory
potency was as follows: hemicholinium-3 > MPTP > MPP > clonidine > procainamide = TMA. The inhibition
observed with these compounds was in the range of 75% to 95%. Unlabeled choline (5 mM) competed with
[3H]choline for the uptake process and caused 100% inhibition, as expected. Interestingly, TEA caused only
about 15% inhibition of the [3H]choline uptake in RBE4 cells. Cimetidine and the neurotransmitter serotonin
were also slightly inhibitory. However, dopamine and norepinephrine, in contrast to serotonin, did not cause
any significant inhibition. Fig. 40 shows the dose-response relationship for the inhibition of the [3H]choline
uptake caused by TEA, MPP, MPTP, hemicholinium-3, and unlabeled choline. Unlabeled choline inhibited
the uptake of [3H]choline by 50% (IC50 value) at a concentration of 12 ± 1 µM. Hemicholinium-3, which is an
choline analogue, inhibited the [3H]choline uptake with an IC50 value of 53 ± 5 µM. The IC50 values
determined for MPP and MPTP were 169 ± 10 µM and 273 ± 34 µM. TEA was the least potent inhibitor
among these compounds with an IC50 value of 8.8 ± 0.9 mM.
The inhibition of the [3H]choline uptake by hemicholinium-3 was competitive. In Fig. 41 the Dixon plot of the
inhibition is shown. In this experiment, the uptake of [3H]choline was measured at two different
concentrations of unlabeled choline (1 and 5 µM). The concentration of hemicholinium-3 was varied over a
range of 25 to 250 µM. The Dixon plots show the 1/uptake rate versus hemicholinium-3 concentration and
were linear at both concentrations of choline. The lines intersected above X-axis, indicating the competitive
nature of the inhibition. The inhibitor constant (Ki) value was about 65 µM.
Fig. 38 Saturation kinetic analysis of choline uptake in RBE4 cells. The uptake of [3H]choline (20 nM) was
measured in confluent RBE4 cells incubated for 10 minutes in sodium containing uptake buffer (pH 8.5) at
room temperature. Unlabeled choline was added at various concentration between 20 nM and 200 µM.
Saturable uptake (filled circles) was calculated by subtracting the nonsaturable uptake (open triangles) from
the whole uptake (open circles) of choline in RBE4 cells. The results are given as whole choline uptake
versus the whole choline concentration. Data are means ± SEM, n = 3.
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Fig. 39 Inhibition of choline uptake in RBE4 cells by various organic cations. The uptake of [3H]choline (10
nM) was measured in confluent RBE4 cells incubated for 10 minutes in sodium containing uptake buffer (pH
8.5) at room temperature. The uptake was measured either in the absence (control) or presence of  2 mM of
organic cations. Unlabeled choline (5 mM) was used as a competitor of [3H]choline uptake. Results are given
as percent of control [3H]choline uptake measured in the absence of inhibitors (0.058 ± 0.001 pmol/mg of
protein/min). Data are means ± SEM. n = 6.
** - p < 0.01, *** - p < 0.001 vs. Control
Fig. 40 Dose-response relationship of the inhibition of choline uptake in RBE4 cells by various organic
cations. The uptake of [3H]choline (10 nM) was measured in confluent RBE4 cells incubated for 10 minutes
in sodium containing uptake buffer (pH 8.5) at room temperature. The uptake was measured either in the
absence (control) or presence of  increasing concentrations of various organic cations. The results are given
as percent of control [3H]choline uptake measured in the absence of inhibitors (0.071 ± 0.006 pmol/mg of
protein/min). Data are means ± SEM. n = 5 - 6. Unlabeled choline  (filled circles), hemicholinium-3 (open
triangles), MPP (filled squares), MPTP (open circles), TEA (filled triangles)
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Fig. 41 Kinetic analysis of choline uptake in RBE4 cells by hemicholinium-3. The uptake of [3H]choline (20
nM) at two different concentrations of unlabeled choline was measured in confluent RBE4 cells incubated for
10 minutes in sodium containing uptake buffer (pH 8.5) at room temperature. The uptake was measured
either in the absence or the presence of  increasing concentrations of hemicholinium-3. Results are given as
Dixon plots (1/ [3H]choline uptake in nmol/mg protein/min versus hemicholinium-3 concentration in µM with 1
µM (filled circles) and 5 µM (open circles) unlabeled choline. Data are means ± SEM, n = 3 - 6.
3.2.5.2. Expression of a choline transporter in the RBE4 cells
The choline transporter described in the present study appears to be a member of the OCT family. When
sodium is replaced by NMDG in the buffer the choline transport increases which is similar to the TEA uptake
mediated by OCTN2 (Wu et al., 1999). Furthermore the uptake of choline into RBE4 cells was inhibited by
substrates or inhibitors of the OCT family members, i.e., procainamide, clonidine, MPP and MPTP and, to a
lesser extent, by cimetidine and TEA. In addition neurotransmitters such as serotonin are known to be
transported by OCT1 and OCT2 (Busch et al., 1996b; Gründemann et al., 1998a). Therefore, it was
investigated in this study if there is a connection between the choline uptake and the expression of organic
cation transporters in RBE4 cells. This is the first study in the literature to address this issue
3.2.5.2.1. Northern blot analysis of the organic cation transporter expression in RBE4 cells
In RBE4 cells the expression of three organic cation transporters (OCT1 – 3) was investigated. Thus far all
three organic cation transporters were identified in mammalian cells. First a Northern analysis was performed
followed by RT-PCR with specific primers for the organic cation transporters OCT1 – 3. Fig. 42 describes the
data obtained from Northern analysis. These studies showed no evidence of the expression of any of the
three OCT's in RBE4 cells. The rat kidney was positive for OCT1 and OCT2 and the rat placenta showed a
positive signal for OCT3 under identical conditions. These two tissues were selected as positive controls
based on the known abundance of mRNA for each of the three OCT’s (Gründemann et al., 1994; Okuda et
al., 1996; Kekuda et al., 1998). OCT1 and OCT2 are expressed abundantly in rat kidney whereas OCT3 is
expressed abundantly in rat placenta. However, ß-actin mRNA was detectable in the lane containing the
poly(A)+RNA from RBE4 cells.
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Fig. 42 Northern blot analysis
of the expression of organic
cation transporters in RBE4
cells. Poly(A)+RNA, isolated
from RBE4 cells (RBE4), rat
kidney (RK) and rat placenta
(RP), was size-fractionated
on a denaturing
formaldehyde-agarose gel
and probed by sequential
hybridization under high
stringency conditions with
[32P]dCTP labeled cDNAs
specific for rat OCT1, OCT2,
OCT3 and ß-actin.
3.2.5.2.2. RT-PCR with specific primers for the organic cation transporters
The RT-PCR data are shown in Fig. 43. The experimental conditions used for the RT-PCR were validated by
demonstrating the RT-PCR products of expected sizes for OCT1, OCT2, and OCT3. As expected, OCT1 and
OCT2 were expressed abundantly in rat kidney. The expression of OCT3 in rat kidney was lower than that of
OCT1 and OCT2, again corroborating the earlier findings (Gründemann et al., 1994; Okuda et al., 1996;
Kekuda et al., 1998). Under similar conditions, RT-PCR was negative for OCT2 and OCT3 with RBE4 cell
mRNA, showing lack of the expression of these two organic cation transporters in these cells. In contrast, the
expression of OCT1 was detectable in RBE4 cells. Thus, even though Northern blot analysis indicated that
OCT1 was not expressed in these cells, the more sensitive RT-PCR was able to detect the presence of
OCT1 mRNA in RBE4 cells. The level of expression of OCT1 in RBE4 cells was, however, much lower than
that in rat kidney. Taken collectively, these data demonstrated that RBE4 cells do not express OCT2 and
OCT3, but express low levels of OCT1. Choline transport is reported to be mediated by OCT1 but the
affinities of the rat OCT1 for choline, TEA and MPP differ from the affinities found at the RBE4 cells
(Gorboulev et al., 1997). Therefore the high-affinity sodium independent choline transport found at the RBE4
cells does not occur via OCT1.
3.2.5.2.3. RT-PCR with degenerated primers for the organic cation and organic anion transporters
Organic cation transporters share about 36% sequence identity with organic anion transporters (Kusuhara et
al., 1999). Some organic cation inhibitors showed inhibitory effects on the transport processes of the organic
cation transporter 3 (OAT3) (Kusuhara et al., 1999). Degenerated primers based on the nucleotide
sequences of the known organic cation transporters were used to perform RT-PCR with mRNA from RBE4
cells and rat kidney. No cDNA band was obtained either with mRNA from RBE4 cells nor with mRNA from rat
kidney. RT-PCR performed with degenerated primers used for the cloning of the OAT3 (Kushuhara et al.,
1999) resulted in two cDNA bands derived with mRNA from RBE4 cells and one cDNA band derived with
mRNA from rat kidney (Fig. 44). Sequencing of the band resulting from the rat kidney mRNA revealed this
band to be a part of the novel liver-specific transporter (NLT) (data not shown) which is predominantly
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expressed in the liver but also in kidney (Sekine et al., 1998b). The two bands derived from RBE4 cell mRNA
showed a homology to a membrane surface protein which is not related to any kind of transporters (data not
shown). Therefore it must be concluded that the degenerated primers did not lead to the discovery of a novel
transporter protein responsible for the [3H]choline transport in RBE4 cells.
Fig. 43 RT-PCR with specific primers for organic cation transporters. Poly(A)+RNA samples, isolated from
RBE4 cells (RBE4) and rat kidney (RK) as a positive control, were used for RT-PCR with specific primers for
rat OCT1, rat OCT2 and rat OCT3. The RT-PCR products were size-fractionated with molecular size-
markers run in parallel on a 1% agarose gel.
Fig. 44 RT-PCR with degenerated primers for
organic anion transporters. Poly(A)+RNA
samples, isolated from RBE4 cells (RBE4)
and rat kidney (RK) as a positive control,
were used for RT-PCR. The RT-PCR
products were size-fractionated with
molecular size-markers run in parallel on a
1% agarose gel.
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3.3. Summary of the investigated transporters expressed in the RBE4 cells
In summary, it could be shown that the RBE4 cells can serve as a suitable tool for transporter studies at the
BBB. These cells do express known transporters of the BBB like system L and system y+ (Tab. 5). The
functional characteristic and molecular nature of the amino acid transporters expressed in the RBE4 cells
has been shown to be in accordance with previous reports. The presence of LAT2, a light chain subunit of
system L, could be shown at an in vitro model of the BBB. This is the first time, at the moment of the
experiments, LAT2 was shown to be expressed at the BBB.
Tab. 5 Known transporters of the BBB investigated in the RBE4 cells
Transporter Substrate Kt Vmax RT-PCR Northern
analysis
System L L-[3H]tryptophan 31.31 µM 1.07 nmol/mg/min LAT1 (+)
LAT2 (+)
LAT1 (+)
System y+ L-[3H]arginine 55.26 µM 0.559 nmol/mg/min cat1 (+) cat1 (+)
Several transport systems, which were not known the be present at the BBB at the time of the experiments,
could be shown to function in the RBE4 cells (Tab. 6). The findings included the serotonin transporter which
has been described previously in the brain. Also a sodium dependent L-carnitine transporter could be shown
to be expressed in the RBE4 cells. At the molecular level the organic cation/carnitine transporter OCTN2 is
responsible for this transport process. Finally a sodium independent choline transport is present at the RBE4
cells. This choline transport was sensitive against hemicholinium-3 and several organic cations but its
molecular nature remained unknown.
Tab. 6 Previously unknown transporters of the BBB which were found to be expressed in the RBE4 cells
Transporter Substrate Kt Vmax RT-PCR Northern
analysis
Serotonin [3H]5-HT 0.397 µM 51.1 fmol/mg/min SERT (+) n.d.
Carnitine L-[3H]carnitine
Acetyl-L-[3H]carnitine
Propionyl-L-[3H]carnitine
[14C]TEA
53.78 µM 3.57 pmol/mg/min OCTN2 (+) OCTN2 (+)
Choline [3H]choline 22.33 µM 51.5 pmol/mg/min OCT1 (+)
OCT2 (-)
OCT3 (-)
OCT1 (-)
OCT2 (-)
OCT3 (-)
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4. Discussion
4.1. Methodical considerations
Drug delivery to the brain is made difficult by the presence of the BBB, which is formed by the capillary
endothelium of the vertebrate brain (Reese and Karnovsky, 1967; Brightman et al., 1970). The purpose of
this study is to determine the existence of several transport systems at the BBB. Such studies could be
useful for drug design and drug supply to the brain by using existing transport systems to overcome the BBB
(Tsuji and Tamai, 1999).
Before the experiments could be started there was the need to select a suitable model for such transporter
studies. The model which has been used in the present study had to have the advantage of less or no need
of animals, an easy handling and a constitution of the BBB comparable to the physiological in vivo situation.
During the several experiments the obtained data have to be reproducible and comparable. For this task
several in vivo and in vitro models are available.
4.1.1. In vivo models of the BBB
Several animal models were established to study the uptake rates of drugs from the blood into the brain
(Bonate, 1995). An in vivo technique often used is the determination of the brain uptake index (BUI) for
several compounds introduced by Oldendorf (1971, 1973). The method is based on the intracarotid injection
of a reference and a test compound radiolabeled with two different nucleotides. The authors examined the
uptake of amino acids, neurotransmitters and hexoses into the brain using this method. Choosing an in vivo
model has the advantage of being close to the physiological conditions. However, the transport parameters
are influenced by physiological factors that cannot kept under strict control during experiments, e.g. cerebral
blood flow, hormone levels and stress levels (Hertz and Paulsen, 1980). Furthermore it is difficult to study
properties of brain capillary endothelial cells in vivo because they represent only a small fraction of less than
0.25% of the total weight in the brain (Pardridge et al., 1990b).
4.1.2. Isolated microvessels of the BBB
Various in vitro models have been developed to study the features of the brain endothelium. They are
simpler in handling and avoid the consequences of general anesthesia and surgical handling.
With the isolated microvessel technique (Joo and Karnushina, 1973), the uptake of substances into the
endothelium could be studied (Betz and Goldstein, 1978; Mrsulja et al, 1976; Spatz et al., 1981). The
advantages of isolated microvessels are the control of the tissue environment and the removal from input
from other tissues. Furthermore the cells have not dedifferentiated and they permit ready access to the
abluminal membrane. Disadvantages are the fact that cellular ATP levels are considerable depleted
concerning to the used isolation procedure (Pardridge, 1983) and that the lumen of the microvessels is
collapsed. This prevents the ready access to the transporters at the luminal membrane. Therefore the
substrates mainly approach the microvessels from the abluminal side, which is exactly the opposite to the in
vivo situation.
4.1.3. Primary endothelial cell cultures of the BBB
The development of primary cultures of endothelial cells allowed the study of transcellular transport of drugs
through the brain endothelial cell monolayers (Bowman et al., 1983, 1981; Audus and Borchardt, 1986; Miller
et al., 1992). Co-culture of primary endothelial cell with astrocytes or the use of astrocytes conditioned media
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resulted in a reconstitution of typical endothelial markers like γ-glutamyltransferase (γ-GT) and alkaline
phosphatase (ALP) (Fukushima et al., 1990) and the formation of tight junctions (Dehouck et al., 1992;
Wolburg et al., 1994). On the other hand, the preparation of primary endothelial cell cultures requires a lot of
laboratory equipment and preparation time. Finally the cells may still be contaminated with other cells like
astrocytes. Decreased levels of the specific BBB enzymatic markers γ-GT and ALP (Fukushima et al., 1990)
were observed after several days in culture (Meyer et al., 1990). Long term culture and several passages of
primary endothelial cell cultures result in a senescence and a loss of the phenotypic appearance of the cells
(Meresse et al., 1989; Diglio et al., 1982; DeBault et al., 1981).
4.1.4. Immortalized endothelial cell cultures
4.1.4.1. RBE4 cells
Considering the large variability in the starting material, the rapid senescence observed after passages
and/or the paucity of pure endothelial cells available in primary cultures, the production of immortalized cell
lines displaying a stable, non-transformed phenotype, represents an alternative tool for BBB studies. Cell
lines could also replace the need of large numbers of animals for preparation of primary cultures. Primary
cultures of rat brain endothelial cells have been successfully immortalized (Roux et al., 1994). The second
passage of these cells was transfected with the plasmid pE1A-neo, which carries the entire E1A region of
the adenovirus 2 (conferring immortalization without oncogenic transformation) and the neo gene for the
resistance to the aminoglycoside G418, geneticin. The immortalizing sequence was stably integrated into the
genome of the resulting cell line RBE4.
The cell division of the RBE4 cells was contact-inhibited and the proliferation of these cells was dependent
on the basic fibroblast growth factor (bFGF) concentration and on dish coating with type 1 collagen. When
RBE4 cells were incubated in medium without bFGF, they formed at confluence a characteristic cobblestone
monolayer and after several days developed sprouts that extended above the monolayer. Such sprouting
cells express γ-GT and ALP activities. In the presence of high concentrations of bFGF (5 ng/ml), the cells
exhibited a spindle-shape morphology and sprouting cells reorganized within 1 day into curvilinear and
bifurcating structures, which thickened and elongated during the following days. Inside these structures γ-GT
and ALP were easily detected whereas in the same condition no cell in the monolayer was positively stained.
The described three-dimensional structures, associated with high levels of γ-GT and ALP, were also induced
by astroglia factors derived from conditioned media or culture of RBE4 cells in the presence (but not in
contact) of rat primary astrocytes (Roux et al., 1994; ElHafny et al., 1996). The presence of high
concentrations of the angiogenic stimulus bFGF is necessary for the maintenance and thickening of these
structures.
RBE4 cells do express transport systems which are known to be abundantly expressed at the BBB including
the sodium independent glucose transporter (GLUT-1) (Pardridge et al., 1990a; Boado and Pardridge, 1990),
the efflux pump P-gp (Lechardeur and Scherman, 1995; Barrand et al., 1995) and the sodium independent
large neutral amino acid transporter (Pardridge, 1977; Audus and Borchardt, 1986; Sanchez del Pino et al.,
1995). The selective expression of GLUT-1 at the cerebral microvessels was shown at whole rat brain
(Farrell and Pardridge, 1991), in isolated microvessels (Boado and Pardridge, 1990; Pardridge et al., 1990a)
and also in RBE4 cells (Regina et al., 1997). The Kt value for 3-O-methylglucose (3-O-MG), a substrate of
the GLUT1 transporter, found in RBE4 cells (14.3 mM) correlated well with the values described in rat brain
microvessels and in primary endothelial cells derived from cerebral bovine capillaries. Another highly
64
enriched protein of the BBB represents the P-glycoprotein (P-gp), a drug-efflux pump. This transporter is
expressed in isolated brain microvessels and primary brain endothelial cells (Lechardeur and Scherman,
1995; Barrand et al., 1995). Several authors have described the specific expression of P-gp also in RBE4
cells (Regina et al, 1998; Begley et al., 1996; ElHafny et al., 1997 a/b). Furthermore the uptake of L-3,4-
dihydroxyphenylalanine (L-DOPA) was reported in RBE4 cells (Gomes and Soares-da-Silva, 1999). This
uptake of L-DOPA was sodium independent and inhibited by 2-aminobicyclo(2,2,1)-heptane-2-carboxylic
acid (BCH) but not by N-(methylamino)-isobutyric acid (MeAIB). Putting these findings together it was
concluded that L-DOPA is taken up into the RBE4 cells by the L-type amino acid transporter, a transporter
present at the BBB (Pardridge, 1977; Audus and Borchardt, 1986; Sanchez del Pino et al., 1995). Also L-
histidine uptake mediated by the system L was described by Reichel et al. (2000) in RBE4 cells.
In summary, it has been shown that RBE4 cells preserve many important properties of the BBB and that, as
for primary cultured brain endothelial cells, other BBB properties can be induced by factors from astrocytes.
The simplicity of the cell line model and the absence of contaminating cells favors the RBE4 cells as an
useful tool to study the expression of BBB specific transport systems.
4.1.4.2. Culture of the RBE4 cells
The RBE4 cells were cultured as described by Roux et al. (1994). The culture conditions were kept constant
to guarantee that the obtained data are comparable. Stem culture of RBE4 cells was done on collagen
coated 75er flasks while, for the uptake experiments, the cells were seeded on 24-well cell++ plates. These
multi-well plates have a industrial positively charged surface and, therefore, no need of a collagen coating.
RBE4 cells grown on these plates showed the same phenotype as RBE4 cells grown on collagen coated
flasks.
Temporarily some RBE4 cells changed their phenotype to smaller cell bodies with a sharp cell border. Those
cells did not grow or grew only with a much slower growing rate on 24-well cell++ plates. It could be observed
that RBE4 cells exhibiting this phenotype appeared after treatment of RBE4 cells cultures with trypsin which
was too highly concentrated or kept for a too long time period on the cells.
For the experiments cells of passages between 26 and 45 were used. It could not be determined if higher
passages have an influence on the uptake rates of the radiotracers. The cells were seeded at a density of 1 *
104 cells/cm2 and they reached confluence after 3 to 4 days in culture (Fig. 2). At that time the cells were
used for the experiments and, as shown in Figure 2, the RBE4 cells were still in a logarithmic growth state.
The observed doubling rate of the RBE4 cells was 20.59 hours. For later uptake experiments the cells were
seeded at a density of 2 * 104 cells/cm2 which cut down the culture time to 2 days. The obtained uptake data
for the cells seeded in a higher density were comparable with previously obtained data with cells seeded in
the lower density. After 6 to 7 days the cells started growing in three dimensional structures as described by
Roux et al. (1994). At that state the cells detached from the surface when they were rinsed with buffer.
Therefore, the plateau phase, shown in Figure 2 ,appeared due to the fact that the cells flow off during
rinsing and not because of a decreased proliferation and/or cell dead.
The conditions for the RBE4 cells differed during the uptake experiments with the several radiotracers. Some
experiments were carried out at 37°C (L-[3H]arginine uptake, L-[3H]carnitine uptake, acetyl-L-[3H]carnitine
uptake, propionyl-L-[3H]carnitine uptake, [14C]TEA uptake) while others were done at room temperature (L-
[3H]tryptophan uptake, [3H]5-HT uptake, [3H]choline uptake) in order to the commonly reported uptake
procedure.
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4.1.4.3. Vitality of the RBE4 cells
The cells had to be in a healthy condition during the experiment to maintain a stable, unchanged transporter
status within the cells which made the experiments comparable with each other. To manifest the vitality of
the cells in physiological buffer especially during uptake experiments at room temperature, the accumulation
of MiBi and FDG in the cells was determined.
4.1.4.3.1. MiBi uptake in RBE4 cells
MiBi represents a lipophilic cation which can easily diffuse through biological membranes (Chiu et al., 1990;
Maffioli et al., 1996). The distribution of the tracer is dependent on mitochondrial and plasma membrane
potentials like other lipophilic cations. In living cells such membrane potentials are maintained by energy
dependent processes.
As shown in Fig. 3 the uptake of MiBi was linear over a time period of at least 60 minutes at room
temperature indicating that the cells still maintained a potential gradient over the cell membrane in the
physiological buffer at this temperature. Therefore, the RBE4 cells could be considered as vital cells under
these experimental conditions. Figure 3 also shows, that the accumulation of MiBi in the RBE4 cells was
significantly decreased at 4°C. Energy dependent processes like the maintenance of membrane gradients
are temperature dependent. At low temperatures the energy production of living cells is slowed down and, as
well as in dead and injured cells, the cells do not maintain their potential gradients over the membranes.
Therefore, MiBi was not accumulated in cells at 4°C.
Verapamil increased the MiBi accumulation in the RBE4 cells due to it’s inhibitory effect on the P-gp
(Piwnica-Worms et al., 1993). As discussed (4.1.4.1.), P-gp is expressed in RBE4 cells (Regina et al, 1998;
Begley et al., 1996; ElHafny et al., 1997 a/b). MiBi is a substrate for the P-gp. Therefore it is transported out
of the cells by this active efflux pump (Piwnica-Worms et al., 1993). Inhibition of the P-gp by verapamil led to
an increasing accumulation of MiBi in the cells (Fig. 3).
4.1.4.3.2. FDG uptake in RBE4 cells
Another radiolabeled tracer, which can provide indirect evidence for the vitality of the RBE4 cells during
uptake conditions, is [18F]FDG. The accumulation of FDG in the cells is based upon the uptake via the action
of glucose transporter followed by the phosphorylation of this tracer (Pauwels et al., 1998). FDG is a glucose
analogue and the initial uptake of FDG via the glucose transporter GLUT1 at the BBB (Farrell and Pardridge,
1991) is almost identical to that of glucose (Visser, 2001). After uptake, FDG undergoes phosphorylation but,
unlike glucose-6-phosphate, FDG-6-phosphate does not undergo further metabolism and, because of its
charge, remains trapped in the cells (Visser, 2001). Thus, vital cells with an functioning metabolism should
accumulate FDG in a higher level than dead or injured cells.
The uptake of FDG into RBE4 cells (Fig. 4) was linear over a time period of at least 120 minutes indicating
that neither the experimental conditions at room temperature nor the physiological uptake buffer had a
negative influence on the metabolism of the RBE4 cells. Compared to uptake studies at 37°C the
metabolism at room temperature (about 23 °C) was expected to be slightly reduced but not virtually absent
as shown for 4°C. During the uptake experiments it was easier to maintain a temperature of about 23°C
(room temperature) over all wells of the plates, than keeping the cells at 37°C. Only in case, that the uptake
of the radiotracer could not be studied at room temperature, the uptake experiments were carried out at
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37°C. This procedure required a larger amount of equipment. Under our circumstances it was unavoidable
that the conditions of the cells change during the experiment at 37°C because of the fact that the cells had to
be taken out of the incubator for applying the radiotracers and washing of the wells at different time points
4.2. Transport of large neutral amino acids
The amino acid transport system L has been proposed to be the major route for the permeation of large
neutral amino acids at the BBB (Pardridge, 1977; Pardridge and Choi; 1986; Audus and Borchardt, 1986).
Various centrally acting drugs and radiopharmaceuticals are neutral amino acids which are transported
across the BBB by the system L (Pardridge, 1998) later designated as LAT (Christensen et al, 1994). The
cloning of LAT1 was first described by Kanai et al. (1998) and it has been shown, that LAT1 is a subunit of
the System L at the BBB (Boado et al., 1999; Matsuo et al., 2000; Prasad et al., 1999). A closely related
protein to LAT1 is LAT2, which shows 50% identity to LAT1 (Segawa et al., 1999) and represents the second
isoform of the system L.
4.2.1. L-Tryptophan uptake in RBE4 cells
It has been shown in this study that the transport of amino acids into RBE4 cells is characterized by similar
features as the transport at the brain endothelium in vivo. The expression of LAT1 in the RBE4 cell line and
the features of the L-[3H]tryptophan uptake correlate with previous in vivo and in vitro studies and strongly
suggest that this cell line can be used as an in vitro model to study the BBB transport of new drugs and
radiotracers which are analogues of amino acids.
The uptake of L-[3H]tryptophan in RBE4 cells was linear over time up to 10 minutes (Fig. 5). Large neutral
amino acids in the plasma, like L-tryptophan, are taken up into the brain across the BBB by system L, which
shows a higher affinity than system L in periphal tissues (Pardridge, 1983; Sanchez del Pino et al., 1995)
The half-saturation constant Kt for the saturable component of the L-tryptophan uptake was determined at 31
µM (Fig. 6). Hence, the transporter affinity for tryptophan was in the same range as published for the rat BBB
in vivo (Kt = 52 µM; Pardridge and Choi, 1986), the cloned bLAT1 obtained from bovine brain endothelium
(Kt = 31.5 µM; Boado et al., 1999) and the cloned hLAT1 obtained from human placenta (15 µM; Prasad et
al., 1999).
The maximal velocity of the L-tryptophan transport at RBE4 cells was calculated to about 1 nmol/mg/min
(Fig. 6). Other neutral amino acids are reported to reveal maximal velocities in about the same range as
those observed at the RBE4 cells for L-tryptophan. The leucine transport observed at bovine and rat brain
endothelial cell cultures exhibited Vmax values of 6.3 nmol/mg/min and 0.9 – 3.2 nmol/mg/min (Audus and
Borchardt, 1986; Kido et al., 2001b). In isolated membrane vesicles of the bovine BBB the sodium
independent uptake of phenylalanine was demonstrated with a Vmax of 0.4 nmol/mg/min for the luminal and
0.1 nmol/mg/min for the abluminal side (Sanchez del Pino et al., 1995). L-DOPA, which is also transported
by the system L, was taken up by RBE4 cells as well as by mouse brain endothelial cells (MBEC) with a Vmax
of about 3.5 nmol/mg/min (Gomes and Soares-da-Silva, 1999; Kageyama et al., 2000). In vivo studies with
L-tryptophan showed Vmax values between 0.021 and 0.033 nmol/mg/min (Miller et al., 1985; Pardridge,
1977) but it has to be taken into account that the protein value includes the protein of the whole brain regions
while in in vitro studies with cell cultures of brain endothelial cells only the protein content of these cells is
calculated.
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The system L amino acid transport system of the BBB is sodium independent, bidirectional, and, therefore
an equilibrative transport system (Sanchez del Pino et al., 1995). Correspondingly, we have shown that the
uptake of L-tryptophan was sodium independent (Fig. 7) and that the specific system L inhibitor BCH clearly
decreased the tracer uptake into the RBE4 cells by about 87% while MeAIB, an inhibitor of system A, was
without effect. Several large neutral amino acids like tryptophan, leucine, phenylalanine and L-DOPA
inhibited the L-tryptophan uptake in RBE4 cells while small neutral amino acids like glycine and alanine or
acidic amino acids (glutamate) did not (Fig. 8). These features characterized the transport of L-tryptophan as
primarily system L mediated (Kanai et al., 1998). The fact that RBE4 cells are endowed with the system L
was also reported by other authors who characterized the uptake of L-DOPA (Gomes and Soares-da-Silva,
1999) and the transport of L-histidine (Reichel et al., 2000) via the system L amino acid transporter using
RBE4 cells as an in vitro model of the BBB. 
4.2.2. Expression of LAT1 in RBE4 cells
Compared to other transport systems, the genetic basis of the neutral amino acid transporter remained for
quite a long time unknown. In 1998, Kanai et al. have cloned a protein from rat C6 glioma cells which
mediates the sodium independent transport of neutral amino acids when coexpressed in Xenopus laevis
oocytes with the heavy chain of the 4F2 antigen (4F2hc, CD98). This protein, designated rLAT1, is not
capable to transport amino acid on its own. But as a heterodimer with the 4F2hc, rLAT1 possesses amino
acid transport activity with the characteristics of system L. Kageyama et al. (2000) have shown that L-DOPA,
a substrate transported by the system L, is transported by the 4F2hc/LAT1 complex in mouse brain capillary
endothelial cells. LAT1 is the light chain of a heterodimeric membrane glycoprotein, CD 98, which was first
identified as a surface antigen in activated lymphocytes (Haynes et al., 1981). While 4F2hc is widely
expressed in several tissues, the expression of LAT1 is restricted to barrier tissues such as testis, placenta
and the BBB (Kanai et al., 1998; Boado et al., 1999). The abundance of the LAT1 mRNA at the BBB is
manifold higher than in other tissues (Boado et al., 1999). In this study it was demonstrated with RT-PCR
and Northern blot analysis (Fig. 9 and 11) and the specific BamH1 digestion pattern of the RT-PCR products
for rat LAT1 (Fig. 10) that the rLAT1 subunit is present in the RBE4 cells. LAT1 is reported to be expressed
in brain and kidney (Prasad et al., 1999, Kanai et al., 1998) where it was cloned from. Therefore, these
tissues were used as a positive control in RT-PCR and/or Northern blot analysis. Rat brain showed a strong
expression of LAT1 in the Northern analysis while the expression of LAT1 in rat kidney was weaker which
correlates with the findings of others (Prasad et al., 1999). Using RT-PCR the expression of LAT1 was
recently also demonstrated in the whole rat brain, rat primary cultured brain endothelial cells and
immortalized rat brain endothelial cells (RBEC1) (Kido et al., 2001b). These data support the findings of the
present study with RBE4 cells and make these cells suitable as an vitro-model of the BBB.
4.2.3. Expression of LAT2 in the RBE4 cells
Another isoform of LAT1, called LAT2, was recently reported by several authors (Pineda et al., 1999; Rossier
et al., 1999; Segawa et al., 1999; Rajan et al., 2000a). It induces, if co-expressed with the 4F2 heavy chain
subunit, an amino acid transport capacity which differs slightly from that produced by LAT1/4F2hc. Similar to
LAT1, it fulfills the definition of an L-type amino acid transporter since it transports large neutral amino acids,
functions sodium independently and accepts BCH, but it differs in the affinities for the uptake of several
amino acid substrates (Rossier et al., 1999; Segawa et al., 1999). Compared with LAT1, which prefers large
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neutral amino acids with branched or aromatic side chain, LAT2 exhibits a remarkably broad substrate
selectivity. It shows a higher apparent affinity for the uptake of neutral amino acids like tryptophan,
phenylalanine, leucine and glutamine and a lower affinity to substrate amino acids like histidine, alanine and
glycine than reported for LAT1. Furthermore the LAT2/4F2hc mediated amino acid transport is stimulated by
acidic pH, in contrast to the LAT1 isoform (Rajan et al., 2000a). The expression of LAT2 in RBE4 cells was
demonstrated in this study by RT-PCR and specific digestion of the PCR products with BamH1 (Fig. 9 and
10). The LAT2 isoform subunit of the system L also differs in their tissue distribution from LAT1. While LAT1
mRNA expression is rather broad, the expression of LAT2 mRNA is restricted to tissues rich in (re)absorbing
epithelia (Rossier et al., 1999). The expression of LAT1, LAT2 and the heavy chain subunit 4F2 in the brain
endothelium was recently shown by Kido et al. (2001b) using mRNA from the whole rat brain, primary
cultures of rat brain endothelial cells and an immortalized rat brain endothelial cell line (RBEC1). Both
subunits might be involved in the transcellular transport of neutral amino acids via system L through the brain
endothelium. Further studies on the polarity of LAT1 and LAT2 in the brain endothelial cells are required to
establish the physiological roles and the pharmacological relevance of system L and its subunits at the BBB.
4.2.4. Heterogeneity of the L-tryptophan transport
Amino acid transport across cellular membranes is mediated by multiple transporters with overlapping
membrane specificity. In the RBE4 cells L-tryptophan showed a significantly stronger inhibition than BCH
(Fig. 7) at similar affinities of those two amino acids in the isolated membranes of brain endothelial cells
(Sanchez del Pino et al., 1995). Similar findings were made by Ganapathy et al. (1986) in human placental
brush-border membrane vesicles, where 500 µM tryptophan showed 65% inhibition on the uptake of 50 nM
L-tryptophan in contrast to 500 µM BCH with only 37% inhibition. The stronger inhibition of the L-tryptophan
uptake in RBE4 cells by tryptophan compared to BCH appeared to be sodium independent because there is
no significant difference observed between the inhibition of BCH and tryptophan in sodium containing and
sodium free incubation buffer. In human red blood cells a so called system T is described (Rosenberg, 1988;
Rosenberg et al., 1980) which prefers L-tryptophan as substrate and is insensitive to BCH (Kansal and
Kansal, 1996). At the BBB a system T is reported which mediates high affinity, low capacity transport of
thyroid hormones (T3 and T4) (Smith, 2000). Others reported the transport of these thyroid hormones to be
sodium independent and inhibited by tryptophan and phenylalanine (Ritchie et al., 1999). The authors
concluded that the thyroid hormones are substrates of an amino acid transport system. System L and was
identified to transport these hormones due to the inhibitory effect of BCH on the thyroid hormone uptake. It
remains unsolved if the amino acid transport system T is present at the BBB and whether it is involved in the
transport of L-[3H]tryptophan in a BCH insensitive and sodium independent manner.
Also, a remaining small part (about 8.5%) of the total uptake of L-tryptophan seemed to be sodium
dependent and MeAIB insensitive because replacement of NaCl by NMDG significantly reduced the uptake
of L-tryptophan (Fig. 7). Studies of the uptake of L-phenylalanine into vesicles prepared from bovine brain
endothelium Sanchez del Pino et al. (1995) have also shown a small sodium dependent component which
was sensitive to BCH. There are several sodium dependent amino acid transporters known at the BBB,
including the system A, the system ASC and the system Bo,+ (Palacin et al., 1998; Kilberg et al., 1993; Smith,
2000). The system A is known to be inhibited by MeAIB (Grammas et al., 1992). Therefore, it can not be
responsible for the sodium dependent uptake of L-tryptophan into RBE4 cells. The system ASC is described
to be MeAIB insensitive but its preferred substrates are alanine, serine and cysteine (Tayarani et al., 1987).
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Furthermore, Christensen et al. (1979) reported that tryptophan is not transported by the ASC system. The
remaining system Bo,+ was considered to be responsible for the transport of L-phenylalanine into bovine
brain endothelial cell vesicles (Sanchez del Pino et al., 1995). This system transports neutral and cationic
amino acids in a sodium and chloride dependent manner (Sloan and Mager, 1999) and is shown to be
expressed exclusively at the abluminal membrane of the BBB (Kilberg, 1993).
The fact that abluminal transporters could be functionally characterized on monolayers of RBE4 cells leads
to the conclusion that these cells might have lost their polarity. Mroczkowska et al. (1996) made a difference
between the luminal and abluminal side of RBE4 cells by considering the monolayer side exposed to the
incubation medium as the luminal side. To study the abluminal transport processes the authors used cell
suspensions of the RBE4 cells derived by scraping the cells from the surface. It should be taken into account
that such a rapid method could have an influence on the vitality of the cells and might not be a useful method
to study abluminal transport processes at the RBE4 cells. However, the data of these authors imply that it
seems to be possible to study luminal as well as abluminal transport processes using monolayers of RBE4
cells.
In conclusion, it was shown that the RBE4 cells may be used as an in vitro model to study the BBB transport
of neutral amino acids via the sodium independent system L. The cells highly express LAT1 and also LAT2
as a second isoform of the system L light chain subunits. The affinity of this transporter to L-tryptophan and
its selectivity for different amino acids was comparable to in vivo studies and to investigations using isolated
brain microvessels or primary brain endothelial cells. 
4.3. Transport of cationic amino acids
Among the several types of amino acid transport systems distinguished by substrate specificity, cationic
amino acids such as L-arginine, L-lysine and L-ornithine share the same transporter with a sodium
independent activity, called system y+ (McGivan and Pastor-Anglada, 1994). System y+ has been found to be
responsible for the majority of L-arginine transport and is found in a variety of tissues (Closs, 2002; Kakuda
et al, 1998). The cell surface receptor (ecoR) for ecotropic host range murine retroviruses (Albritton et al.,
1989) has been identified as a transporter for cationic amino acids (Wang et al., 1991; Kim et al., 1991) and
in its role is referred to the cationic amino acid transporter cat1. This protein has the functional characteristic
of the cellular transport system classically known as system y+ (Deves and Boyd, 1998). The transport of
cationic amino acids, like L-arginine, through the BBB may be essential, because the brain cannot
synthesize this amino acid by its own at adequate rates to meet the needs for brain metabolism and protein
synthesis (Smith, 2000).
4.3.1. L-Arginine uptake in RBE4 cells
In RBE4 cells the uptake of L-arginine was found to be sodium independent and inhibited by the cationic
amino acid ornithine (Fig. 13). On the other hand, glutamate ,an acidic amino acid, did not have any
inhibitory effect on the L-arginine uptake. These findings are also reported by others (Stoll et al., 1993; Kim
et al., 1991) as specific features of the system y+. The system L inhibitor BCH and the system A inhibitor
MeAIB did not have any influence on the L-arginine uptake into the RBE4 cells, indicating that these amino
acid transport systems are not involved in the L-arginine transport in these cells. These data agree well with
previous studies (Stoll et al., 1993; Low and Grigor, 1995) which also did not show any influence of BCH or
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MeAIB on the system y+ mediated cationic amino acid uptake. The half saturation constant for the L-arginine
uptake was 55 µM in the present study (Fig. 12). Comparable affinities were found for the L-arginine uptake
into rat cerebral cortex (56 µM; Stoll et al, 1993), in ecoR expressing oocytes (77 µM; Wang et al., 1991) and
in ecoR transfected mink fibroblasts cells (53 µm; Wang et al., 1994). In a human endothelial cell line the L-
arginine uptake was mediated by cat1, a member of the cationic amino acid transporter gene family, with a
Kt of 68 µM (Closs et al., 2000). 
The observed Vmax value for the L-arginine uptake in RBE4 cells was about 0.6 nmol/mg/min (Fig. 12). This
value is only slightly higher than the Vmax values observed in primary neuronal cultures from rat
hypothalamus/brainstem with a Vmax of 0.1 nmol/mg/min (Stevens and Vo, 1998) and cat1+/+ mouse
embryonic fibroblasts with a Vmax of 0.4 nmol/mg/min (Nicholson et al., 1998). Using the in situ brain
perfusion technique Stoll et al. (1993) estimated the maximal velocity of the rat brain arginine uptake at
about 0.024 nmol/mg/min but this value includes the protein content of the whole brain region.
4.3.2. Expression of cat1 in the RBE4 cells
The cell surface receptor for ecotropic host-range murine retroviruses (ecoR) (Albritton et al., 1989) was
identified as a widely expressed sodium independent transporter for the cationic amino acids lysine, arginine
and ornithine (Kim et al., 1991; Wang et al., 1991) previous known as system y+. Four homologous human
and rodent genes defining the family of cationic amino acid transporters (cat1, -2a, 2b and -3) (Palacin et al.,
1998), each of which has a distinct expression pattern. At the mRNA level, cat1 is expressed in various
tissues and cell types, except the liver, and is believed to be a ubiquitous form of the cat gene family. Within
the rat brain, however, cat1 mRNA is more than 40 fold enriched in the brain capillaries compared to the
whole brain, suggesting its role in amino acids transport by endothelial cells at the BBB (Stoll et al., 1993).
Other authors reported the expression of cat1 but not cat2a or cat2b in a human endothelial cell line (Closs
et al., 2000). In the present study the expression of cat1 was demonstrated by RT-PCR (Fig. 14) and
subsequent sequencing (Fig. 15) or specific digestion (Fig. 16) of the RT-PCR products. In rats the cat1
gene is shown to be expressed in brain and kidney and highly enriched in brain capillary cells (Smith and
Stoll, 1998). Northern blot analysis with the previously sequenced cat1 RT-PCR product (Fig. 15) revealed
an expression of cat1 in rat brain and kidney (Fig. 17) as reported. The weak signal for the RBE4 cells may
be due to the fact that there might not be an even amount of mRNA on the different lanes of the blot and the
RBE4 lane contains less mRNA than the other lanes.
4.3.3. Heterogeneity of the L-arginine transport
The L-arginine uptake found in RBE4 cells can be assigned due to the involvement of system y+. The uptake
of L-arginine did not include any sodium dependent part (Fig. 13) because replacement of sodium ions by
NMDG did not decrease the uptake of the amino acid into the RBE4 cells. Sodium independent L-arginine
uptake into cells can be mediated by several amino acid transporters including the system y+ encoding cat
gene family, the system y+L and system b0,+.
Besides cat1 three other isoforms belong to the cat gene family of the system y+ (cat2a, cat2b and cat3.)
which differ in their tissues distribution, kinetics and regulatory properties (Deves and Boyd, 1998). Cat2a
and cat2b are distinct proteins encoded by alternatively spliced mRNA's originated from one primary
transcript of the cat2 gene (Closs et al., 1993b, MacLeod et al., 1994). While cat2a expression is restricted to
the liver, cat2b is expressed in different tissues including brain but absent in liver. The apparent affinity of
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cat2b for the L-arginine uptake was about 70fold higher than the cat2a isoform (38 µM versus 2.7 mM)
(Kavanaugh et al., 1994). The fourth member of the cationic amino acids transport family, cat3, was recently
cloned from rat brain and revealed a Kt value of about 100 µM for L-arginine (Hosokawa et al., 1997). Only
the expression of cat1 was shown in the rat brain endothelium (Stoll et al., 1993). The expression of cat2b
and cat3 has not been shown in the cerebral microvessel endothelial cells.
The system y+L and the system b0,+ amino acid transporters belong to the family of the heterodimeric amino
acid transporters (Wagner et al., 2001). The system y+L consists of two different isoforms of light chains
y+LAT1 (Torrents et al., 1998) and y+LAT2 (Bröer et al., 2000) and the heavy chain 4F2hc. The L-arginine
transport mediated by the mouse y+LAT1/4F2hc heterodimer is reported with a Kt of approx. 90 µM in the
absence and approx. 340 µM in the presence of sodium in the incubation medium (Pfeiffer et al., 1999).
y+LAT2/4F2hc mediated L-arginine transport revealed a transport affinity of about 130 µM in sodium
containing as well as in sodium free incubation medium (Bröer et al., 2000). In cultured human fibroblasts the
Kt of the system y+L mediated L-arginine uptake could be determined at 45 µM (Dall’Asta et al., 2000).
The light chain of system b0,+ is named b0,+AT and was first reported to be associated with the heavy chain
rBAT (Chairoungdua et al., 1999). Further studies revealed evidence that the b0,+ amino acid transporter
subunit (b0,+AT) interacts with rBAT as well as with 4F2hc to constitute functionally competent b0,+-like amino
acid transport systems (Rajan et al., 2000b). The transport of L-arginine mediated by the 4F2hc/b0,+AT
complex exhibit a Michaelis-Menten constant of 12 µM while rBAT/b0,+AT complex mediated L-arginine
uptake had a Kt value of 88 µM. Neither system y+L nor system b0,+ have been shown to be expressed at the
BBB.
There is only one sodium dependent transport system for cationic amino acids. This system transports
cationic as well as neutral amino acids in a sodium dependent manner and is called system B0,+ (Sloan and
Mager, 1999). The amino acid transport of system B0,+ is attenuated in the presence of BCH. The
involvement of system B0,+ in the L-arginine uptake in RBE4 cells can be excluded because there was no
sodium dependent L-arginine uptake observed and, in addition, BCH did not inhibit the L-arginine uptake in
these cells (Fig. 13).
In summary the present study has shown the uptake of L-arginine as specific for the cationic amino acid
transport system y+. Furthermore the expression of this amino acid transporter was shown on the molecular
level by proofing the expression of the cat1 gene in the RBE4 cells. According to previous reports RBE4 cells
express the cationic amino acid transporter cat1 with the typical features of L-arginine transport known for
the BBB (Stoll et al., 1993). Therewith it was again shown that RBE4 cells could serve as an useful tool to
study transport processes at the BBB in vitro.
4.4. 5-HT transport at RBE4 cells
5-HT transporters have been characterized most extensively in brain, platelets and placenta, where they are
found to be largely identical in their transport kinetics for 5-HT and sensitivity to antagonists (Cool et al.,
1991; Blakely et al., 1991a; Hoffman et al., 1991; Launay et al., 1992; Ramamoorthy et al., 1993; Kekuda et
al. 1997, Prasad et al. 1997; Humphreys et al., 1988). The current study provided strong evidence that the 5-
HT transporter is functionally expressed also at the brain endothelium. Using [3H]imipramine and
[3H]paroxetine it was previously demonstrated specific binding of these ligands to isolated microvessels of
porcine brain (Brust et al. 1995, 1996a). This binding was attributed to the presence of a 5-HT transporter at
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the BBB. Furthermore the specific, sodium dependent and antidepressant sensitive 5-HT uptake was found
in isolated microvessels of the gerbils brain (Spatz et al., 1981).
4.4.1. Comparison of the 5-HT uptake in different cell types
We have shown that citalopram, the most selective 5-HT uptake blocker known (Hyttel, 1982) and
clomipramine significantly inhibited the total uptake of 5-HT in primary endothelial cell cultures of porcine
brain and in the RBE4 cell line to a similar amount whereas in accordance with findings of Small et al. (1976)
no such specific transport of 5-HT has been found at fibroblasts (Fig. 24). In JAR cells a sodium dependent
5-HT transporter was cloned which is sensitive to antidepressants like paroxetine, fluoxetine and imipramine
(Ramamoorthy et al., 1993). Comparison of the 5-HT uptake in JAR cells and RBE4 cells revealed a
significant inhibition of the 5-HT uptake by citalopram in both cell types (Fig. 25). In contrast RBE4 cells took
up only about 6 % of the 5-HT taken up by JAR cells. Therefore it must be concluded that RBE4 cells seem
to express a similar 5-HT transporter as found on JAR cells but with a much lower amount of transporter
proteins on the cell surface.
4.4.2. Ion dependence of the 5-HT uptake in RBE4 cells
4.4.2.1. Dependence of the 5-HT uptake on sodium ions
RBE4 cells were used to further characterize this 5-HT uptake. Specific transport of 5-HT was generally
shown to be energetically coupled to the transmembrane concentration gradient of sodium which is
maintained by the activity of the Na+/K+-ATPase (Talvenheimo et al., 1983; Rudnick, 1977; Povlock and
Amara, 1997; Spatz et al., 1981). Rudnick (1977) reported that with each molecule of 5-HT passing the cell
membrane also a single positive charge is passing while potassium ions are transported out of the cell. The
Na+/K+-ATPase expression in brain capillaries was shown to be associated with the abluminal membrane
(Betz et al., 1980). Inhibition of the Na+/K+-ATPase with ouabain resulted in a significant reduction of the 5-
HT uptake indicating dependence of the 5-HT transport on the generation of a sodium gradient by the
Na+/K+-ATPase (Fig. 21).
A 1:1 coupling of serotonin and sodium fluxes by the 5-HT transporter is suggested (Talvenheimo et al.,
1983; Rudnick, 1977). The transport system at RBE4 cells showed also dependence on sodium (Fig. 20).
From these data it was calculated that about 2/3 of 5-HT uptake is sodium independent which corresponds
well to the non-specific uptake (62%) determined using citalopram as specific uptake blocker (Fig. 23).
Hence the specific transport could be totally inhibited by replacing sodium in the incubation medium. On the
other hand the question arises whether the 5-HT-transporter in vivo is also responsible for only 25% of 5-HT
uptake into the endothelium. As explained below (4.4.7.) the situation in vivo is expected to be different from
in vitro because of cell-specific transporter regulation.
Interestingly, replacement of sodium ions by choline resulted in a more than 50% inhibition of total 5-HT
uptake (Fig. 20), significantly more than under lithium replacement, which leaves the possibility that a sodium
independent choline transporter is involved in the 5-HT uptake. Such transport mechanism is present at the
brain endothelium (Cornford et al., 1978). A sodium independent choline transport was found at the RBE4
cells and is described elsewhere in this study (4.6.). The choline transport was slightly influenced by
serotonin (Fig. 39). Not only in RBE4 cells but also in fibroblasts the 5-HT uptake was significantly reduced at
4oC while no specific 5-HT uptake was measured in fibroblasts. Slow temperature sensitive uptake
mechanisms such as pinocytosis may be responsible for this effect.
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4.4.2.2. Dependence of the 5-HT uptake on calcium ions
4.4.2.2.1. Influence of glycoproteins on the 5-HT uptake
A dependence of the 5-HT transport on extracellular calcium is reported by Nishio et al. (1995, 1996). EGTA
in the extracellular medium reduced the 5-HT uptake into blood platelets but only at 37°C and not at room
temperature (Fig. 22). The involvement of a cell surface recognition site, for example the glycoprotein GP
IIb/IIIa, was considered. This GP IIb/IIIa complex contains calcium ion storage sites within the extracellular
domain and chelation of the calcium ions in the store causes functional inhibition (Lanza et al., 1992). It is
generally accepted that the inhibitory regulation of the GP IIb/IIIa complex by EGTA is temperature
dependent (Gonzalez-Rodriguez et al., 1994). Thus dissociation of the GP IIb/IIIa complex occurred only at
37°C, but not at room temperature (Golden et al., 1990). Treatment with EGTA caused a reduction of the 5-
HT uptake also in RBE4 cells (Fig. 22) and this effect was only seen at 37°C. Thus RBE4 cells showed the
same temperature dependent effect of EGTA on the 5-HT uptake as reported in blood platelets. Therefore,
RBE4 cell seem to express the same or a similar glycoprotein complex as described in blood platelets.
Various glycoprotein subtypes are expressed in RBE4 cells and other cerebral endothelial cells responsible
for the modulation of different intracellular signaling (Fabian et al., 1998). It can be concluded that in RBE4
cells, in correlation with blood platelets, EGTA induced a depletion of calcium ions from its storage sites on a
possible glycoprotein complex indicating its dissociation and therefore its dysfunction, which might result in
the inhibition of the 5-HT transport activity.
4.4.2.2.2. Influence of the 5-HT2 receptor on the 5-HT uptake
At the brain endothelium 5-HT2 receptors are localized at the luminal surface (Cohen, 1989; Olesen, 1985;
Brust et al., 1996b). Exposure of endothelial cells to 5-HT causes a rise in the intracellular calcium (Cohen,
1989) and an increase in the BBB permeability (Sharma et al., 1990; Olesen, 1985) mediated by a 5-HT2
receptor. The intracellular increase of calcium ions can be inhibited by ketanserin, a 5-HT2 receptor
antagonist (Akiyoshi et al., 1996). The permeability effect was also inhibited by ketanserin (Sharma et al.,
1990; Olesen, 1985) and dependent on extracellular calcium (Olesen, 1985). Ketanserin also caused a
decrease of the 5-HT accumulation in RBE4 cells as chelation of extracellular calcium does (4.4.2.2.1.) (Fig.
23). A correlation between the 5-HT2 receptor and the 5-HT transporter in the cells could be suggested as
already done by others (Cohen, 1989; Launay et al., 1998). Launay et al. (1998) reported the control of the
5-HT transport (a) directly through phosphorylation of the transporter, and (b) indirectly through
phosphorylation of the Na+/K+-ATPase, the energy source of the 5-HT transport, by the 5-HT2B receptor at
mouse clonal stem cells. Also antidepressants inhibited the intracellular calcium ion mobilization mediated by
5-HT2 receptors (Akiyoshi et al., 1996; Juneja et al., 1994). In addition, preclinical and earlystage clinical
studies have indicated that selective blockers of the 5-HT2 receptors might be useful antidepressants (Baxter
et al., 1995). Further studies are required to determine the relation between the 5-HT receptors and the 5-HT
uptake site at the brain endothelium.
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4.4.2.2.3. Influence of verapamil on the 5-HT uptake
In the present study verapamil inhibited the 5-HT uptake in RBE4 cells as well as in JAR cells (Fig. 23, 24
and 25), the latter are known to express the sodium dependent 5-HT transporter (Ramamoorthy et al., 1993).
Specific binding sites for calcium channel blockers were demonstrated at cerebral microvessels of rats
(Dooley et al., 1987) and voltage dependent calcium channels as a target of verapamil were reported in
bovine capillary endothelial cells (Bossu et al., 1992). Verapamil, a calcium channel blocker, inhibited the
influx of extracellular Ca2+ ions into the cells. The increase of intracellular calcium ion levels induced by 5-HT
results from an influx of extracellular calcium through calcium channels, which can be blocked by verapamil
(Juneja et al., 1994; Olesen, 1985). Therefore the inhibitory effect of verapamil on the 5-HT uptake in the
brain endothelium and in JAR cells seemed to be indirectly through the inhibition of the increase of the
intracellular calcium ion level. In contrast, no inhibitory effect of verapamil on the 5-HT uptake was observed
in blood platelets (Nishio et al., 1995). It is possible that the effect of the calcium chelation (4.4.2.2.1.) and
the effect of verapamil were based on different mechanisms of inhibitory influence on the 5-HT transport at
RBE4 cells. Anyway the effect caused by verapamil was severalfold higher than that caused by EGTA.
4.4.3. Influence of specific transport inhibitors on the 5-HT uptake in the RBE4 cells
4.4.3.1. Influence of specific inhibitors of the sodium dependent 5-HT transporter on the 5-HT uptake
Pharmacologically, the 5-HT uptake in RBE4 cells exhibited properties that are similar to those of 5-HT
transporters described in the plasma membrane of platelets, placenta, lymphocytes, in the rat and human
brain and in cells transfected with human 5-HT transporter (Launay et al., 1992; O’Reilly and Reith, 1988;
Ramamoorthy et al., 1993; Faraj et al., 1994; Marcusson et al., 1989; Rotondo et al., 1996; Qian et al.,
1997). Potent and specific inhibitors of the neuronal 5-HT transporter are citalopram, paroxetine,
clomipramine, imipramine and fluoxetine (Brust et al., 1995, 1996a; Cohen et al., 1996; Spatz et al. 1981;
Akunne et al., 1992; Schloss and Betz, 1995; D’Amato et al., 1987; O’Reilly  and Reith, 1988). Those
inhibitors had the highest inhibitory potencies towards the 5-HT uptake in RBE4 cells (Fig. 23) with an
average inhibition of 25% of the total 5-HT uptake at room temperature. The concentration of the inhibitors
(10 or 50 µM) blocked the 5-HT uptake completely during the experiments because inhibitor constants are in
the nanomolar range. According to the effects of the specific inhibitors at RBE4 cells the presence of a
sodium dependent, antidepressant sensitive 5-HT transporter could be validated corresponding to the results
obtained by RT-PCR (4.4.6., Fig. 26).
4.4.3.2. Influence of specific inhibitors of other neurotransmitter transporter on the 5-HT uptake
The lack of an inhibitory effect of tetrabenazine and reserpine indicated no influence of a vesicular 5-HT
transporter in RBE4 cells (Fig. 23). Both pharmaceuticals are potent inhibitors of the sodium independent
vesicular 5-HT transporter (Knepper et al., 1988; Erickson and Eiden, 1993; DaSilva et al., 1994; Yelin and
Schuldiner, 1995; Rudnick et al., 1980). Anyway it is unlikely that a vesicular 5-HT transporter is present in
the endothelial cells. First, Reese and Karnovsky (1967) found only a very small amount of vesicles in the
endothelium and, second, endothelial cells of the brain do not have a need for a storage of 5-HT like neurons
have.
Surprisingly, also GBR 12909, a ligand which is most selective for the dopamine transporter (Heikkila and
Manzino, 1984), decreased the 5-HT transport (Fig. 23). To study whether this drug inhibited the 5-HT
uptake by a different mechanism, co incubation with citalopram was performed. No additive effect was
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observed. Therefore the involvement of a dopamine transporter on the 5-HT transport at RBE4 cells could be
excluded.
4.4.3.3. Influence of specific inhibitors of the P-gp on the 5-HT uptake
Verapamil is known to be a potent inhibitor of the P-gp (Drion et al., 1996; Begley et al., 1996; Piwnica-
Worms et al., 1993) which is an efflux-pump of several chemotherapeutic agents and also present at the
BBB (Jette et al., 1995). Despite the fact that the P-gp is also present in RBE4 cells (Regina et al, 1998;
Begley et al., 1996; ElHafny et al., 1997 a/b) and that the P-gp inhibitor verapamil also decreases 5-HT
uptake co incubation experiments performed with citalopram excluded the possibility of an involvement of
this pump in the transport of serotonin (Fig. 23).
A further proof that the P-gp was not involved in the transport of 5-HT at RBE4 cells was the different
inhibitory effect of colchicine and quinidine (Fig. 23), which are known to be potent P-gp inhibitors (Drion et
al., 1996; Begley et al., 1996; Jette et al., 1995). While quinidine revealed a decrease of the 5-HT uptake in
RBE4 cells colchicine did not. The inhibitory potency of verapamil and quinidine must, therefore, be
attributed to other interactions with the 5-HT uptake.
4.4.4. Kinetics of the 5-HT uptake in RBE4 cells
In our study a Vmax of the 5-HT transport of 51.1 fmol/mg/min was found (Fig. 19) which is factor 30-40 less
than in membrane preparations of the mouse brain (Hoffman et al., 1991) and in JAR human placental
choriocarcinoma cells (Cool et al., 1991). The transport affinity of 397 nM was similar to that found for cloned
human 5-HT transporters in human lymphocytes (Faraj et al., 1994), platelets (Rudnick, 1977, Launay et al.,
1992) and placenta (Ramamoorthy et al., 1993). For the mouse brain a similar affinity of the cloned 5-HT
transporter was found (Chang et al., 1996). In contrast, in brain and placental membrane preparations a 5- to
10-fold higher affinity was found (O´Reilly and Reith, 1988; Cool et al., 1990). The major kinetic alterations of
the 5-HT transporter observed so far are reductions or elevations of transport capacity rather than a change
in apparent transport affinity (Qian et al., 1997). This was also confirmed by our study in which we found a
similar transport affinity but a lower transport capacity for 5-HT as measured in other cellular systems.
4.4.5. Unspecific 5-HT uptake in RBE4 cells
We have measured a rather high non-specific uptake in our study (between 67% and 75%). Also JAR cells
having a much higher transport capacity for 5-HT showed a non-specific uptake of more than 50% under our
circumstances (Fig. 25). At shorter incubation time a lower non-specific uptake (about 25 %) was observed in
this cell line (Prasad et al., 1996). Similar results were obtained using either a high concentration of
citalopram or replacement of sodium ions by lithium (Fig. 20). Serotonin showed a slightly inhibitory effect on
the sodium independent choline uptake in RBE4 cells (Fig. 39). Replacement of sodium chloride by choline
chloride in the incubation buffer caused a 50% inhibition of the 5-HT uptake which was more than observed
with LiCl. These findings pointed out that a part of the unspecific 5-HT uptake in RBE4 cells might be due to
the transport via the sodium independent choline transporter (see 4.6.).
During incubation at 4oC a significantly lower unspecific 5-HT uptake in RBE4 cells was found than observed
at room temperature. The unspecific 5-HT uptake in RBE4 cells at room temperature was considered as the
remaining 5-HT uptake after replacement of sodium with choline chloride in the incubation medium. From
these difference the presence of another uptake mechanism for serotonin may be suggested. The
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transporter for the neurotransmitter serotonin, dopamine and noradrenaline have a 69% to 80% homology in
their DNA sequence and belong to the same family of Na+/Cl- dependent transporters (Povlock and Amara,
1997). It is unlikely that the dopamine or norepinephrine transporter were responsible for the high unspecific
5-HT uptake in RBE4 cells for several reasons. First, sodium replacement should have blocked also these
transporters. Second, no specific binding of [3H]WIN35,428 or [3H]nisoxetine as selective ligands for the
dopamine or norepinephrine transporter was found in RBE4 cells (unpublished data). Third, similar uptake of
5-HT was measured during incubation with citalopram alone and co incubation with GBR 12909 a selective
dopamine transport inhibitor (Heikkila and Manzino., 1984).
4.4.6. Expression of the 5-HT transporter in RBE4 cells
In the present study, it was shown using RT-PCR that the immortalized rat brain endothelial cell line RBE4
also expresses the 5-HT transporter mRNA (Fig. 26). The primers were designed from the known sequence
of the rat cDNA serotonin transporter (SERT) (Hoffman et al. 1991) and placental tissue was used as a
reference with known expression of the 5-HT transporter (Prasad et al., 1996). For both cases identical RT-
PCR products were found. Moreover one of the PCR products obtained from the RBE4 cell mRNA was
sequenced and showed 99% homology with the corresponding sequence of the cloned rat 5-HT transporter
(Fig. 27). It is expected that the 5-HT transporter demonstrated in RBE4 cells is also present in the brain
endothelium of living animals and humans. Evidence for this assumption is derived from further functional
studies.
4.4.7. Differences between in vitro and in vivo expression of the 5-HT transporter
The functional expression of the 5-HT transporter in brain endothelial cells in vivo may be different from the
expression in the immortalized RBE4 cell line in vitro. Polymorphism in the 5-HT transporter gene (Lesch et
al., 1996; Lesch, 1998) and alternative splicing (Bradley and Blakely, 1997) may be linked to different cell-
specific expression. However the different biochemical characteristic of the 5-HT transporter in RBE4 cells
may also be related to posttranslational modifications (phosphorylation/dephosphorylation, glycosylation
etc.), which are known for the neuronal 5-HT transporter (Lesch, 1998; Ramamoorthy et al., 1998). It has
been shown that protein kinase C activation regulates human 5-HT transporter via altered cell surface
expression (Qian et al., 1997). A time dependent reduction in 5-HT uptake capacity after acute application of
the protein kinase C activator phorbol 12-myristate 13-acetate (ß-PMA) has been demonstrated in a human
5-HT transporter expressing cell line. This is expected to be caused by a redistribution of transporter protein
from the cell surface (Qian et al., 1995). Considering the possibility of different protein kinase C expression in
RBE4 cells and brain endothelial cells in vivo (Krizbai et al., 1995) it is rather likely that the 5-HT transporter
is downregulated in RBE4 cells. 
The second messenger dependent regulation of the 5-HT transporter suggests the involvement of receptor-
mediated events at the brain endothelial plasma membrane. 5-HT receptors could be candidate targets for
such type of regulation. The expression of a 5-HT2 receptor subtype has already been demonstrated at the
brain endothelium by radioligand binding and RT-PCR studies (Brust et al., 1996b; Cohen et al., 1999). And
the influence of receptor antagonists on the 5-HT transport in RBE4 cells is shown above (4.4.2.2.2.).
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4.4.8. Physiological role of the 5-HT transporter at the BBB
The physiological role of a 5-HT transporter in the brain endothelial cell membrane is unknown at this time.
Both the substrate 5-HT and monoamine oxidase (MAO), its deaminating enzyme, were demonstrable in
brain endothelial cells histochemically and biochemically (Maruki et al., 1984). The possible physiological
function of the 5-HT transporter is expected to limit the action of this neurotransmitter on the cerebral
vasculature. The transporter may play a role in the clearance of serotonin from the plasma. As 5-HT is a
potent vasoactive compound, effective removal of 5-HT from plasma may play a significant role in the
regulation of cerebral blood flow. In addition to their well-established role in BBB functions, there has been
accumulating evidence suggesting that capillaries have the potential to modulate vasomotricity and
participate in the regulation of vascular perfusion (Cohen et al., 1996). Thus smooth muscle contractile
proteins have been detected in both endothelial cells and pericytes of brain capillaries (Owman et al., 1978;
Nehls and Drenckhahn, 1993; Boado and Pardridge, 1994). The origin of 5-HT fibers innervating brain
microvessels is expected to be the raphe nuclei (Cohen et al., 1996). The brain endothelium also plays a key
role in determining BBB permeability. Intravenous 5-HT has been shown to decrease the permeability and
the electrical resistance of endothelial cell membranes (Sharma et al., 1990; Olesen, 1985). This increase in
permeability is mediated by 5-HT2 receptors and dependent on extracellular calcium. Furthermore in
peripheral endothelial cells a number of important biochemical (changes of intracellular calcium and various
enzyme activities) and structural changes (actin stress fiber assembly, cell surface area) have been noted
following exposure to 5-HT (for review see Cohen, 1989).
In conclusion, this study has demonstrated that a 5-HT transporter is functionally expressed in the brain
endothelium which may be involved in the regulation of cerebral microcirculation and/or blood-brain barrier
permeability.
4.5. L-carnitine transport at RBE4 cells 
Carnitine has long been known for its stimulation of fatty acid oxidation which has been attributed to its
function as a shuttle for activated fatty acids at the mitochondrial membrane (Bremer, 1983). It has recently
been shown that a specific high-affinity transporter (OCTN2) is responsible for the carnitine uptake from the
blood into the cells (Wu et al., 1998; Tamai et al., 1998; Sekine et al., 1998a). Carnitine has also been
successfully used as a pharmacological agent for the treatment of chronic degenerative diseases of the brain
(Spagnoli et al., 1991). However, very little is known about how this small hydrophilic molecule is transported
across the blood-brain barrier.
4.5.1. Comparism of the L-carnitine uptake in different cell types
Sodium dependent L-carnitine uptake has been described in human and rat placenta (Wu et al., 1998, 1999;
Prasad et al., 1996), human, rat and mouse kidney (Wu et al., 1999; Tamai et al., 1998; Rebouche and
Mack, 1984 rat intestine (Sekine et al., 1998a) and human hepatoma cells (Yokogawa et al., 1999). In slices
of the rat cerebral cortex, in synaptosomes isolated from guinea pig, mouse neuroblastoma cells and primary
rat cortical cultures a sodium dependent carnitine uptake is reported (Zoccarato et al., 1983; Huth et al.,
1981; Nałęcz et al., 1995; Virmani et al., 1994). In RBE4 cells sodium independent uptake of L-carnitine was
observed (Mroczkowska et al., 1996, 1997).
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This study has shown that the sodium dependent uptake of L-carnitine was also present in primary rat brain
endothelial cells and in RBE4 cells (Figs. 31 and 35). In both cell types the sodium dependent uptake was
inhibited by L-carnitine as well as by the organic cation TEA. The RBE4 cells had a slightly higher (about
5%) sodium dependent L-carnitine uptake than the primary cells. The OCTN2 transporter was expected to
mediate the sodium dependent transport of L-carnitine at both cell types.
However, a small part of about 13% of the remaining sodium independent L-carnitine uptake in primary rat
brain endothelial cells seemed to be mediated by a second, sodium independent, transporter which is also
sensitive to the organic cation TEA but, in contrast to the sodium dependent part, also significantly inhibited
by choline (Fig. 31). A sodium independent L-carnitine transport was also observed at monolayers of RBE4
cells (Mroczkowska et al., 1996, 1997) but no influence of organic cations on this uptake was reported by
these authors. Due to the inhibitory effects of TEA and choline the sodium independent L-carnitine uptake
observed in the primary cells may be assigned to an organic cation transporter but no L-carnitine transport
via an organic cation transporter is reported except the sodium sensitive OCTN2 transporter (Tamai et al,
1998; Wu et al., 1999).
4.5.2. Sodium dependence of the L-Carnitine uptake in RBE4 cells
The OCTN2 transporter mediates the transport of L-carnitine only in the presence of sodium ions, whereas
the transport of organic cations via the same transporter is sodium independent (Wu et al., 1999). This is an
unique finding among the various sodium coupled organic solute transporters and even within the organic
ion transporter superfamily to which OCTN2 belongs (Koepsell, 1998; Zhang et al., 1998). These features
were also demonstrable for the L-carnitine uptake process at the RBE4 cells (Fig. 28 and 30). About 50% of
the total uptake of L-carnitine was sodium dependent as shown by replacement of sodium ions with NMDG.
These findings are in contrast with the findings of Mroczkowska et al. (1996) who described the
accumulation of L-carnitine in RBE4 cells to be not dependent on sodium. The reasons for these
discrepancies are discussed in section 4.5.8..On the other hand, the uptake of TEA into RBE4 cells was
sodium independent in the present study. Moreover, the RBE4 cells also accumulated fatty acid esters of
carnitine such as propionyl-L-carnitine and acetyl-L-carnitine in a sodium dependent manner (Fig. 30). These
two acylesters of carnitine are known substrates for OCTN2 transporter (Wu et al. 1999).
4.5.3. Kinetics of the L-carnitine uptake in RBE4 cells
The maximal transport velocity determined in our study was 3.57 pmol/mg protein/min (Fig. 29) which is
about 0.3% of the transport capacity for large neutral amino acids (see also 4.2.1.) and about 5% of the
specific transport capacity for serotonin at the RBE4 cells (see also 4.4.4.). Compared to other carnitine
transport studies, this transport capacity is about an order of magnitude lower than at neuroblastoma NB-2a
cells (Nałęcz et al., 1995) and two orders of magnitude lower than at rat kidney brush-border-membrane
vesicles (Rebouche and Mack, 1984; Stieger et al., 1995). The Vmax value of the L-carnitine transport
recently found at RBEC1 cells was 6.46 pmol/mg/min (Kido et al., 2001a) and is in agreement with the data
described in the present study.
The Michaelis-Menten constant Kt of the L-carnitine transport at the RBE4 cells was about 54 µM (Fig. 29).
Hence the affinity of the OCTN2 transporter in RBE4 cells was an order of magnitude lower than the affinities
reported for the OCTN2 transporter cloned from the human kidney (Kt= 4.3 µM, Tamai et al., 1998) and
human placenta (Kt= 5.0 µM, Seth et al., 1999) but within the same range as found for the OCTN2
79
transporter cloned from the rat intestine (Kt= 25 µM, Sekine et al., 1998a), and the OCTN2 transporter
cloned from the rat placenta (Kt= 22 µM, Seth et al., 1999) or the L-carnitine transport process at renal brush
border membrane vesicles of rat (Kt= 17-55 µM, Rebouche and Mack, 1984; Stieger et al., 1995). At the
RBEC1 cells a Kt value of 33 µM was determined (Kido et al., 2001a). Altogether these data reveal that the
rat carnitine transporter (OCTN2) has a lower affinity towards L-carnitine than the human transporter.
4.5.4. Expression of OCTN2 in RBE4 cells
The current study provided strong evidence that the sodium dependent carnitine transporter OCTN2 is
functionally expressed in the endothelium of the blood-brain barrier. In this study, it was shown using RT-
PCR and Northern blot analysis that the immortalized rat brain endothelial cell line RBE4 expresses the
OCTN2 mRNA (Fig. 32 and 33). This transporter was recently cloned from human placenta (Wu et al., 1998)
and from human kidney (Tamai et al., 1998). It is also expressed in the rat kidney (Wu et al., 1999) which
was used as a reference tissue in our study. For the kidney tissue and the RBE4 cells, identical RT-PCR
products were obtained in our study (Fig. 32). Also the Northern blot analysis revealed a weak signal in
RBE4 cells using a OCTN2 specific probe. We speculate that the OCTN2 transporter demonstrated in RBE4
cells is also expressed in the brain endothelium of animals and humans. Evidence for this assumption is
derived from the finding that OCTN2-specific transcripts were detected by Northern blot and in situ
hybridization in the brain (Wu et al., 1998). Very recently a study was published reporting the expression of
OCTN2 in the whole rat brain, in primary cultures of brain endothelial cells and in a immortalized rat brain
endothelial cell line (RBEC1) using RT-PCR (Kido et al., 2001a). Their findings are identical with our results
found in RBE4 cells.
4.5.5. cDNA transfection with an cDNA clone derived from RBE4 cells
In this study, a rat OCTN2 clone isolated from the RBE4 cell cDNA library was expressed in HeLa (human
cervix carcinoma) cells using the vaccinia virus expression technique (Blakely et al., 1991b). The molecular
identity of the clone as rat OCTN2 was established by restriction analysis and partial sequencing. The
functional identity of the clone was established by heterologous expression in mammalian cells. The
transport of L-carnitine and TEA was compared in cDNA-transfected cells and in cells transfected with the
vector alone (Fig. 34 and 35). The cloned RBE4 OCTN2 was able to transport L-carnitine and TEA. Under
similar experimental conditions, similar uptake values were found by others (Wu et al., 1999; Seth et al.,
1999) for the cloned rat placental OCTN2 transporter. The rat OCTN2 showed a comparable ability to
transport L-carnitine and TEA.
4.5.6. Substrate and inhibitor specificity of the L-carnitine uptake in RBE4 cells
The OCTN2 transporter is reported to be a sodium dependent carnitine transporter as well as a sodium
independent cation transporter (Wu et al., 1999). Identical results were observed in HeLa cells transfected
with the OCTN2 cDNA clone derived from RBE4 cells with similar uptake values for L-carnitine and TEA (Fig.
34 and 35). However, for the human OCTN2 transporter, a severalfold greater ability to transport L-carnitine
than to transport TEA was observed (Seth et al., 1999). These differential characteristic of rat and human
OCTN2 were used as diagnostic criteria to analyze the transport functions of chimeras from human and rat
OCTN2 and to identify the domains involved in TEA transport and L-carnitine transport (Seth et al., 1999). It
was reported that the TEA transport site consists of a domain containing the first 122 amino acids and a
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domain containing amino acids 240-449 of the transporter protein. The L-carnitine transport site consists of a
domain containing amino acids 123-239 and a domain containing the C-terminal 108 amino acids. These
studies have shown that there is a significant spatial separation of the transport sites for different substrates
(Seth et al., 1999).
Besides L-carnitine the OCTN2 transporter was also able to mediate the transport of acetyl-L-carnitine and
propionyl-L-carnitine in a sodium dependent manner (Fig 30). The specific OCTN2 mediated uptake of the
carnitine esters was thereby 57% to 80% higher than the L-carnitine uptake. Similar findings are reported by
others (Wu et al., 1999; Kido et al., 2001a). Other authors demonstrated the lack of any effect of short- and
medium-chain acylcarnitines on the carnitine accumulation in the RBE4 cells (Mroczkowska et al., 2000).
This would indicate an involvement of a protein different from OCTN2 in their studies.
In addition to the different substrates, various inhibitors of OCTN2 transport were used in the present study.
The same inhibitory profile for the transport of L-carnitine and TEA was found as reported by Wu et al.
(1999), i.e. L-carnitine>TEA>MPP>choline (Fig. 35). L-carnitine, TEA and MPP are reported to be potent
inhibitors of the transport of L-carnitine and TEA (Wu et al., 1998, 1999) while choline had only a moderate
effect on the uptake of TEA (Wu et al., 1998, 1999). The inhibitory effect of choline on the L-carnitine
transport seems to be organ-specific. The reasons for this are unclear. The L-carnitine uptake mediated by
human and rat placental OCTN2 and OCTN2 derived from rat brain revealed a weak sensitivity to choline
(Wu et al., 1998, 1999; Kido et al., 2001a). In contrast choline did not have any inhibitory effect on the L-
carnitine uptake of cells expressing OCTN2 from human kidney and CT1, representing the rat homologue of
the OCTN2, from rat intestine (Tamai et al., 1998; Sekine et al., 1998a). However in RBE4 cells choline
exhibited a weak but significant inhibition on the L-carnitine uptake.
These data clearly suggest that the sodium dependent transport of L-carnitine in the rat brain endothelium is
mediated by OCTN2.
4.5.7. Physiological relevance of the expression of OCTN2 at the BBB
4.5.7.1. Transport of L-carnitine at the BBB
The OCTN2 transporter is expressed in several tissues including heart, placenta, skeletal muscle, kidney
liver and brain (Wu et al., 1998). As shown by in situ hybridization this transporter has a widespread
expression in the central nervous system (Wu et al., 1999). L-Carnitine uptake and exchange in different
tissues is primarily related to its role in the regulation of fatty acid oxidation (Bremer, 1983). The
concentrations in most tissues are more than tenfold higher than in the blood. Active transport systems such
as OCTN2 are therefore required to maintain this concentration gradient for L-carnitine across the plasma
membrane of these cells. The turnover time of L-carnitine in the rat brain (about 220 h) is very long
compared to the rat kidney (about 0.4 h ) and liver (about 1.3 h) (Brooks and McIntosh, 1975). L-Carnitine
and its derivates accumulate also in the nervous tissue (Bresolin et al., 1982; Shug et al., 1982), although
the level of ß-oxidation of fatty acids in adult brain is relatively low (Warshaw and Terry, 1976). That leads to
the question of the significance of L-carnitine transport at the BBB and the function of L-carnitine in the brain.
The concentration of L-carnitine in various rat brain regions differs by more than factor six with the highest
values found in the hypothalamus and the lowest in olfactory tracts (Bresolin et al., 1982). No correlation
exists to the activity of the carnitine palmitoyltransferase, an inner mitochondrial enzyme which is involved in
the ß-oxidation. This suggests that the major function of L-carnitine in the brain is different from that in
peripheral tissues (Bresolin et al., 1982; Nałęcz and Nałęcz, 1996). Indeed carnitine was found to stimulate
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the acetylcholine synthesis in adult rat cerebral cortex and neuroblastoma cells when administered together
with choline (Wawrzeńczyk et al., 1994, 1995). Acetyl-L-carnitine was shown to be a potential source of
acetyl groups for the synthesis of acetylcholine (Dolezal and Tucek, 1981; White and Scates, 1990). The
acetyl groups provided as acetyl-L-carnitine therefore can be effectively utilized for the acetylcholine
synthesis in the cytosol. The accessibility of choline and acetyl moieties could be limiting factors of the
acetylcholine synthesis (Wawrzeńczyk et al., 1995). It was therefore suggested that L-carnitine stimulates
the acetylcholine synthesis by delivering acetyl moieties to the cytoplasm. This may explain at least part of
the beneficial effects of L-carnitine and acetyl-L-carnitine administration to patients with neurodegenerative
diseases (Forloni et al., 1994; Spagnoli et al., 1991; Brevetti et al., 1992). Carnitine in vivo is mainly
synthesized in the liver and taken up by other tissues from circulation (Bøhmer, 1974). The expression of a
carnitine transporter(s) at the BBB may therefore be a prerequisite to supply the brain with L-carnitine. The
ability of OCTN2 to transport the acetyl-ester of L-carnitine could be of special importance for the brain
because of the use of this compound for acetylcholine synthesis.
4.5.7.2. Transport of organic cations at the BBB
The significance of the organic cation transport function of OCTN2 remains unknown. Many organic cations
recognized as substrates by OCTN2 are pharmacologically active and are currently used as therapeutic
agents. OCTN2 may play a significant role in the disposition and pharmacokinetics of these drugs in the
body (Wu et al., 1999). With regard to the BBB, the transport of the organic cation MPP has been
characterized at RBE4 cells (Martel et al., 2001). It has been shown that MPP is transported across the
apical and basolateral membrane by a sodium independent carrier-mediated mechanism. Moreover the
basolateral-to-apical transport (brain-blood direction) was significantly higher than the apical-to basolateral
transport (blood-brain direction) which suggests that the primary physiological function of organic cation
transport at the BBB is the removal of organic cations from brain. This is in line with the elimination function
of these transporters in the liver and the kidney (Muller and Jansen, 1997; Inui et al., 2000).
4.5.8. Distribution of OCTN2 within the cell
Recently Mroczkowska et al. (1996) have studied the transport of L-carnitine at RBE4 cells and found it to be
independent on a sodium gradient. However the authors have used L-[14C]carnitine with much lower specific
activity which may have caused difficulties in the separation of the sodium dependent from the sodium
independent component. In primary cultures of porcine brain capillary endothelial cells, the same authors
(Mroczkowska et al., 1997) described a sodium dependent L-carnitine uptake and a sodium independent
uptake as well. The sodium dependent uptake was only measurable in cell suspensions. Under these
conditions, a reduction of L-carnitine uptake by ouabain pretreatment (36%) and by amiloride/furosemide
pretreatment (70%) was observed. Various amino acids (leucine, BCH, phenylalanine) but not acylcarnitines
inhibited the uptake significantly. On the cell monolayer, only a saturable sodium independent uptake was
measured. The authors defined the monolayer site as the apical site and the site attached to the plastic
surface as the basolateral site. From these data, the authors proposed an asymmetrical uptake of L-carnitine
in the blood-brain barrier, where transport at the apical membrane occurs via a novel transport system
sensitive to butyrobetaine and the transport at the basolateral membrane is mediated by amino acid
transport systems. In the present study, clear evidence was obtained at RBE4 cells that the sodium
dependent transport is mediated by OCTN2. The question arises whether this transporter is expressed at the
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apical or/and basolateral membrane. The blood-brain barrier is asymmetric with regard to the expressed
transport systems. The glucose transporter (GLUT1) and the transporter for large neutral amino acids (LAT1)
are present at both membranes whereas those which depend on a sodium gradient, provided by the Na+/K+-
ATPase, such as the amino acid transport systems A and ASC are present primarily at the basolateral
membrane (Davson and Segal, 1996). The findings of  Mroczkowska et al. (1997) fit into that scheme and
suggest basolateral expression of sodium coupled L-carnitine transport. However, the substrate specificity of
the sodium dependent L-carnitine transport system described by Mroczkowska et al. (1997) does not
correlate with the substrate specificity of the sodium dependent L-carnitine transport mediated by the OCTN2
transporter. Our studies demonstrated the expression of OCTN2 in RBE4 cell monolayers. Since the
basolateral membrane should not be accessible in monolayers cultured on impermeable plastic supports as
it was done in our study, it must be speculated that OCTN2 is expressed in the apical membrane or the
RBE4 cells may not be enough polarized (see also 4.2.4.). The question arises if the apparent sodium
dependent L-carnitine uptake in RBE4 cells may include the transport characteristic at both the blood and
the brain side membranes. Uptake data of carnitine and acetyl-carnitine evaluated by the brain perfusions
technique revealed a sodium dependent uptake from the blood site of the BBB (Kido et al., 2001a). But the
expression of the sodium dependent L-carnitine transporter at the brain side of the endothelial cells can not
be excluded by these in vivo experiments. Whether or not OCTN2 is also present in the basolateral
membrane of the RBE4 cells is not known.
In conclusion, this study has demonstrated that the carnitine/organic cation transporter OCTN2 is functionally
expressed in the brain endothelium. It is probably involved in the regulation of the L-carnitine supply of the
brain and may be of relevance for the therapeutic potential of L-carnitine and L-carnitine esters in the
treatment of neurodegenerative diseases. 
4.6. Choline transport at RBE4 cells
In the brain choline is an essential nutrient of the brain but synthesized only in small amounts (Blusztajn and
Wurtman, 1983). Since choline is a precursor of acetylcholine and of essential constituents of the cell
membrane (e.g. phosphatidylcholine) the brain has to be supplied with choline from the blood (Klein et al.,
1993; Löffelholz, 1998). Choline as a polar, water-soluble cation, is not expected to diffuse passively across
the BBB and hence requires a specific transport system. Indeed, in vivo studies revealed a saturable choline
uptake from the blood into the brain in rats which was further demonstrated in primary cerebral capillary
endothelial cell cultures (Cornford et al., 1978; Karlsson et al., 1984; Estrada et al., 1990). This uptake
process was sensitive to hemicholinium-3. 
4.6.1. Sodium dependence of the choline uptake in RBE4 cells
The choline transport observed at the RBE4 cells was clearly independent on sodium (Fig. 36 and 37). The
independence of the choline transport on sodium was also described for one of the two choline transporter in
the brain (Happe and Murrin, 1993; Yamamura and Snyder, 1973), for the choline transport into rat lung
epithelial cells( Fisher et al., 1989, 1992; van Rossum and Boyd, 1998) and vesicles from rat intestine,
placenta and liver (Saito et al., 1992; Grassl, 1994; Moseley et al., 1996) and porcine alveolar epithelium
(Oelberg and Xu, 1998). At the rat and mouse BBB also a sodium independent choline transporter was
described (Estrada et al., 1990; Allen and Smith, 2001; Sawada et al., 1999). Interestingly the choline uptake
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at RBE4 cells increased when sodium was replaced isoosmotically by NMDG. Similar findings were also
made by several authors at the rat BBB (Allen and Smith, 2001), in human placental vesicles (Grassl, 1994)
and in the lung epithelium (Fisher et al., 1989).
4.6.2. Kinetics of the choline uptake in RBE4 cells
RBE4 cells expressed a saturable transport system for the uptake of choline which exhibited a high affinity
for choline with a Kt value of 10-20 µM (Fig. 38). Based on the kinetic data, we speculated that a single
transport system was responsible for choline uptake in these cells. It is however possible, though unlikely,
that the observed choline uptake was mediated by more than one transport system that are kinetically
indistinguishable. The kinetic characteristic of the choline transport system at RBE4 cells was very similar to
that reported recently by Sawada et al. (1999) at the mouse brain capillary endothelial cell line MBEC4.
Choline uptake in MBEC4 cells was also sodium independent and saturable with a Kt value for choline of
about 20 µM. Murakami et al. (2000) compared the in vitro data obtained from MBEC4 cells with in vivo data
of the BBB transport in mice and concluded that the transport mechanism of choline at the BBB is retained in
the in vitro model. In vivo studies revealed Kt values for choline which differed between 200-400 µM
(Cornford et al., 1978; Pardridge and Oldendorf, 1977) and 40-80 µM (Allen and Smith, 1999; Murakami et
al., 2000), dependent on the method and the specific activity of the radiotracer (Allen and Smith, 2001). The
lower affinities measured in vivo could partly be explained by the fact that the in vivo studies measure the net
flux into the brain which includes two transport process, the luminal transport of choline from the blood into
the endothelial cells and the abluminal transport from these cells into the brain. At isolated capillaries from
the rat and the bovine brain and primary endothelial cell cultures Kt values between 6 and 18 µM were
measured (Galea and Estrada, 1992; Estrada et al., 1990; Shimon et al., 1988, 1989). The in vitro data
obtained from isolated microvessels and primary cultures of cerebral endothelial cells are closer related to
the kinetic data obtained in the present study indicating the similarity of the studied transport systems at the
BBB.
The Vmax value determined at the RBE4 cells was 51.6 pmol/mg/min (Fig. 38). Similar data were reported at
isolated microvessels from rat and bovine brain with Vmax values between 18 and 81 pmol/mg/min (Shimon
et al., 1989, 1988; Galea and Estrada, 1992). The Vmax value of RBE4 cells was only 1/10 of that found in
cultures of mouse and bovine cerebral endothelial cells (Sawada et al., 1999; Estrada et al, 1990). In vivo
studies at the rat and the mouse BBB lead to Vmax values between 2.4 to 10 pmol/mg/min (Murakami et al.,
2000; Cornford et al., 1978; Allen and Smith, 1999, 2001; Mooradian, 1988).
At placental and intestinal brush border membrane vesicles a sodium independent choline transport with a Kt
of 300 µM (Grassl, 1994) and 159 µM, respectively, (Saitoh et al., 1992) and in rat liver membrane vesicles a
choline uptake with a Kt value of 340 µM was observed (Moseley et al., 1996). Furthermore in lung epithelial
cells a sodium independent choline uptake was reported with an estimated Kt value of 18 µM (van Rossum
and Boyd, 1998; Oelberg and Xu, 1998; Fisher et al., 1989). Those choline transport systems in nonneuronal
tissues resemble closely that described at the BBB including the sensitivity to hemicholinium-3.
Compared to RBE4 cells the Vmax value of the choline transport was about 30 times lower at rat liver plasma
membrane vesicles (1.8 pmol/mg/min, Moseley et al., 1996) but two magnitudes higher at vesicles from
porcine alveolar epithelial cells (5.3 nmol/mg/min, Oelberg and Xu, 1998). At human placenta brush border
membrane vesicles a Vmax value of 30 nmol/mg/min (Grassl, 1994) is reported while at vesicles of the rat
intestine brush border membrane vesicles the choline transport revealed a maximal transport activity of 332
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pmol/mg/min (Saitoh et al., 1992). These data indicate that the Vmax values of the sodium independent
choline transport differ between different tissues by more than three magnitudes.
4.6.3. Inhibitor specificity of the choline uptake in RBE4 cells
The choline transport system at the RBE4 cells recognized several other organic cations including MPP,
MPTP, clonidine, procainamide and TMA as substrates (Fig. 39 and 40). Monoamines (e.g., dopamine,
serotonin and norepinephrine) exhibited little or no affinity for the transport system (Fig. 39) and TEA, a
prototypical organic cation that is used widely in studies involving the transport of organic cations, interacted
with the transport system with very low affinity (IC50 value, approx. 10 mM) (Fig. 39 and 40). However, there
were notable differences between RBE4 cells and mouse brain capillary endothelial cells (MBEC) (Sawada
et al., 1999) in the potencies with which various organic cations compete with choline for the uptake process.
Hemicholinium-3 inhibited choline uptake in MBEC cells with an IC50 value of approx. 700 µM which is an
order of magnitude higher than the IC50 value found in RBE4 cells (approx. 50 µM) (Fig. 40). Similarly,
procainamide at a concentration of 2 mM inhibited choline uptake in RBE4 cells by about 70%, indicating
that the IC50 value for the inhibition is much lower than 2 mM. In contrast, the IC50 value for the inhibition of
choline uptake by procainamide in MBEC4 cells was considerably much higher (approx. 7 mM) than in RBE4
cells. The inhibition data with monoamines are, however, comparable in both cell types. It is surprising that
while the kinetic parameters of choline uptake are similar between the two cell types, the inhibitory potencies
for various organic cations are significant different between RBE4 cells and MBEC4 cells. The reason for
these discrepancies are not known.
The inhibitory potency of hemicholinium-3 on the BBB transport of choline was also described by others
(Karlsson et al., 1984; Allen and Smith, 1999, 2001; Cornford et al., 1978). Inhibitors constants (Ki)
determined using the brain perfusions technique range from 57 to 62 µM and are in agreement with the Ki
value found in RBE4 cells. In other tissues inhibitor constants for hemicholinium-3 between 5 and 300 µM
(Grassl, 1994; van Rossum and Boyd, 1998) are reported for the choline uptake representing differences of
up to two magnitudes. The question arises if the sodium independent, hemicholinium-3 sensitive choline
transport processes reported at other tissues are related to each other or if they represent the same
transporter protein but different splicing variants.
4.6.4. Molecular bases of the choline transport
4.6.4.1. Comparism of the choline transport at RBE4 cells with the choline transporters of the brain
and other tissues
There are at least two distinct transport systems for choline in the brain, both being sensitive to inhibition by
hemicholinium-3 (Happe and Murrin, 1993; Yamamura and Snyder, 1973). These two systems are
distinguished primarily by their dependence on sodium. One of the systems is energized by a
transmembrane sodium gradient and exhibits a very high affinity for choline (Kt approx. 1 µM) and
hemicholinium-3 (Ki < 1 µM). The other is sodium independent and exhibits a Kt value of 33 to 93 µM µM for
choline and a Ki value of 50 to 122 µM for hemicholinium-3. The sodium dependent choline transporter,
designated CHT1, has been recently cloned from rat and human (Okuda et al., 2000; Okuda and Haga,
2000; Apparsundaram et al., 2000). The functional characteristic of choline uptake in RBE4 cells strongly
suggests that the sodium dependent choline transporter is not expressed in these cells. This is supported by
RT-PCR data that showed the lack of expression of CHT1 mRNA in these cells (Friedrich et al., 2001).
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The properties of the sodium independent choline transporter described in the brain bears marked similarity
to those of the choline uptake process in RBE4 cells. A similar transport system has been described not only
in the brain but also at various epithelial cells derived from nonneuronal tissues (van Rossum and Boyd,
1998; Fisher et al., 1992, 1989; Oelberg and Xu, 1998). Therefore, it appears that expression of the sodium
independent choline transport system may not be restricted to the central nervous system. This system is
likely to play a critical role in the delivery of choline in various cell types of neuronal as well as nonneuronal
origin. The expression of this transporter also participates in the delivery of choline to the brain across the
blood-brain barrier. However, the molecular identity of this transporter remains unknown.
4.6.4.2. Similarities of the choline transport at RBE4 cells to the OCT family
An organic cation transporter (OCT1) located on the basolateral membrane of renal proximal tubes has been
cloned (Gründemann et al., 1994). Subsequently, other homologues including OCT2, OCT3, OCTN1 and
OCTN2 have been reported (Okuda et al., 1996; Kekuda et al., 1998; Tamai et al., 1997; Wu et al., 1998),
and collectively they have been designated as the organic cation transporter (OCT) family. The choline
transporter described in the present study appears to be a member of the OCT family. First, the choline
transport increased when sodium was replaced by NMDG in the buffer like the TEA uptake mediated by
OCTN2 (Wu et al., 1999) (Fig. 36 and 37). Second, the uptake of choline in RBE4 cells was inhibited by
substrates or inhibitors of the OCT family members, (i.e. procainamide, clonidine, MPP and MPTP and, to a
less extent, by cimetidine and TEA) (Fig. 39 and 40). Also it should be mentioned that neurotransmitters
such as serotonin are known to be transported by OCT1 and OCT2 (Busch et al., 1996b; Gründemann et al.,
1998a). Therefore, it was investigated in this study if there is a connection between the choline uptake and
the expression of organic cation transporters in RBE4 cells. This is the first study in the literature to address
this issue
Among the three different organic cation transporters thus far identified in mammalian cells at the molecular
level, OCT1 and OCT2 transport choline (Gorboulev et al., 1997). The transport process is sodium
independent and has a Kt value of about 600 µM in the case of OCT1 and about 200 µM in the case of
OCT2. OCT3 does not recognize choline as substrate (Kekuda et al., 1998; Gründemann et al., 1998b; Wu
et al., 2000). RBE4 cells do not express OCT2 and OCT3 but contain detectable levels of OCT1 mRNA,
indicating a low but significant expression of this transporter (Fig. 43).
Even though OCT1 mRNA was expressed at low levels in RBE4 cells, there was no detectable transport
function found at these cells that can be ascribed specifically to OCT1 (Friedrich et al., 2001). Choline
transport reported in the present study does not appear to be mediated by OCT1. The affinity of rat OCT1 for
choline is about 30 times lower than found in RBE4 cells (Gorboulev et al., 1997). While the rat OCT1 exhibit
a affinity of about 600 µM for choline the Kt of choline transport at RBE4 cells was determined 20 µM (Fig.
38). Furthermore, rat OCT1 transports TEA with a Kt value of about 100 µM (Gorboulev et al., 1997) whereas
the choline transport system identified at RBE4 cells interacted with TEA with a very low affinity (Fig. 40).
The IC50 value for TEA to inhibit choline uptake in these cells was about 80 times higher than the Kt value for
the TEA transport via rat OCT1. Similarly, MPP is transported by rat OCT1 with very high affinity of (Kt about
10 µM), but the IC50 value for MPP to inhibit the choline uptake in RBE4 cells was about 170 µM (Fig. 40).
These data clearly show that even though RBE4 cells express low levels of OCT1, the sodium independent
choline uptake detected in these cells did not occur via OCT1. This suggests that a hitherto unidentified
organic cation transporter is responsible for choline uptake in RBE4 cells.
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4.6.4.3. Relations of the choline transport at RBE4 cells to the OAT family
Organic cation transporters share about 36% sequence identity with organic anion transporters (Kusuhara et
al., 1999). Furthermore some organic cation inhibitors showed also inhibitory effects on the transport
processes of the organic anion transporter OAT3 (Kusuhara et al., 1999). RT-PCR with degenerated primers
of the OAT family resulted only in a single cDNA band resembling the NLT transporter in rat kidney (Fig. 44).
This transporter is known to be expressed only in liver and kidney and was renamed OAT2 (Sekine et al.,
1998b). In RBE4 cells, however, degenerated primers did not result in any transporter-like cDNA. Even
OAT3 is expressed in the brain it remains unknown if this transporter is also expressed at the BBB
(Kusuhara et al., 1999).
4.6.5. Physiological relevance of the expression of a choline transporter at the BBB
In this study it was demonstrated that choline is taken up by brain capillary endothelial cells. However, the
brain choline level is approximately 2.5 µM, one quarter of that in plasma (Tucek, 1984). In cerebral capillary
endothelial cells with intact endocellular choline pools [3H]choline was only partially metabolized and 63% of
the accumulated tritium remained as free choline in the cells (Estrada et al., 1990). Also, it was confirmed by
these authors by studying the choline efflux out of the preloaded cells, that only a small fraction of the
intracellularly accumulated choline was transported back into the external incubation medium. These results
suggest that the brain capillary endothelial cells may provide a gating mechanism that can contribute to the
physiological control of the choline concentration in the brain extracellular fluid.
Acetylcholine synthesis in cholinergic nerve endings is dependent on the neuronal uptake of choline from the
extracellular space via the high affinity, hemicholinium-3 sensitive, sodium dependent choline transporter
(CHT1) located at these nerve endings (Löffelholz, 1998). This choline transporter is the rate limiting step
and regulatory step in the synthesis of acetylcholine (Kuhar and Murrin, 1978). The extracellular choline in
the brain represents a general pool that is maintained by a variety of sources, mainly plasma choline, free
intracellular choline, choline containing phospholipids and acetylcholine (Löffelholz, 1998). Since choline is
only minimally synthesized in the brain (Blusztajn and Wurtman, 1983), the transport of free choline through
the BBB seems to be the only likely mechanism which contributes to the supply of choline to the brain under
physiological conditions (Klein et al., 1993).
In conclusion this study has shown that a sodium independent choline transporter is present at the BBB. This
transporter is sensitive against hemicholinium-3 and typical inhibitors of the family of the organic cation
transporters. The molecular basis of this transporter remains unknown. The transporter is expected to supply
the brain with choline as a precursor of the neurotransmitter acetylcholine and for choline containing
phospholipids of the membrane
4.7. Recent development of the brain drug delivery via specific transporters of the BBB
The purpose of the present study was to investigate the expression and characteristic of several transport
systems at the BBB. The results could be used to take advantage of the saturable nutrient transporters as
portals for the drug delivery to the brain parenchyma. The specific delivery of certain compounds to the brain
could be improved by designing them based on the knowledge of the functional characteristic of the BBB
transporters.
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4.7.1. Recent brain drug delivery via BBB located transporters
Many valuable pharmaceuticals are excluded from the CNS due to their hydrophilicity or charge. These
limitations have been overcome by numerous methods (Begley, 1996; Tsuji and Tamai, 1999; Pardridge et
al, 1992; Pardridge, 1988, 1989). Physiologic-based strategies involve the production of chimeric nutrients or
chimeric peptides. Chimeric nutrients are drugs that are structurally related to nutrients that normally undergo
carrier mediated transport through the BBB. Examples of chimeric nutrients are [18F]-fluorodeoxyglucose
(FDG), L-3,4-dihydroxy-6-[18F]fluorophenylalanine (F-DOPA) and 3-o-methyl-6-[18F]fluoro-L-3,4-dihydroxy-
phenylalanine (OMFD).
FDG represents a glucose analogue and enters the brain via the glucose transporter GLUT1 present at the
BBB (Pauwels et al., 1998; Pardridge et al., 1990a). The radiolabeled FDG is used for tumor diagnostics
because of its enhanced uptake into tumors (Pauwels et al., 1998).
The system L, which transports neutral amino acids into the CNS, is another obvious target for drug
analogues or complexes which might have reactivity with this system. Among them are 3,4-
dihydroxyphenylalanine (L-DOPA) which is used for the treatment of Parkinson’s disease (Carlsson, 1987;
Wade and Katzmann, 1975), the tyrosine hydroxylase inhibitor α-methyltyrosine (Brogden et al., 1981) and
the antihypertensive drug α-methyldopa (Markovitz and Fernstrom, 1977). The radiopharmaceutical F-DOPA
is used for the imaging of dopaminergic diseases (Barrio et al, 1997), and OMFD is a promising tracer for
brain tumor imaging (Füchtner et al., 1999; Syhre et al., 1999). Although most chemotherapeutic agents do
not cross the BBB, melphalan is one example of a polar oncologic agent that does cross, owing to its affinity
for the BBB neutral amino acid transport system (Greig et al., 1987).
To date, the most successful exploitation of system L is the delivery of L-DOPA to the brain for the treatment
of Parkinsonism (Carlsson, 1987; Wade and Katzmann, 1975). Dopamine given orally is ineffective as it is
not a substrate for system L and thus does not enter the brain readily. It is also subject to rapid metabolism
at the level of the BBB by monoamine oxidase (MAO) and catechol-O-methyl transferase (COMPT) (Firnau
et al., 1975). Fortunately L-DOPA is a substrate for system L (Gomes and Soares-da-Silva, 1999) and the
enzyme L-amino acid decarboxylase (AAD or DOPA decarboxylase) within the BBB will convert L-DOPA to
dopamine during passage through the barrier. The dopamine can be taken up by cells in the substantia nigra
to replace their missing neurotransmitter. Although some further dopamine must be lost as the result of MAO
and COMT activity in the CNS sufficient appears to reach the nerve cells.
4.7.2. Use of the present study for brain drug delivery
The present study describes the use of the RBE4 cells as an in vitro model of the BBB to study the
expression of several transport systems. The experiments were done with monolayers of the cells and do not
discriminate between luminal and abluminal uptake of the compounds. For brain drug delivery not only the
uptake of a compound from the blood into the endothelial cells is important but also the uptake from the
endothelial cells into the brain. To accomplish the study of a drug transport through the BBB the in vitro
model of the RBE4 cells could be improved. Therefore, the cells would have to be seeded on porous
membranes in co-culture with astrocytes on the other side of the membrane to achieve a polarization of the
endothelial cells (Dehouck et al., 1990; Staness et al., 1999; ElHafny et al., 1996; Abbott et al., 1995). The
results obtained in the present study are useful to design drugs which can be transported by the described
transporters. Concerning the maximal velocity rates of the transporters only the sodium independent choline
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transporter and the amino acid transporters (system L and system y+) seem to have the properties to
transport sufficient amounts of a compound through the BBB.
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5. Summary
The delivery of nonlipophilic drugs to the brain is severly hindered by the restrictive nature of the blood-brain
barrier (BBB) (Reese and Karnovsky, 1967; Brightman et al., 1970). The present study was performed under
the purpose of determining the functional and molecular characteristic of several transport systems, which
are expressed at the BBB. The brain capillary endothelial cells, which form the BBB, do posses specific
transport systems that potentially can be exploited as means to transport therapeutic molecules to the brain
(Begley, 1996). The development of effective BBB drug delivery strategies in the future will be closely linked
to the new knowledge of the molecular and cellular biology as well as the functional characteristic of the
brain capillary transport processes.
Many in vitro and in vivo techniques are available to study the expression and functional characteristic of
transporters at the BBB (Takakura et al., 1991; Bonate, 1995). In the present study an immortalized rat brain
endothelial cell line (RBE4) was used, which has the advantage that there is no need of animals or
preparation time. In addition, such a cell line provides a pure cell population and has an easy handling. The
RBE4 cells have been recently established (Roux et al., 1994) and show characteristic features of the BBB
in vivo like the expression of specific endothelial markers (e.g. γ-glutamyltransferase, alkaline phosphatase)
and transport systems, known to be expressed at the BBB (e.g. glucose transporter GLUT1, P-glycoprotein
(P-gp)).
The strategy of the present study follows three steps:
First, the in vitro model was investigated in order to determine the time when the cells reached confluence
and when they were in the best condition for the experiments. Furthermore the influence of the experimental
conditions such as buffers and temperature on the vitality of the RBE4 cells was investigated using suitable
radiotracers for this purpose.
Second, the functional and molecular characterization of two sodium independent amino acid transport
systems (system L and system y+) was performed. These transport systems are already well characterized
at the BBB (Smith, 2000) and serve as indicators to provide evidence on the suitability of the in vitro model
for the present study.
And third, there are indications for the presence of uptake mechanisms for serotonin (5-HT), L-carnitine and
choline at the BBB. But these transport processes were not fully characterized at the BBB so far. Therefore,
the functional characteristic and molecular identity of these transport systems was investigated.
The investigations of the present study have shown that the RBE4 cells reached confluence, depending on
the density of seeding, after two to three days and that these cells kept their vitality under experimental
conditions for several hours. Therefore, the RBE4 cells have served as in vitro model of the BBB in this
study.
The uptake of L-tryptophan, a neutral amino acid, exhibited a half saturation constant (Kt) of 31 µM and a
maximal velocity rate (Vmax) of about 1 nmol/mg/min in RBE4 cells. Furthermore this uptake process showed
sodium independence and was inhibited by several large neutral amino acids like tryptophan, leucine,
phenylalanine and L-DOPA (L-3,4-dihydroxyphenylalanine). In contrast, small neutral amino acids like
glycine and alanine or acidic amino acids like glutamate did not influence the L-tryptophan uptake into RBE4
cells. The specific inhibitor for system L, BCH, showed a strong inhibition of the L-tryptophan transport while
MeAIB, a specific inhibitor of the sodium dependent amino acid transport system A, had no influence. The
expression of LAT1 and LAT2, the two different light chains of system L, could be shown in RBE4 cells and
in rat brain. At the time of the experiments the expression of the light chain of the second isoform of system
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L, LAT2, was not known at the brain endothelium. The transport characteristic of the cationic amino acid
transport system y+ was studied using radiolabeled L-arginine. The kinetic constants of the L-arginine uptake
into RBE4 cells were determined with a Kt value of about 55 µM and a Vmax of 0.56 nmol/mg/min. The
transport of L-arginine at RBE4 cells was independent on sodium and decreased by the cationic amino acid
ornithine but not by the acidic amino acid glutamate. The specific inhibitors of system L and system y+, BCH
and MeAIB respectively, did not influence the L-arginine uptake into RBE4 cells. Reverse transkriptase-
polymerase chain reaction (RT-PCR) studies and Northern blot analysis revealed the existence of the
cationic amino acid transporter cat1 in RBE4 cells, rat brain and rat placenta. The obtained results
concerning the L-tryptophan and L-arginine uptake in the RBE4 cells correlate well with previous reports
about the characteristic of these amino acid transporters at the BBB. These findings lead to the conclusion
that the RBE4 cells are a suitable in vitro model of the BBB for transporter studies.
Studies were performed in order to investigate the transport characteristic and the molecular identity of
transport systems not yet fully described at the BBB. Uptake studies with radiolabeled 5-HT exhibited a
saturable, sodium dependent transport at RBE4 cells with a Kt value of about 0.40 µM and a Vmax of about 52
fmol/mg/min. Typical 5-HT uptake inhibitors like paroxetine, clomipramine, imipramine, fluoxetine and
citalopram decreased the 5-HT uptake into RBE4 cells. In contrast, reserpine and tetrabenazine, which are
typical inhibitors of the vesicular monoamine transporter, did not have any inhibitory effect. Verapamil and
quinidine, which are potent inhibitors of the P-gp, a drug-efflux pump at the BBB, showed a strong inhibition
of the 5-HT transport at RBE4 cells, while colchicine, also a P-gp inhibitor, did not have any effect. In
addition, at a human choriocarcinoma cell line (JAR), which is known to express the sodium dependent 5-HT
transporter, the inhibition of the 5-HT uptake by verapamil was also observed. It could be shown that the
inhibitory effect of verapamil and quinidine is not due to the effect on the P-gp. The 5-HT uptake into RBE4
cells was also decreased by GBR 12909, a powerful inhibitor of the dopamine transporter, while dopamine
itself at a concentration of 1 mM was without any inhibitory potency. There was no additive effect on the 5-
HT uptake observed when RBE4 cells were co-incubated with GBR 12909 and citalopram indicating that
GBR 12909 acts directly at the 5-HT transporter. Interestingly, ketanserin, a 5-HT2A receptor antagonist
decreased the 5-HT uptake in RBE4 cells indicating a relation between the 5-HT transporter and the 5-HT
receptor. The 5-HT uptake into RBE4 cells was also dependent on a sodium gradient over the cell
membrane, which is generated by an ouabain sensitive Na+/K+-ATPase. Therefore the 5-HT transport at
RBE4 cells was decreased under the influence of ouabain. The comparison of the 5-HT uptake of RBE4
cells with primary endothelial cells from porcine brain and JAR cells revealed that all three cell types exhibit a
5-HT uptake which is inhibited with citalopram. On the other hand, a hamster lung fibroblastic cell line (V79)
did not show any specific 5-HT uptake. RT-PCR with specific primers revealed the expression of the sodium
dependent serotonin transporter (SERT), which is also reported in other tissues like the brain or blood
platelets, in RBE4 cells and rat placenta.
The uptake of L-carnitine into RBE4 cells was shown to be sodium dependent and saturable with a Kt value
of 54 µM and a maximal velocity of about 3.6 pmol/mg/min. Also the acyl esters acetyl-L-carnitine and
propionyl-L-carnitine were taken up by the RBE4 cells in a sodium dependent manner. In contrast, the
organic cation TEA (tetraethylammonium) follows a sodium independent uptake mechanism at RBE4 cells.
The expression of the organic cation/carnitine transporter OCTN2 in the RBE4 cells and rat kidney was
shown by RT-PCR and Northern blot analysis. Expression studies in HeLa (human cervix carcinoma) cells
with a cDNA clone derived from the screening of the RBE4 cell cDNA library exhibit a specific L-carnitine
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uptake which was sodium dependent and inhibited by L-carnitine and the organic cations TEA, MPP (1-
methyl-4-phenylpyridinium) and choline. In addition the OCTN2 transfected HeLa cells exhibit a specific
sodium independent TEA uptake which was inhibited by L-carnitine, TEA, MPP and moderately by choline.
Uptake studies in primary rat brain endothelial cells showed a L-carnitine mechanism similar to that observed
at RBE4 cells.
A sodium independent transport process for choline was shown at RBE4 cells. This saturable choline
transport exhibit a Kt value of about 22 µM and a maximal velocity of about 52 pmol/mg/min. The inhibitory
potency of several compounds on the choline uptake was hemicholinium-3 > MPTP (1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine) > MPP > clonidine > procainamide = TMA (tetramethylammonium). The
neurotransmitters dopamine and norepinephrine, in contrast to serotonin, did not have an inhibitory effect on
the choline uptake into RBE4 cells. The choline transport observed at the RBE4 cells showed strong
correlation with the transport processes reported for the organic cation transporter family (OCT). Northern
blot analysis and RT-PCR with specific primers of the organic cation transporters OCT1, OCT2 and OCT3
revealed only the expression of OCT1 in RBE4 cells. But it could be shown that OCT1 was not responsible
for the sodium independent choline uptake into RBE4 cells. Furthermore a RT-PCR with degenerated
primers based on the nucleotide sequences of the known organic cation transporters did not lead to any
result. In addition RT-PCR with degenerated primers for the organic anion transporter family resulted not in
the identification of a novel transporter protein which could be responsible for the choline transport at the
RBE4 cells.
The present study has shown that the RBE4 cells are a suitable model of the BBB for transporter studies.
These cells do express the amino acid transport systems L and y+, which are known to be present at the
BBB. Furthermore the expression of two sodium dependent transporters, the 5-HT transporter (SERT) and
the organic cation/carnitine transporter OCTN2, was shown at the RBE4 cells. Also a sodium independent
choline uptake into the cells was discovered but the molecular identity remained unknown.
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